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PrefaCe
This thesis is part of the ongoing Nijmegen Usher syndrome research project, initiated 
in the nineties by Cor Cremers. This is the sixth PhD thesis on Usher syndrome after 
the theses written by Annelies van Aarem (1996, Heterogeneity in the Usher syndrome), 
Mariette Wagenaar (2000, The Usher syndrome, a clinical and genetic correlation), Ron-
ald Pennings (2004, Hereditary Deaf-Blindness, clinical and genetic aspects), Erwin van 
Wijk (2009, Dissection of the molecular pathology of Usher syndrome) and Ferry Kersten 
(2011, Keeping an eye on novel members of the Usher protein network). Furthermore, 
two other theses have described performance outcomes of Usher syndrome patients 
(Godelieve Damen 2007, Cochlear Implantation and Quality of Life Assessment and 
Rutger Plantinga 2007, Hereditary Hearing Impairment). In October 2012, two Usher 
syndrome patients, Ivonne Bressers and Gracia Tham, published a report on problem-
atic hearing aid fitting in patients with Usher syndrome, based on interviews with care 
professionals and patients. This report, together with ongoing questions about the 
variability in presentation of clinical symptoms in Usher syndrome patients, laid the 
foundation for this thesis. Unlike the previous theses, this manuscript focuses entirely 
on patients with two mutations in USH2A. Depending on the mutations, such genotype 
is associated with either Usher syndrome type IIa or nonsyndromic Retinitis Pigmentosa. 
The patient played a pivotal role in the realization of this thesis. First, patients were an 
essential source of inspiration by writing their report on problematic hearing aid fitting. 
Secondly, Nicole Lo-A-Njoe - Kort, a patient with Usher syndrome type IIa, conducted 
part of the research described in Chapter 2.1 as part of a scientific internship to obtain 
her medical degree. Finally, the energy, involvement and enthusiasm of Usher syndrome 
patients participating in research have been a driving force. Patient involvement in care 
and research is adopted by our institution, the Radboud university medical centre and 
the supervisors of this thesis. Because of this, the structure of the introduction and 
discussion is written as a care program for a patient with Usher syndrome. Detailed 
descriptions and definitions are presented in grey boxes.

Chapter 1
Introduction
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Patients and syMPtoMs
In this thesis, patients with pathogenic mutations in USH2A in different stages of their 
care program have been studied. Study objects include patients from the first presenta-
tion at the outpatient clinic up to fully genotyped and phenotyped patients who have 
had optimal hearing rehabilitation. 
Usher syndrome is an autosomal recessively inherited condition that is characterized by a 
combination of sensorineural hearing impairment, vision loss due to Retinitis Pigmentosa 
(RP), and in some cases vestibular abnormalities (see box 1 and 2). Other symptoms in-
cluding low odour identification, reduced nasal mucociliary clearance, decreased motility 
and velocity of sperm, mental deficiencies, cerebral atrophy and ataxia have also been 
described in Usher syndrome patients.1-7 However, these symptoms have, so far, not been 
adopted as part of the clinical diagnosis of Usher syndrome and need further research.
Box 1. Hearing and sensorineural hearing impairment
In a person with normal anatomy of the hearing organ, a longitudinal sound wave travels through the 
external auditory canal to the tympanic membrane (1 in figure 1). The middle ear contains three auditory 
ossicles: the malleus, incus and stapes, which connect the tympanic membrane to the oval window (2 in 
figure 1). Sound vibrations are transmitted via the ossicles to the inner ear by the movement of the stapes 
footplate located in the oval window (3 in figure 1). Consequently, in the inner ear, the basilar membrane 
starts to move in a vertical direction resulting in deflection of the hair cell stereocilia. The sensory inner 
and outer hair cells are located in the Organ of Corti (4 and 5 in figure 1). These cells are responsible for 
converting sound vibrations into an electric action potential. This action potential travels via the auditory 
nerve to the primary auditory cortex (6 in figure 1). Sensorineural hearing impairment is considered as a 
loss or malfunctioning of the sensory organ in the cochlea and/or hearing associated neural structures. 
Due to this malfunctioning, the sound is not adequately transmitted to the auditory cortex, causing 
hearing impairment.
The combination of hearing and visual impairment was first described by the German 
ophthalmologist Albrecht von Graefe in 1858. However, the syndrome was named after 
the Scottish ophthalmologist Charles Howard Usher (1865-1942). The prevalence of 
Usher syndrome is estimated to range from 4.4 to 6.2 per 100,000 inhabitants. Therefore, 
Usher syndrome is considered to be a rare disease by the definition of the European 
Commission (see box 3).8-10 Usher syndrome accounts for 3-6% of all childhood deafness, 
for 10-20% of the RP population and for 75% of the hereditary deafblindness popula-
tion.9, 11, 12 From the first clinical descriptions on Usher syndrome patients, it was clear 
that hearing impairment and RP varied among patients in both onset, severity and 
progression. In 1977, Davenport and Omenn proposed the first clinical classification to 
group the most important variations. This classification, reviewed by Smith and al. in 
1994, is shown in Table 1.13-15
12
table 1. Clinical classification of Usher syndrome
Hearing impairment Visual impairment Vestibular function
Usher syndrome type I Congenital, severe to 
profound
Diagnosis before puberty, 
progressive
Absent
Usher syndrome type II Congenital, moderate to 
severe
Diagnosis around puberty, 
progressive
Intact
Usher syndrome type III Variable onset, 
progressive
Variable age of diagnosis, 
progressive
Variable
Box 2. Vision and retinitis pigmentosa
In a healthy individual, light enters the eye through the pupil and is refracted by the cornea and lens before 
being projected on the retina. The retina contains the light-sensitive photoreceptor cells which use opsins to 
absorb the light and transmit a signal via a transduction pathway up to the cortex (Figure 2). Retinal photore-
ceptor cells are divided into rods and cones (Figure 3). Rods are concentrated on the outer edges of the retina 
and responsible for peripheral vision and vision in dim light, whereas cones are concentrated in the central 
region of the retina and responsible for colour vision. Synonyms for Retinitis Pigmentosa (RP) are pigmentary 
retinopathy and tapetoretinal degeneration. The term “retinitis” suggests an inflammatory process, however, 
this is not the case. RP is characterized by degeneration of the retinal photoreceptor cells avnd leads to for-
mation of pigment deposits (hence the term pigmentosa) in the retina. The deterioration in RP is thought to 
be caused by a progressive peripheral to central degeneration of these light-sensitive cells.16
Box 3. European Commission’s definition of Rare Diseases
1. Life-threatening or chronically debilitating disease
2. Affecting fewer than 5 people in 10,000
3.  Combined efforts are needed to prevent or reduce the disease and preserve the quality of life and socio-
economic potential
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figure 1. Schematic illustration of a sound wave travelling through the human ear. Abbreviation: N = Nerve
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Usher syndrome type II is the most common clinical type of Usher syndrome and ac-
counts for more than half of all patients. As mentioned in Table 1, patients with Usher 
syndrome type II present with congenital hearing impairment.17 In addition, patients 
develop the first clinical signs of RP around puberty. The most frequently reported 
first visual complaint is nightblindness. From this moment onwards, the average delay 
before a clinical diagnosis of Usher syndrome type II is about 10 years, at a mean age of 
26 years. (For detailed information on ages see chapter 2.2). In contrast to the other two 
clinical types of Usher syndrome, patients with Usher syndrome type II have an intact 
vestibular function.
light
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figure 2. Anatomy of the human eye (adapted with permission from thesis E. van Wijk)
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figure 3. Cellular structure of the retina (adapted with permission from thesis E. van Wijk)
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froM a CliniCal to a genetiC diagnosis
After the onset of visual complaints, the combination with pre-existing hearing impair-
ment normally leads to a suspicion of Usher syndrome and, often, genetic testing will 
then be performed. As Usher syndrome is an autosomal recessively inherited disorder, 
patients must have a pathogenic mutation on both alleles of an Usher syndrome-
associated gene to induce a phenotype. Already in 1959, Hallgren et al. suggested that 
the difference in phenotypic outcome between Usher syndrome patients could be 
caused by mutations in different genes.18 So far, mutations in six different genes result 
in Usher syndrome type I. Mutations in USH2A, ADGRV1 and WHRN result in Usher syn-
drome type II and defects in CLRN1 lead to Usher syndrome type III. Furthermore, it has 
been reported that mutations in PDZD7 can act as a modifier of retinal disease in Usher 
syndrome type IIa or, together with mutations in ADGRV1, act in a model of digenic 
inheritance resulting in Usher syndrome type II (Table 2, http://hereditaryhearingloss.
org, visited 10-11-2016). At a molecular level, Usher syndrome associated genes are 
translated into proteins which have a specific function in the eye and ear. These proteins 
function together in a dynamic Usher protein network (see box 4).17-19
table 2. Genes and loci associated with Usher syndrome
type genetic 
type
gene Chomosomal 
location
Protein oMiM reference
Type I USH1b MYO7A 11q13.5 myosin VIIa 276903 20
USH1c USH1C 11p15.1 harmonin 276904 21-23
USH1d CDH23 10q22.1 cadherin 23 601067 24-26
USH1e unknown 21q21 602097 27
USH1f PCDH15 10q21-22 Protocadherin 15 602083 28, 29
USH1g USH1G 17q24-25 SANS 606943 30, 31
USH1h unknown 15q22-23 312632 32
USH1j CIB2 15q23-q25.1 CIB2 614869 33
USH1k unknown 10p11.21-q21.1 614990 34
Type II USH2a USH2A 1q41 usherin 276901 35-37
USH2c ADGRV1 5q14.3-q21.3 ADGRV1 605472 38, 39
USH2d WHRN 9q32 Whirlin 611383 40
Type III USH3 CLRN1 3q21-q25 Clarin-1 276902 41, 42
Modifier PDZD7 10q24.31 PDZD7 43
OMIM: Online Mendelian Inheritance in Man
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Box 4. Usher protein network
Usher syndrome type I and Usher syndrome type II proteins function together in a multiprotein scaffold: the 
Usher protein network. This network is present in different compositions at different subcellular locations 
during different stages of inner ear and retinal development. Although its precise function is still unknown, 
several proposed functions have been attributed to the protein network. First, it has been shown to be cru-
cial for the elongation of stereocilia and organisation of hair bundles.44-46 Secondly, in the photoreceptor 
periciliary region, it has been proposed to function in the transport and docking of vesicles that contain es-
sential proteins for outer segment formation, maintenance and function.47 Finally, there are indications that 
the Usher protein network is involved in synapse formation and synaptic transmission in the hair cells and 
photoreceptor cells.47, 48 The Usher protein network is illustrated in figure 4. 
Box 5. Genetic testing
Individuals are genetically discriminated from each other by thousands of DNA variations. Most of the time 
these variations do not directly affect general health directly. These variants are called Single Nucleotide 
Polymorphisms (SNP, often pronounced SNIPs) and occur in at least 1% of the population. If variations do 
affect health, they are called mutations. Modern diagnostic strategies include, amongst other, Copy Number 
Variation analyses, linkage analyses, and multiple methods for sequence analysis. Currently, the two most fre-
quently used strategies for sequence analysis are Sanger sequencing and Whole Exome Sequencing (WES). 
With Sanger sequencing the precise order of nucleotides within a specific gene is determined, whereas with 
WES, the nucleotide sequence of all known exons (EXpressed regiON) within the human genome is deter-
mined in one assay. These sequences are compared with that of unaffected controls (e.g. the Exome Variant 
Server, http://evs.gs.washington.edu/EVS/) in order to find abnormal variants or mutations.49, 50
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figure 4. The Usher protein network. Identified protein-protein interactions are indicated. The Black boxes 
represent Usher syndrome-associated proteins. The grey boxes indicate other know proteins interacting 
with the Usher proteins. (Adapted with permission from thesis E. van Wijk)
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In 1995, Kimberling et al. identified the first locus for Usher syndrome localised at 
chromosome 1q41 (long arm of chromosome 1).36 Three years later, in 1998, Eudy et al. 
identified mutations in USH2A to be causative for Usher syndrome type II.35 In 2004, van 
Wijk et al. identified 51 additional exons of USH2A that altogether encode a novel, long 
isoform of usherin (see box 6 and figure 5).37 Usher syndrome type IIa (USH2a) is the 
most common genetic type of Usher syndrome and has been reported to represent 72 
to 82% of Usher syndrome type II cases.
Box 6. Usherin
USH2A is translated into the protein usherin. In the inner ear, usherin is part of a complex, forming transient 
basal links, or ankle links of the hair bundle. These links are thought to be essential for the proper organiza-
tion and development of the cochlear hair bundle (see Box 1). Besides that, usherin is found at the synaptic 
region of hair cells and in spiral ganglia.51 In the photoreceptor cells of the retina, usherin has been found at 
the apical region of the inner segment, the so called “periciliary region”, and at the synaptic region of these 
sensory cells. At the periciliary region, usherin is thought to be part of a protein that is involved in the dock-
ing and transportation of vesicles from the inner towards the outer segment of the photoreceptor cell.52 
tHe ConsequenCe of a genetiC diagnosis of usH2a
The clinical and genetic diagnosis of USH2a has a big impact on patients as they are 
confronted with an uncertain future. Much is still unknown about the natural course of 
the disease.
+ ex 71
FN3 FN3LamGFN3EGFLamLamNTLamG/
TspN/
PTX
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PBM
figure 5. Schematic representation of the architecture of usherin isoform A and isoform B, the protein 
involved in Usher syndrome type IIa. (Adapted with permission from thesis E. van Wijk)
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Usher syndrome type II is characterized by a congenital, moderate to severe bilateral 
hearing impairment which is more prominent in the higher frequencies. Originally, pro-
gression of hearing impairment was not considered to be part of the Usher syndrome 
type II phenotype. Both Davenport and Omenn (1977) and Smith et al. (1994) considered 
the absence of progression as minimal diagnostic criteria for Usher syndrome type II.13, 14 
However, previous studies suggested a progressive nature of the hearing impairment 
in USH2a patients.53-56 In chapter 2.1 of this thesis, hearing impairment in a large inter-
national sample of 110 genetically confirmed USH2a patients was evaluated. This study 
was performed to evaluate the severity and progression of hearing impairment and to 
identify potential genotype-phenotype correlations.
Box 7. Truncating versus nontruncating mutations
As a consequence of the large amount of unique disease causing mutations in USH2A (>500; LOVD-USHbases 
57), the effect of only a handful mutations has been studied at a molecular level. Mutations can be differentiat-
ed into predicted protein truncating or nontruncating mutations. These predictions are made by the current 
knowledge of the effect of certain mutations on protein translation and by bio-informatic prediction algo-
rithms. Truncating mutations result in a shortened protein or an absent protein as a consequence of Non-
sense Mediated mRNA Decay (NMD).58 In contrast, nontruncating mutations presumably lead to (misfolded) 
proteins with reduced function. This might have advantages (e.g. residual function) and disadvantages (e.g. 
unwanted interactions with other proteins and toxic aggregation and accumulation of misfolded proteins).
The visual impairment caused by RP is known to be progressive. Initially, the degen-
eration of rods leads to a gradual loss of peripheral vision resulting in tunnel vision.59 
This is followed by degeneration of cones in the central retina leading to a decrease in 
visual acuity. Eventually, the majority of USH2a patients become legally blind around 
the age of 54. In chapter 2.2 of this thesis, the onset and progression of visual symptoms 
in patients with two pathogenic mutations in USH2A was evaluated. In this chapter, an-
other disorder associated with mutations in USH2A is introduced: nonsyndromic retinitis 
pigmentosa (nsRP). USH2A-associated nsRP presents without congenital hearing impair-
ment. In chapter 2.2 the onset and progression of visual symptoms were compared 
between patients with USH2a and patients with USH2A-associated nsRP. In chapter 2.3, 
the audiological profile of USH2A-associated nsRP patients was studied in detail. This is 
considered important to properly differentiate the clinical presentation of patients with 
USH2a versus USH2A-associated nsRP.
tHe world after tHe diagnosis of usH2a
Full participation in family and society is considered to be very important by all patients 
with Usher syndrome. They demonstrate an enormous ambition to contribute to family, 
18
working life and research (for examples see the Dutch websites http://www.ushersynd-
room.nl and http://www.swodb.nl ). To enable this, proper hearing rehabilitation is of 
utmost importance. As a consequence of their congenital hearing impairment, patients 
with USH2a usually use bilateral hearing aids from a young age.12 The most basic prin-
ciple of hearing aids is to receive sounds through a microphone, to amplify the sound 
and to present it to the patient through a small speaker placed in the external ear canal. 
Today’s sophisticated hearing aids, however, offer multiple complex settings combined 
in programs in which the incoming sounds can be manipulated. Owing to these com-
plex settings and programs, fitting procedures are prolonged to find the best setting, 
especially for patients with multiple impairments. Difficulties with hearing aid fitting 
were described by two patients with Usher syndrome, Gracia Tham and Ivonne Bressers. 
In their report “Extremely soft and yet incredibly close”, patients and care professionals 
were interviewed to investigate fitting procedures and difficulties with hearing aids in 
patients with Usher syndrome.60 One of the most important reported difficulties was 
the inability to localise sounds and to estimate the distance of the sound source while 
using hearing aids. In chapter 3.1 of this thesis, patients with USH2a were fitted with 
new hearing aids after which sound localisation and speech perception performances of 
different hearing aid programs were compared. The programs used different algorithms 
to amplify the incoming sounds and therefore affected normal sound localisation cues 
in different ways (see Box 8). 
Box 8. Sound localisation
In humans, sound localisation in the horizontal plane is mainly achieved by using two sound cues. For the 
lower frequencies (<1.5 kHz), the difference in sound arrival at both ears, the Interaural Time Difference 
is used. To localise higher frequency sounds (> 3 kHz), humans use the difference in sound level between 
both ears, the Interaural Level Difference.61 
In a select group of USH2a patients, severe progression eventually results in severe to 
profound hearing impairment for which hearing aids provide insufficient rehabilita-
tion. In these cases, cochlear implantation is the designated choice of rehabilitation. A 
cochlear implant is a semi-implantable technical device which receives sound through 
a microphone, encodes the sound with a speech processor and stimulates the auditory 
nerve directly through a set of electrodes implanted in the cochlea. At the Radboud uni-
versity medical centre in Nijmegen, cochlear implants have been implanted in children 
and in adults with different types of Usher syndrome. The performances after cochlear 
implantation have been described for patients with deafblindness and in particular 
two other types of Usher syndrome, Usher syndrome type I and III. In chapter 3.2 of 
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this thesis, the performance and quality of life of patients with USH2a after cochlear 
implantation is evaluated.
Concluding this introduction, the aims of this thesis were
1. To extensively evaluate the hearing and visual phenotype in patients with USH2a 
and USH2A-associated nsRP. (chapters 2.1, 2.2 and 2.3) 
2. To identify genotype-phenotype correlations in patients with USH2a and USH2A-
associated nsRP. (chapters 2.1, 2.2 and 2.3)
3. To optimize hearing aid fitting in patients with USH2a for a better performance in 
communication and sound localisation (chapter 3.1)
4. To report the performances of patients with USH2a after cochlear implantation. 
(chapter 3.2)
20
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Chapter 2
Genotype–phenotype correlations 
in patients with mutations in USH2A

Chapter 2.1
A combination of two truncating 
mutations in USH2A causes more 
severe and progressive hearing 
impairment in Usher syndrome 
type IIa
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aBstraCt
Objectives: Usher syndrome is an inherited disorder that is characterized by hearing 
impairment (HI), retinitis pigmentosa, and in some cases vestibular dysfunction. Usher 
syndrome type IIa is caused by mutations in USH2A. HI in these patients is highly hetero-
geneous and the present study evaluates the effects of different types of USH2A muta-
tions on the audiometric phenotype. Data from two large centres of expertise on Usher 
syndrome in the Netherlands and Sweden were combined in order to create a large 
combined sample of patients to identify possible genotype-phenotype correlations.
Design and methods: A retrospective study on HI in 110 patients (65 Dutch and 45 Swed-
ish) genetically diagnosed with Usher syndrome type IIa. We used methods especially 
designed for characterizing and testing differences in audiological phenotype between 
patient subgroups. These methods included Age Related Typical Audiograms (ARTA) 
and a method to evaluate the difference in the degree of HI developed throughout life 
between subgroups.
Results: Cross-sectional linear regression analysis of last-visit audiograms for the best 
hearing ear demonstrated a gradual decline of hearing over decades. The congenital 
level of HI was in the range of 16 - 33 dB at 0.25 - 0.5 kHz, and in the range of 51 - 60 dB 
at 1 - 8 kHz. The annual threshold deterioration was in the range of 0.4 - 0.5 dB/year at 
0.25 - 2 kHz and in the range of 0.7 - 0.8 dB/year at 4 - 8 kHz. Patients with two truncating 
mutations, including homozygotes for the common c.2299delG mutation, developed 
significantly more severe HI throughout life than patients with one truncating muta-
tion combined with one nontruncating mutation, and patients with two nontruncating 
mutations.
Conclusions: The results have direct implications for patient counselling in terms of 
prognosis of hearing and may serve as baseline measures for future (genetic) therapeu-
tic interventions.
Published as: Hartel, B.P., Lofgren, M., Huygen, P.L., Guchelaar, I., Lo-A-Njoe - Kort, N., 
Sadeghi, A.M., van Wijk, E., Tranebjaerg, L., Kremer, H., Kimberling, W.J., Cremers, C.W., 
Moller, C., & Pennings, R.J. (2016). A Combination of Two Truncating Mutations in USH2A 
causes more Severe and Progressive Hearing Impairment in Usher syndrome type IIa. 
Hear Res. doi: 10.1016/j.heares.2016.06.008
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introduCtion
Usher syndrome is an autosomal recessively inherited disorder that is characterized 
by sensorineural hearing impairment (HI), retinitis pigmentosa (RP), and in some cases 
vestibular dysfunction. RP is a progressive retinal degenerative disease that eventually 
leads to functional blindness. It first presents with nightblindness and, as the disease 
progresses, deterioration in both visual field size and visual acuity.1 Usher syndrome 
is clinically and genetically heterogeneous and the leading cause of hereditary deaf-
blindness. The estimated prevalence ranges from 4.4 to 6.2 per 100,000 inhabitants.2-4
Three types of Usher syndrome can be distinguished. These types are differentiated 
by degree and progression of HI, onset of RP, and the presence or absence of vestibular 
abnormalities. Usher syndrome type I (OMIM276900) is characterized by congenital, se-
vere to profound HI, pre-pubertal onset of RP, and vestibular areflexia. Usher syndrome 
type II (OMIM276901) presents with congenital, moderate to severe HI, RP that first 
manifests in the second decade of life and in rare cases vestibular abnormalities. Finally, 
Usher syndrome type III (OMIM276903) has a variable onset and degree of HI, RP, and 
vestibular abnormalities.5 In addition, HI in Usher syndrome type III has been reported 
to be progressive.6, 7
Further classification is based on genetic aetiology. To date, 14 loci and 11 genes have 
been identified to be associated with Usher syndrome.8 Three genes have been associ-
ated with Usher syndrome type II: USH2A, GPR98, and DFNB31.9-13
Usher syndrome type II is the most common type of Usher syndrome accounting for 
more than half of the patients.4 About 72-87% of Usher syndrome type II patients carry 
mutations in USH2A leading to Usher syndrome type IIa (USH2a).14-16 This gene encodes 
a transmembrane protein called usherin (OMIM608400). In the cochlea, usherin is pres-
ent in the developing hair bundles and the synapse of hair cells, as well as in the spiral 
ganglion cells.13, 17, 18 In the retina, usherin has been localised in the periciliary membrane 
complex of mouse, frog, and primate photoreceptors.17, 19-21 Apart from causing USH2a, 
mutations in USH2A can also lead to nonsyndromic autosomal recessively inherited RP.22
Mutations in USH2A can generally be distinguished into two types. The first group of 
mutations is collectively named protein truncating mutations. The second group of 
mutations is called protein nontruncating mutations, for example missense mutations.
The most common mutation in USH2A is c.2299delG, p.(Glu767Serfs*21) with a carrier 
allele frequency of 16-44%.10, 23 This truncating mutation causes a frameshift at codon 
767 resulting in a premature termination codon presumably leading to nonsense-
mediated mRNA decay.24 Recently, it was demonstrated that this frameshift mutation 
most probably results in the combined skipping of exon 12 and 13.25
30
Previous studies have evaluated the degree and progression of HI in relatively small 
groups of subjects with USH2a. The audiogram configuration in patients with USH2a is 
down-sloping with mild-to-moderate HI in the low-mid frequencies and moderate-to-
severe HI in the higher frequencies. Several studies reported a progressive type of HI.26-29 
To the best of our knowledge, no previous studies have analysed the audiometric data 
of more than 100 patients carrying two pathogenic mutations in USH2A. Since the iden-
tification of USH2A, and the identification of the transcript encoding the long isoform of 
usherin, many mutations in USH2A have been identified.10, 11, 30 As previously suggested, 
the observed variation in the USH2a audiometric phenotype could in part be the result 
of different mutations in USH2A.31, 32 Previous studies have tried to explain the observed 
variation by comparing audiometric phenotypes of patients carrying specific mutations 
or mutation combinations.
This study presents the overall audiometric phenotype of 110 genotyped USH2a 
patients. A comparison was made between the phenotypes of four subgroups with 
different combinations of types of mutations: two truncating mutations, including a 
separate subgroup of patients that are homozygous for the common c.2299delG muta-
tion, the combination of a truncating mutation and a nontruncating mutation, and two 
nontruncating mutations. Knowledge of these audiometric phenotypes is important 
for counselling and for the establishment of baseline characteristics for future genetic 
therapeutic approaches.
Patients and MetHods
Patients
All patients with USH2a were extracted from databases of the Swedish and Dutch exper-
tise centres on Usher syndrome. A total number of 208 patients were identified (Swed-
ish: 87 and Dutch: 121). All patients were clinically diagnosed with Usher syndrome type 
II based on medical history, ophthalmologic, and audiovestibular examinations. These 
examinations were performed in various clinical settings in Sweden and the Nether-
lands over the past decades. Patients without any mutation identified (n=23), only one 
mutation identified (n=50), more than two mutations identified (n=5), and missing 
audiological data (n=13) were excluded from the study. In revision, seven additional 
patients (six Swedish, two men and four women, and one Dutch woman) were excluded 
because it was questioned whether they had two pathogenic USH2A mutations. After 
exclusion, 110 USH2a patients with two pathogenic mutations in USH2A were evaluated. 
These patients, 54 men and 56 women, had a mean age of 44 years (range 14-70).
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audiometric evaluation
Pure tone air and bone conduction thresholds for sound frequencies ranging from 0.25 
to 8 kHz were assessed according to common clinical standards. Bone conduction thresh-
olds were only measured to exclude middle ear problems. The patients’ demographic, 
clinical, audiological, and genetic data were obtained from the respective databases at 
the University Hospital Orebro in Sweden (n=45) and the Radboud university medical 
centre in Nijmegen, the Netherlands (n=65). Some of the presented patients have been 
included in previous reports from both centres.27-29, 33-35
data analysis
The last audiogram for the best hearing ear, obtained at an age of between 10 and 70 
years, was used for cross-sectional analyses. The lower age limit was used because data 
often showed inconsistencies in audiometric evaluations under the age of 10 years. An 
upper age limit of 70 years was used because many of the thresholds that were mea-
sured at the higher frequencies appeared to be out of scale above this age.
Cross-sectional linear regression analyses were performed, for each frequency 
separately, to evaluate the congenital HI level (threshold intercept), the progression, 
i.e. slope or Annual Threshold Deterioration, (ATD, in dB/year), as well as the degree of 
HI developed throughout life in these patients. Residuals around the regression lines 
were inspected and it was tested whether they showed a normal distribution in first 
approximation by applying the Kolmogorov-Smirnov (KS) test. The congenital level of 
HI was considered to be significant if the 95% confidence interval (CI) for the threshold 
intercept did not include 0 dB HL. Progression was considered to be significant if the 
95% CI for the positive slope (ATD) did not include 0 dB/ year.
Patient subgroups for analysing genotype-phenotype correlations
To determine pathogenicity of the truncating mutations the Leiden Open Variant Data-
base was consulted. If a truncating mutation was not previously described, the Exome 
Aggregation Consortium (ExAC) database was consulted for the percentage of alleles 
with the newly found mutation in normal hearing patients. For all missense mutations, 
in addition to the above described method, the Combined Annotation Dependent 
Depletion (CADD) score was used. All nontruncating variants exceeded a CADD score 
of 15, the score suggested by the authors to identify predicted pathogenic mutations. 
The present 110 patients were divided into three subgroups by their combination of mu-
tation types to evaluate genotype-phenotype correlations. The first subgroup, designated 
as 2T, comprised 58 patients with two truncating mutations. The second subgroup, 1T, con-
sisted of 31 patients with one truncating and one nontruncating mutation. Finally, subgroup 
2nT consisted of 21 patients with two nontruncating mutations. A separate subgroup of 15 
patients with homozygous c.2299delG mutations was selected from subgroup 2T.
32
age related typical audiograms (arta)
The results of the cross-sectional linear regression analyses on the whole group of 
patients and the subgroups 2T, 1T and 2nT, as well as the separate subgroup of homo-
zygous c.2299delG patients were used to calculate the ATD values and to construct Age 
Related Typical Audiograms (ARTA) as described previously.36
Comparing Hi between mutation types
Pairwise testing focused on the level of HI developed throughout life, while controlling 
for age. This test was applied to pairwise comparisons between the subgroups 2T, 1T 
and 2nT, as well as between the subgroup of patients with homozygous c.2299delG 
mutations, and either of the subgroups 1T and 2nT. The procedure is illustrated in 
Supplemental Figure SF.1. For each audio frequency, i.e. pair of regression lines, a mean 
regression line was constructed. The intercept and slope of this line represented the 
mean value of the intercepts and slopes of the regression lines pertaining to the respec-
tive subgroups. The calculated mean intercept and slope values of this line were used to 
generate forced residuals in a “nonlinear” fitting procedure, using the equation Y = slope. 
X + intercept, with threshold Y (dB HL) and age X (years). For the validity of this method, 
it was first checked for each separate subgroup that the forced residuals passed the 
KS test, that linear regression of the residuals on age did not show any significant cor-
relation, and that one-way analysis of variance (ANOVA) between the residuals at each 
frequency did not disclose any significant differences. Then a paired Student’s t-test with 
6 frequency pairs was performed between the residuals in each subgroup. The outcome 
of this test included the across-frequencies mean difference in threshold between the 
subgroups, with its 95% CI.
Apart from testing the degree of HI developed throughout life between subgroups, 
the values obtained for the intercepts and slopes for each frequency were compared 
between the subgroups 2T, 1T and 2nT by applying one-way ANOVA, followed by 
Tukey’s Multiple Comparison test. We wished to make pairwise comparisons also in a 
second set of subgroups with the subgroup 2T replaced by the subgroup of homozy-
gous c.2299delG patients. Applying again one-way ANOVAs and Tukey’s tests would 
have caused duplicate testing of the same pair of subgroups 1T and 2nT in the context 
of different data sets. We therefore applied Student’s t-test (unpaired) to test on the 
difference in intercept or slope only in pairwise comparisons between the subgroup of 
c.2299delG homozygotes and either subgroup 1T or 2nT. Welch’s correction was applied 
if Bartlett’s test detected unequal variances.
The significant differences found were labelled as substantial, in the sense of being 
clinically relevant, if the 95% CI of the difference for intercept was sufficiently remote 
(>5 dB) from zero and/or the 95% CI of the difference for slope was sufficiently remote 
(>0.20 dB/year) from zero.
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general and simultaneous testing
A general significance level of P=0.05 was applied in all separate tests. Binomial distri-
bution statistics were generally used for simultaneous assessment of any pairwise test 
items over all audio frequencies. Simultaneous significance was accepted if such differ-
ences were significant at two or more frequencies (P<0.05 tail probability in the binomial 
distribution with N=6, p=0.05, q=0.95). All analyses in this study were performed using 
Prism 5.03 software (GraphPad, San Diego, CA, USA).
results
audiometric evaluation
Cross-sectional analyses of the pure tone threshold data of all patients were performed 
(Figure 1). The panel for each frequency in this figure includes the linear regression 
line with the fitted equation. The residuals from the linear regression line passed the 
normality (KS) test. The threshold intercepts were significantly positive at all frequencies, 
which underlines the known congenital component of HI in patients with USH2a. The 
congenital level of HI was in the range of 16-33 dB at 0.25-0.5 kHz, and of 51-60 dB at 1-8 
kHz. Progression was in the range of 0.4-0.5 dB/year at 0.25-2 kHz and of 0.7-0.8 dB/year 
at 4-8 kHz; it was significant at all frequencies.
arta
For each frequency, thresholds predicted by the linear regression line for the fixed ages 
of 10, 20, 30, 40, 50, 60, and 70 years were used to construct the ARTA shown in Figure 
2. The ATD values are reflected in the ARTA by the distance between the consecutive 
thresholds at each frequency depicted per decade. This distance (in dB) equals the 
deterioration in 10 years’ time, i.e. 10 times the ATD, which was approximately 4-5 dB at 
0.25-2 kHz, and 7-8 dB at 4-8 kHz.
USH2A mutations
Table 1 shows all the different pathogenic USH2A mutations (n=48) that were identified 
in the present combined patient sample. Thirty-two of these mutations were predicted 
to be truncating (18 nonsense mutations, 12 deletions or insertions and two intronic 
mutations predicted to affect splicing), and 16 mutations were predicted to be nontrun-
cating. A total number of 48 c.2299delG alleles were identified, which represent 21.8% 
of all alleles. A total of 15 patients (14%) were homozygous and 18 (16%) heterozygous 
for the c.2299delG mutation.
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figure 1. Cross-sectional analyses of best-ear air conduction thresholds (dB HL) in 110 patients with Usher 
syndrome type IIa. Each data point represents one patient’s threshold. Panel inset: the linear regression 
equation Y = slope. X + intercept, with Y for threshold (dB HL) and X for age (years).
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Comparing Hi between mutation types
Similar cross-sectional regression analyses as shown in Figure 1 were performed on the 
previously described subgroups of 2T, 1T, 2nT and homozygous c.2299delG patients; the 
obtained linear regression parameter values were used to construct four ARTA (Figure 3).
Inspection of the threshold lines in these ARTA gives the impression that the level of HI 
developed throughout life was systematically higher in either the 2T or the homozygous 
c.2299delG subgroup as compared with the 2nT or the 1T subgroup. The results of for-
mal tests on the level of HI developed throughout life are listed in Table 2. The patients 
in either subgroup 2T or in the subgroup of homozygous c.2299delG developed a sig-
nificantly higher level of HI throughout life compared to patients in either subgroup 1T 
or 2nT. All the corresponding significant across-frequencies mean differences between 
these subgroups were about 10-11 dB HL. There was no significant difference in the level 
of HI developed throughout life between the subgroups 1T and 2nT.
Pairwise comparisons focusing on progression and the level of congenital Hi
We wished to find out whether the detected significant differences in the level of HI 
developed throughout life were associated primarily with a difference in the level of 
congenital HI (intercept of regression line) or in progression (slope of regression line). 
The ARTA depicted in Figure 3 seem to suggest more progression in HI in either the 2T 
or the homozygous c.2299delG subgroup as compared with the 2nT or the 1T subgroup 
at most frequencies. This appears from comparing the distances between the threshold 
lines in the separate ARTA for the subgroups involved. Table 3 lists the results of Tukey’s 
USH2a (n=110)
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figure 2. Age Related Typical Audiograms (ARTA) for the total Usher syndrome type IIa (USH2a) group 
(n=110). Italics indicate age (years).
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table 1. Spectrum of USH2A mutations in this study
nucleotide change Predicted effect no. (%) of alleles loVd exaC (%)
a. truncating mutations
Nonsense mutations
c.187C>T p.(Arg63*) 7 (3.2) P
c.779T>G p.(Leu260*) 3 (1.4) P
c.949C>A p.(Tyr318Cysfs*17) 3 (1.4) UV4
c.1227G>A p.(Trp409*) 12 (5.5) P
c.1876C>T p.(Arg626*) 4 (1.8) P
c.2242C>T p.(Gln748*) 1 (0.5) P
c.2983C>T p.(Gln995*) 4 (1.8) P
c.3932C>A p.(Ser1311*) 3 (1.4) P
c.4405C>T p.(Gln1469*) 1 (0.5) P
c.7931G>A p.(Trp2644*) 2 (0.9) P
c.8079G>A p.(Trp2693*) 2 (0.9) New 0
c.8557A>T p.(Arg2853*) 3 (1.4) P
c.10450C>T p.(Arg3484*) 4 (1.8) P
c.10525A>T p.(Lys3509*) 3 (1.4) New 0
c.10684G>T p.(Glu3562*) 1 (0.5) P
c.11864G>A p.(Trp3955*) 9 (4.1) P
c.13822C>T p.(Arg4608*) 2 (0.9) P
c.14131C>T p.(Gln4711*) 1 (0.5) P
Deletions and insertions
c.238_239insCGTA p.(Thr80Argfs*29) 2 (0.9) P
c.545_546delAA p.(Lys182Argfs*33) 1 (0.5) P
c.920_923dup p.(His308Serfs*16) 3 (1.4) P
c.2299delG p.(Glu767Serfs*21) 48 (21.8) P
c.3558delT p.(Cys1186Trpfs*51) 1 (0.5) P
c.4628-30487_6325+8822del p.(Gly1542_Leu2110delinsAsp) 6 (2.7) P
c.4773del p.(Val1592*) 1 (0.5) New 0
c.7121-8313_11048-962delins12 del Ex 38-56 10 (4.5) New 0
c.8954delG p.(Gly2985Alafs*3) 2 (0.9) P
c.9372-?_9570+? del Ex 48 2 (0.9) New 0
c.11875_11876delCA p.(Gln3959Asnfs*53) 2 (0.9) P
c.13207-13208delGG p.(Gly4403Profs*15) 1 (0.5) P
nucleotide change iVs position no. (%) of alleles loVd exaC (%)
B. intronic mutations
c.8682-9A>G IVS43-9A>G 2 (0.9) UV2 0.009
c.15053-2A>T p.(?) 1 (0.5) New 0
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tests following one-way ANOVAs in pairwise comparisons focussing on subgroup 2T 
versus 1T.
As compared to subgroup 1T, subgroup 2T showed a significantly higher level of con-
genital HI at 4-8 kHz, which was only substantial at 4 kHz. The congenital level of HI in 
subgroup 2T was significantly lower than in subgroup 1T at 0.5 kHz, but the difference 
was not substantial (Table 3).
Subgroup 2T also showed significantly more progression than subgroup 1T at 0.25-2 
kHz, which was substantial at 0.25-0.5 kHz (Table 3 and Supplemental Figure SF.2A, B). It 
seems that the higher level of HI developed throughout life by subgroup 2T as compared 
to subgroup 1T was predominantly associated with a higher level of congenital HI at the 
higher frequencies and more progression at the lower frequencies.
As compared to subgroup 2nT, subgroup 2T showed a significantly higher level of 
congenital HI at 0.25-4 kHz, which was substantial at 0.25-0.5, and 2 kHz (Supplemental 
Figure SF.3A, B and Supplemental Table ST1.A).
Subgroup 2T showed significantly more progression than subgroup 2nT only at 8 
kHz, which was almost substantial (Supplemental Figure SF.3C, D and Supplemental 
Table ST1.A). Apart from that, subgroup 2T showed significantly less progression than 
table 1. Spectrum of USH2A mutations in this study (continued)
nucleotide change Predicted effect no. (%) of alleles loVd exaC (%) Cadd
C. nontruncating mutations
c.653T>A p.(Val218Glu) 1 (0.5) UV3 0.004 29.7
c.802G>A p.(Gly268Arg) 1 (0.5) UV3 0.001 34.0
c.1036A>C p.(Ans346His) 16 (7.3) P 0.010 26.6
c.1256G>T p.(Cys419Phe) 25 (11.4) P 0.005 34.0
c.1606T>C p.(Cys536Arg) 11 (5.0) P 0.001 25.3
c.2276G>T p.(Cys759Phe) 3 (1.4) P 0.078 33.0
c.4810G>C p.(Asp1604His) 1 (0.5) UV3 0 26.9
c.5018T>C p.(Leu1673Pro) 2 (0.9) New 0 31.0
c.6722C>T p.(Pro2241Leu) 1 (0.5) New 0 29.0
c.9815C>T p.(Pro3272Leu) 2 (0.9) UV3 0.003 35.0
c.10421A>G p.(Tyr3474Cys) 1 (0.5) New 0.001 27.5
c.10561T>C p.(Trp3521Arg) 3 (1.4) UV3 0.002 26.2
c.11819A>C p.(Tyr3940Ser) 2 (0.9) New 0 26.5
c.12695C>G p.(Pro4232Arg) 1 (0.5) UV3 0.001 27.2
c.13262T>C p.(Leu4421Pro) 2 (0.9) New 0 25.6
c.14408T>C p.(Ile4808Thr) 1 (0.5) New 0 24.0
total number of alleles 220 (100)
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table 2. Results (P value and across-frequencies mean difference with 95% CI) of the paired Student’s t test 
for pairwise comparison of the level of HI developed throughout life between the subgroups as indicated. 
An example of such a test is shown in figure 1.
subgroups P value Mean difference (dB) 95%Ci (dB) frequency summary
2T vs. 1T 0.00018 10.39 7.67 to 13.10 Hi(2t) > Hi(1t)
2T vs. 2nT 5.81 × 10-5 9.70 7.70 to 11.69 Hi(2t) > Hi(2nt)
1T vs. 2nT 0.71 0.55 -3.06 to 4.16 HI(1T) = HI(2nT)
c.2299delG.Hz vs. 1T 0.0023 10.71 8.01 to 13.42 Hi(c.2299delg.Hz) > Hi(1t)
c.2299delG.Hz vs.2nT 0.00074 9.51 6.17 to 12.84 Hi(c.2299delg.Hz) > Hi(2nt)
Abbreviations: 2T, two truncating mutations; 1T, one truncating mutation and one non-truncating mu-
tation; 2nT, two nontruncating mutations; c.2299delG.Hz, subgroup of 2T patients with homozygous 
c.2299delG mutations, HI=Hearing Impairment, kHz=kilohertz; bold=significant (P < 0.05).
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figure 3. ARTA for the subgroups of patients with two truncating mutations (2T), two nontruncating muta-
tions (2nT), one truncating mutation in combination with a missense mutation (1T), and for the subgroup 
of patients with homozygous c.2299delG mutations. Italics indicate age (years).
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subgroup 2nT at 2 kHz. The difference was not substantial. Given the isolated finding of a 
significant difference (in progression) at a specific frequency (one out of six frequencies), 
this finding was not simultaneously significant (Methods).
It seems that the higher level of HI developed throughout life by subgroup 2T as 
compared to subgroup 2nT was primarily associated with a higher level of congenital 
HI at most frequencies.
As compared to subgroup 2nT, subgroup 1T showed a significantly higher level of 
congenital HI than subgroup 2nT at 0.25-2 kHz, which was also substantial at 0.25-0.5 
kHz. It also showed a significantly, but not substantially, lower level of congenital HI at 
4-8 kHz. Furthermore, subgroup 1T showed significantly less progression at 0.25, 0.5 
and 2 kHz; the difference was substantial at 0.25-0.5 kHz. It also showed significantly 
more progression at 8 kHz, which was neither substantial nor simultaneously significant 
(Supplemental Table ST1.B).
There is no doubt that the subgroups 1T and 2nT developed fairly similar mean levels 
of HI throughout life (Table 2). However, the contributions to that level of HI made 
by the congenital level of HI and by postnatal progression were quite different, and 
counteractive, in different frequency regions. At all frequencies, except 4-8 kHz, the 1T 
table 3. 2T versus 1T (ANOVA with Tukey’s test)
Results of Tukey’s tests following one-way ANOVAs on intercept and slope for the pairwise comparison of 
subgroups 2T and 1T. Entries in column Summary significant were only made for significant results. Bold 
print in bottom rows indicates relative frequencies that are simultaneously significant (2/6 or higher) ac-
cording to binomial distribution statistics.
frequency 
(kHz)
Δ(intercept) (dB) Δ(slope) (dB/year)
Δ P value 95%Ci summary Δ P value 95%Ci summary
0.25 -3.78 P > 0.05 -7.64 to 0.08 0.31 P < 0.001 0.23 to 0.39 2T > 1T
0.5 -6.90 P < 0.001 -10.84 to -2.96 2T < 1T 0.38 P < 0.001 0.29 to 0.46 2T > 1T
1 2.81 P > 0.05 -1.42 to 7.04 0.12 P < 0.01 0.03 to 0.22 2T > 1T
2 3.22 P > 0.05 -0.97 to 7.41 0.16 P < 0.001 0.07 to 0.25 2T > 1T
4 13.94 P < 0.001 9.42 to 18.46 2T > 1T 0.03 P > 0.05 -0.06 to 0.13
8 8.11 P < 0.001 3.19 to 13.03 2T > 1T 0.01 P > 0.05 -0.10 to 0.12
Summary 
significant
2T < 1T in 1/6
0.5 kHz
2t > 1t in 4/6
0.25-2 kHz
2t > 1t in 2/6
4-8 kHz
Summary 
substantial
2T > 1T in 1/6
4 kHz
2T > 1T in 2/6
0.25-0.5 kHz
Abbreviations: 2T, two truncating mutations; 1T, one truncating mutation and one non-truncating muta-
tion, Δ, difference in slope or intercept.
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patients initially showed a higher level of HI than the 2nT patients, but later in life they 
also developed a lower degree of progression at most of these frequencies. At 8 kHz, the 
opposite was true: the 1T patients initially had a lower level of HI than the 2nT patients, 
but later in life they developed relatively more progression.
disCussion
This study presents detailed audiometric analyses of 110 patients with a clinical and 
genetic diagnosis of USH2a. This is the most extensive audiological study of genotyped 
USH2a patients, so far. Cross-sectional linear regression analyses demonstrated a signifi-
cant level of congenital HI, that ranged from ~15 dB at the lower frequencies to ~60 dB 
at the higher frequencies, as well as significantly progressive HI with an ATD that ranged 
from ~0.4 dB/year at the lower frequencies to ~7 dB/year at the higher frequencies 
(Figure 1). The HI developed throughout life in patients with two truncating mutations 
in USH2A, including patients with homozygous c.2299delG mutations, was significantly 
more severe compared to HI in patients with a combination of one truncating muta-
tion and one nontruncating mutation, as well as compared to that of patients with two 
nontruncating mutations in this gene. 
Smith et al. (1994) described a set of clinical criteria to be used for the diagnosis of Usher 
syndrome type I and Usher syndrome type II.5 Usher syndrome type III had previously 
been proposed as a separate type by Davenport and Omenn (1977) but was not yet fully 
defined in 1994.37 As a minimum diagnostic criterion for Usher syndrome type II, “no 
progression” of HI was proposed. Progression of HI was described to possibly differenti-
ate between Usher syndrome type II and Usher syndrome type III. At that time the first 
loci were identified for Usher syndrome, but it was not until 1995 that the first Usher 
syndrome type I gene (MYO7A) was identified.38 In 1998, Eudy et al. identified USH2A 
as the first gene for Usher syndrome type II and since then more genes associated with 
Usher syndrome have been discovered (see Introduction). With the current genotyping 
techniques, phenotypic features, such as progression of HI, became less important for 
establishing a diagnosis. An example of this was described by Pennings et al. (2003) 
who stated that Usher syndrome type III can mimic Usher syndrome type I, as well as 
type II.39 However, knowledge of HI characteristics, including progression, is of utmost 
importance for patient counselling and for establishing baseline characteristics for the 
evaluation of future genetic therapeutics.
In their report, Pennings et al. (2003) included ARTA based on 36 USH2a patients with at 
least one known mutation in USH2A.40 They found a downsloping audiogram configura-
tion with a mean threshold slope of -9 dB per octave and progression by 0.5 dB per 
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year. After comparison with the ISO 7029 norms, progression only persisted at 0.25-0.5 
kHz.27 In 2004, Sadeghi et al. reported on audiological thresholds of 80 USH2a patients 
with one or two mutations in USH2A.28 They presented decade-specific progression rates 
with a peak progression in the fifth decade of almost 10 dB per 10 years covering the 
frequencies 0.5-2 kHz. Compared to Sadeghi et al. (2004), our data suggest a more linear 
progression, as shown in Figure 1. This difference might be explained by the difference 
in patient sample. In this study, all patients carried two pathogenic mutations whereas in 
the study of Sadeghi et al. (2004) patients with one mutation in USH2A or linkage analy-
ses were also included. This might have created a phenotypically more heterogeneous 
sample. Another explanation might be the difference in analyses. Sadeghi et al. (2004) 
constructed decade audiograms using more than one audiogram from their patients, 
whereas this study only used one (the last) audio-gram from each patient to construct 
the ARTA. Several of the patients from the previously mentioned studies were included 
in this study.16, 27, 28, 40, 41 In the present study, in contrast to these previous studies, all 
patients carry two mutations in USH2A.
To investigate genotype-phenotype correlations, the present study focussed on the pre-
dicted truncating or nontruncating effect of mutations on usherin, the USH2A protein 
product. Predicted truncating mutations lead to premature termination of translation 
and result in a truncated or even absent protein as a result of nonsense-mediated mRNA 
decay. The nearly complete absence of usherin might result in a more severe phenotype 
compared to an altered protein resulting from a nontruncating missense mutation. Such 
a difference is supported by previous findings in patients with mutations in CDH23, the 
gene coding for cadherin 23. Truncating mutations usually lead to Usher syndrome type 
Id, whereas two alleles with missense mutations lead to DFNB12, a nonsyndromic type 
of recessively inherited sensorineural hearing.42, 43
Using the method illustrated in Supplemental Figure SF.1, it appeared that patients 
carrying two truncating mutations (subgroup 2T or the subgroup of c.2299delG homo-
zygotes) developed significantly more HI throughout life than patients with only one 
truncating mutation (1T) or patients with no truncating mutations (2nT). The across-
frequencies mean difference was 10-11 dB (Table 2). This might seem to be a minor 
difference, however, focussing on separate frequencies disclosed incidental differences 
between subgroups as great as ~20 dB (data not shown), which are certainly clinically rel-
evant. Such incidental differences were associated with pairwise comparisons between 
ARTA pertaining to the oldest patients at either the lowest frequencies, 0.25-0.5 kHz, 
(subgroups 2T and 1T, as well as subgroups c.2299delG.Hz and 2nT), or at the highest 
frequency, 8 kHz (subgroups 2T and 2nT, as well as subgroups c.2299delG.Hz and 2nT). In 
42
addition, a similar significant, and substantial, difference in the congenital level of HI was 
found at 0.25-0.5 kHz between the subgroups 1T and 2nT (Supplemental Table ST1.B).
Almost all pairwise comparisons were associated with a significant across-frequency 
mean difference in the level of HI developed throughout life (Table 2). Fairly balanced 
contributions to that difference were made by two components, the difference in the 
level of congenital HI (intercept) and the difference in progression incorporated in the 
difference in threshold increase, i.e. ∆(ATD*age). In the comparison between 2T versus 1T 
and 2T versus 2nT, the major contributions by these two components were co-operative. 
However, in the two comparisons c.2299delG versus 1T, and c.2299delG versus 2nT, the 
two components made mainly counteractive contributions Supplemental Table ST.1. In 
the end, the predominant positive contribution associated with progression accounted 
for the significant difference in the level of HI developed throughout life (Table 2).
Although it seems clinically relevant to be able to conclude that the patients in 
subgroups 1T and 2nT showed similar features in terms of the level of HI developed 
throughout life, it is intriguing to see that there were significant differences in terms of 
the congenital level of HI and the degree of progression. We have no ready explanation 
in terms of genotypic differences. However, such an explanation might be found in the 
heterogeneous compositions of the patient subgroups in terms of mutation combina-
tions (Supplemental Table ST.2). In a separate study, we are attempting to pinpoint sig-
nificant phenotypic differences between different mutation combinations by analysing 
extensive, individual, longitudinal data.
In conclusion, it can be stated that there is variability in the phenotypic presentation in 
USH2a. Overall, HI is congenital, progressive and typically presents with downsloping 
audiograms. Patients with two truncating mutations in USH2A show more severe and 
progressive sensorineural HI compared to USH2a patients without two truncating muta-
tions. The exact mechanisms behind these phenotypic variations are not yet elucidated 
but we speculate that a complete lack of usherin due to two truncating mutations has 
a more negative effect on hearing physiology compared to the presence of an altered 
form of usherin in cases with one or two nontruncating mutations. This does not exclude 
possible effects of environmental factors, epigenetics or genetic modifiers. Further 
molecular studies are needed to clarify the function of usherin and to unfold the patho-
physiology of hearing impairment caused by specific USH2A mutations.
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supplemental figure sf.1 (A-E). Plots explaining pairwise testing on the HI level developed throughout 
life between subgroups (2T and 1T). (A-C), Combined regression plots for both subgroups at 4 kHz, as an ex-
ample, with a common dividing line (A), and plots of the residuals for both subgroups (B-C) forced around 
that line. (D-E), Outline of the procedure relating to all frequencies. (A), The (dotted) dividing line is the 
mean regression line, i.e., its slope and intercept each represent the mean value of the slopes and the in-
tercepts of the regression lines pertaining to the respective subgroups 2T (black continuous line and open 
squares) and 1T (grey dashed line and open circles). (B-C), Residuals from forced linear regression of the 
thresholds at 4 kHz for subgroup 2T (B) and subgroup 1T (C) on age, using the obtained mean slope and 
intercept values as imposed regression parameter values. (D-E), Scatter plots showing the forced residuals 
at each frequency for subgroup 2T (D) and 1T (E). A paired t test (6 pairs) was applied to the forced residuals 
in both subgroups with a significant outcome (P = 0.00018).). The difference between the across-frequency 
means of the subgroups was 10.39 dB with a 95%CI of 7.67 to 13.10 dB. The conclusion is that the patients 
in subgroup 2T developed significantly more HI throughout life than the patients in subgroup 1T, with an 
overall mean, age-independent difference of ~10 dB. 
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supplemental figure sf.2 (A-D). Comparison between the subgroups 2T and 1T. (A), Plots with regression 
lines for the thresholds at 0.5 kHz. The dashed gray line represents the 1T subgroup; the continuous line 
represents the 2T subgroup. (B), Results of Tukey’s test following ANOVA on the slopes for the subgroups at 
this frequency. Box and whisker plot showing mean and SD. Asterisk indicates a significant and substantial 
difference. (C), Regression plots for 4 kHz. (D), Results of Tukey’s test following ANOVA on the intercepts for 
the subgroups at this frequency. The differences in slope and intercept were significant and substantial, as 
is shown in panels (B) and (D).
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supplemental figure sf.3 (A-D). Comparison between the subgroups 2T and 2nT. Similar presentations 
as in figure 5, now for 0.5 kHz (A, B) and 8 kHz (C, D). The dashed gray line represents the 2nT subgroup, the 
continuous line represents the 2T subgroup. The differences in slope and intercept were significant. The 
difference in intercept (B) was also substantial (*), but the difference in slope (D) was marginally substantial 
(~*), i.e. close to but just under 0.20 dB/y.
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supplemental table st.1. Results of Tukey’s tests following one-way ANOVAs on intercept and slope(A-B) 
for the pairwise comparison of subgroups 2T - 2nT (A),1T - 2nT (B), and results of Student’s t test on intercept 
and slope (C-D) for the pairwise comparison of the subgroups c.2299delG homozygotes and 1T (C), as well 
as the subgroups c.2299delG homozygotes and 2nT (D). Further legend and abbreviations: see Table 3.
A. 2T versus 2nT (ANOVA with Tukey’s test)
frequency 
(kHz)
Δ(intercept) (dB) Δ(slope) (dB/year)
Δ P value 95%Ci summary Δ P value 95%Ci summary
0.25 12.64 P < 0.001 8.16 to 17.11 2T > 2nT -0.07 P > 0.05 -0.17 to 0.02
0.5 14.24 P < 0.001 9.70 to 18.78 2T > 2nT -0.07 P > 0.05 -0.17 to 0.03
1 9.15 P < 0.001 4.28 to 14.02 2T > 2nT 0.01 P > 0.05 -0.10 to 0.11
2 12.05 P < 0.001 7.22 to 16.88 2T > 2nT -0.13 P < 0.01 -0.24 to -0.03 2T < 2nT
4 7.64 P < 0.01 2.43 to 12.85 2T > 2nT 0.05 P > 0.05 -0.06 to 0.17
8 -1.69 P > 0.05 -7.36 to 3.98 0.32 P < 0.001 0.20 to 0.44 2T > 2nT
Summary 
significant
2t > 2nt in 
(5/6)
0.25-4 kHz
2T > 2nT in 
(1/6) 
8 kHz
Summary 
substantial
2T > 2nT in 
(3/6)
0.25-0.5, 2 kHz
B. 1T versus 2nT (ANOVA with Tukey’s test)
frequency 
(kHz)
Δ(intercept) (dB) Δ(slope) (dB/year)
Δ P value 95%Ci summary Δ P value 95%Ci summary
0.25 16.42 P < 0.001 11.44 to 21.39 1T > 2nT -0.39 P < 0.001 -0.49 to -0.28 1T < 2nT
0.5 21.14 P < 0.001 16.10 to 26.18 1T > 2nT -0.45 P < 0.001 -0.56 to -0.34 1T < 2nT
1 6.34 P < 0.05 0.93 to 11.75 1T > 2nT -0.12 P > 0.05 -0.23 to 0.001
2 8.83 P < 0.001 3.49 to 14.19 1T > 2nT -0.29 P < 0.001 -0.41 to -0.17 1T < 2nT
4 -6.30 P < 0.05 -12.09 to -0.51 1T < 2nT 0.02 P > 0.05 -0.11 to 0.15
8 -9.80 P < 0.01 -16.08 to -3.52 1T < 2nT 0.31 P < 0.001 0.17 to 0.44 1T > 2nT
Summary 
significant
1t > 2nt in 
4/6
0.25-2 kHz
1t < 2nt in 
3/6
0.25-0.5, 2 
kHz
1t < 2nt in 
2/6
4-8 kHz
1T > 2nT in 
1/6
8 kHz
Summary 
substantial
1T > 2nT in 
2/6
0.25-0.5 kHz
1T < 2nT in 
2/6
0.25-0.5 kHz
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C. c.2299delG homozygotes versus 1T (Student’s t test)
frequency 
(kHz)
Δ(intercept) (dB) Δ(slope) (dB/year)
Δ P value 95%Ci summary Δ P value 95%Ci summary
0.25 -3.11 0.48 -12.26 to 6.04 0.34 0.0014 0.15 to 0.53 delG > 1T
0.5 -13.59 0.0071 -22.89 to -4.29 delG < 1T 0.57 P < 0.001 0.38 to 0.76 delG > 1T
1 -9.85 0.0025 -16.03 to -3.67 delG < 1T 0.37 P < 0.001 0.24 to 0.50 delG > 1T
2 -7.54 0.057 -15.35 to 0.27 0.37 0.0001 0.21 to 0.53 delG > 1T
4 4.34 0.37 -5.68 to 14.36 0.20 0.054 -0.004 to 0.41
8 1.62 0.71 -7.43 to 10.67 0.16 0.053 -0.002 to 0.32
Summary 
significant
delg < 1t in 
2/6
0.5-1 kHz
delg > 1t in 
4/6
0.25-2 kHz
Summary 
substantial
delG > 1T in 
3/6
0.5-2 kHz
D. c.2299delG homozygotes versus 2nT (Student’s t test)
frequency 
(kHz)
Δ(intercept) (dB) Δ(slope) (dB/year)
Δ P value 95%Ci summary Δ P value 95%Ci summary
0.25 13.31 0.0085 3.83 to 22.79 delG > 2nT -0.04 0.65 -0.24 to 0.15
0.5 7.55 0.13 -2.32 to 17.42 0.12 0.23 -0.08 to 0.33
1 -3.51 0.34 -10.82 to 3.80 0.25 0.0025 0.10 to 0.41 delG > 2nT
2 1.29 0.76 -7.21 to 9.79 0.08 0.36 -0.10 to 0.26
4 -1.96 0.68 -11.61 to 7.69 0.22 0.033 0.02 to 0.43 delG > 2nT
8 -8.18 0.073 -17.18 to 0.82 0.47 P< 0.001 0.27 to 0.66 delG > 2nT
Summary 
significant
delG > 2nT 
in 1/6
0.25 kHz
delg > 2nt 
in 3/6
1, 4-8 kHz
Summary 
substantial
delG > 2nT 
in 1/6
8 kHz
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supplemental table st.2. Spectrum of USH2A mutation combinations in this study.
Abbreviations: see Table 2.
2t
allele 1 allele 2 Patients (%)
c.187C>T, p.(Arg63*) c.187C>T, p.(Arg63*) 3 (2.7)
c.238_239insCGTA, p.(Thr80Argfs*29) c.238_239insCGTA, p.(Thr80Argfs*29) 1 (0.9)
Tac.545_546delAA, p.(Lys182Argfs*33) c.11875_11876delCA, p.(Gln3959Asnfs*53) 1 (0.9)
c.779T>G, p.(Leu260*) c.2299delG, p.(Glu767Serfs*21) 1 (0.9)
c.779T>G, p.(Leu260*) c.10450C>T, p.(Arg3484*) 1 (0.9)
c.779T>G, p.(Leu260*) c.4628-30487_6325+8822del, p.(Gly1542_
Leu2110delinsAsp)
1 (0.9)
c.920_923dup, p.(His308Serfs*16) c.920_923dup, p.(His308Serfs*16) 1 (0.9)
c.949C>A , p.(Tyr318Cysfs*17) c.4773del, p.(Val1592*) 1 (0.9)
c.949C>A , p.(Tyr318Cysfs*17) c.11864G>A, p.(Trp3955*) 1 (0.9)
c.949C>A , p.(Tyr318Cysfs*17) c.2299delG, p.(Glu767Serfs*21) 1 (0.9)
c.1227G>A, p.(Trp409*) c.1227G>A, p.(Trp409*) 3 (2.7)
c.1227G>A, p.(Trp409*) c.2299delG, p.(Glu767Serfs*21) 2 (1.8)
c.1876C>T, p.(Arg626*) c.1876C>T, p.(Arg626*) 1 (0.9)
c.1876C>T, p.(Arg626*) c.2299delG, p.(Glu767Serfs*21) 1 (0.9)
c.2242C>T, p.(Gln748*) c.4405C>T, p.(Gln1469*) 1 (0.9)
c.2299delG, p.(Glu767Serfs*21) c.2299delG, p.(Glu767Serfs*21) 15 (13.6)
c.2299delG, p.(Glu767Serfs*21) c.7121-8313_11048-962delins12, del Ex 38-56 1 (0.9)
c.2299delG, p.(Glu767Serfs*21) c.11875_11876delCA, p.(Gln3959Asnfs*53) 1 (0.9)
c.2299delG, p.(Glu767Serfs*21) c.15053-2A>T, p.(?) 1 (0.9)
c.2983C>T, p.(Gln995*) c.2983C>T, p.(Gln995*) 2 (1.8)
c.3932C>A, p.(Ser1311*) c.10450C>T, p.(Arg3484*) 2 (1.8)
c.3932C>A, p.(Ser1311*) c.13207-13208delGG, p.(Gly4403Profs*15) 1 (0.9)
c.4628-30487_6325+8822del, 
p.(Gly1542_Leu2110delinsAsp)
c.4628-30487_6325+8822del, p.(Gly1542_
Leu2110delinsAsp)
1 (0.9)
c.7121-8313_11048-962delins12, del 
Ex 38-56
c.7121-8313_11048-962delins12, del Ex 38-56 2 (1.8)
c.7121-8313_11048-962delins12, del 
Ex 38-56
c.8954delG, p.(Gly2985Alafs*3) 2 (1.8)
c.8079G>A, p.(Trp2693*) c.8079G>A, p.(Trp2693*) 1 (0.9)
c.8557A>T, p.(Arg2853*) c.4628-30487_6325+8822del, p.(Gly1542_
Leu2110delinsAsp)
2 (1.8)
c.8682-9A>G, IVS43-9A>G c.8682-9A>G, IVS43-9A>G 1 (0.9)
c.9372-?_9570+?, del Ex 48 c.9372-?_9570+?, del Ex 48 1 (0.9)
c.10450C>T, p.(Arg3484*) c.10684G>T, p.(Glu3562*) 1 (0.9)
c.10525A>T, p.(Lys3509*) c.2299delG, p.(Glu767Serfs*21) 1 (0.9)
c.11864G>A, p.(Trp3955*) c.11864G>A, p.(Trp3955*) 3 (2.7)
total 58 (52.7)
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1t
allele 1 allele 2 Patients (%)
c.187C>T, p.(Arg63*) c.1036A>C, p.(Ans346His) 1 (0.9)
c.920_923dup, p.(His308Serfs*16) c.1036A>C, p.(Ans346His) 1 (0.9)
c.1227G>A, p.(Trp409*) c.1256G>T, p.(Cys419Phe) 2 (1.8)
c.1227G>A, p.(Trp409*) c.13262T>C, p.(Leu4421Pro) 2 (1.8)
c.1876C>T, p.(Arg626*) c.10561T>C, p.(Trp3521Arg) 1 (0.9)
c.2299delG, p.(Glu767Serfs*21) c.1036A>C, p.(Ans346His) 2 (1.8)
c.2299delG, p.(Glu767Serfs*21) c.1256G>T, p.(Cys419Phe) 3 (2.7)
c.2299delG, p.(Glu767Serfs*21) c.1606T>C, p.(Cys536Arg)  3 (2.7)
c.2299delG, p.(Glu767Serfs*21) c.9815C>T, p.(Pro3272Leu) 1 (0.9)
c.3558delT, p.(Cys1186Trpfs*51) c.1256G>T, p.(Cys419Phe) 1 (0.9)
c.4628-30487_6325+8822del, 
p.(Gly1542_Leu2110delinsAsp)
c.12695C>G, p.(Pro4232Arg)
1 (0.9)
c.7121-8313_11048-962delins12, del 
Ex 38-56
c.1256G>T, p.(Cys419Phe)
2 (1.8)
c.7121-8313_11048-962delins12, del 
Ex 38-56
c.6722C>T, p.(Pro2241Leu)
1 (0.9)
c.7931G>A, p.(Trp2644*) c.11819A>C, p.(Tyr3940Ser) 2 (1.8)
c.8557A>T, p.(Arg2853*) c.802G>A, p.(Gly268Arg) 1 (0.9)
c.10525A>T, p.(Lys3509*) c.1256G>T, p.(Cys419Phe) 2 (1.8)
c.11864G>A, p.(Trp3955*) c.1256G>T, p.(Cys419Phe) 1 (0.9)
c.11864G>A, p.(Trp3955*) c.2276G>T, p.(Cys759Phe) 1 (0.9)
c.13822C>T, p.(Arg4608*) c.1036A>C, p.(Ans346His) 2 (1.8)
c.14131C>T, p.(Gln4711*) c.1606T>C, p.(Cys536Arg)  1 (0.9)
total 31 (28.2)
2nt
allele 1 allele 2 Patients (%)
c.653T>A, p.(Val218Glu) c.14408T>C, p.(Ile4808Thr) 1 (0.9)
c.1036A>C, p.(Ans346His) c.1036A>C, p.(Ans346His) 4 (3.6)
c.1036A>C, p.(Ans346His) c.2276G>T, p.(Csy759Phe) 1 (0.9)
c.1036A>C, p.(Ans346His) c.4810G>C, p.(Asp1604His) 1 (0.9)
c.1256G>T, p.(Cys419Phe) c.1256G>T, p.(Cys419Phe) 2 (1.8)
c.1256G>T, p.(Cys419Phe) c.1606T>C, p.(Cys536Arg)  7 (6.4)
c.1256G>T, p.(Cys419Phe) c.2276G>T, p.(Csy759Phe) 1 (0.9)
c.1256G>T, p.(Cys419Phe) c.9815C>T, p.(Pro3272Leu) 1 (0.9)
c.1256G>T, p.(Cys419Phe) c.10421A>G, p.(Tyr3474Cys) 1 (0.9)
c.5018T>C, p.(Leu1673Pro) c.5018T>C, p.(Leu1673Pro) 1 (0.9)
c.10561T>C, p.(Trp3521Arg) c.10561T>C, p.(Trp3521Arg) 1 (0.9)
total 21 (19.1)

Chapter 2.2
Visual prognosis in USH2A-
associated retinitis pigmentosa 
is worse for patients with Usher 
syndrome type IIa than for those 
with nonsyndromic retinitis 
pigmentosa
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aBstraCt
Objectives: USH2A mutations are an important cause of retinitis pigmentosa (RP) with or 
without congenital sensorineural hearing impairment. We studied genotype-phenotype 
correlations and compared visual prognosis in patients with Usher syndrome type IIa 
(USH2a) and USH2A-associated nonsyndromic RP (nsRP).
Design and participants: Clinic-based, longitudinal, multicenter study. Consecutive pa-
tients with USH2a (n=152) and USH2A-associated nsRP (n=73) from ophthalmogenetic 
clinics in the Netherlands and Belgium.
Methods: Data on clinical characteristics, visual acuity, visual ﬁeld measurements, retinal 
imaging, and electrophysiological features were extracted from medical charts over a 
mean follow-up of nine years. Cumulative lifetime risks of low vision and blindness were 
estimated using Kaplan-Meier survival analysis.
Results: Participant groups had similar distributions of gender (48% versus 45% males 
in USH2a versus USH2A-associated nsRP; P=0.8), ethnicity (97% versus 99% European; 
P=0.3), and median follow-up time (6.5 years versus 3 years; P=0.3). USH2a patients dem-
onstrated symptoms at a younger age (median age, 15 years versus 25 years; P<0.001), 
were diagnosed earlier (median age, 26 years versus 36.5 years; P<0.001), and became 
visually impaired 13 years earlier (median age, 41 years versus 54 years; P<0.001) based 
on VF and 18 years earlier based on VA (median age, 54 years versus 72 years; P<0.001) 
than USH2A-associated nsRP patients. The presence of two truncating mutations in 
USH2A was associated mostly with the syndromic phenotype, whereas other combina-
tions were present in both groups. We found novel variants in USH2a (25%) and USH2A-
associated nsRP (19%): 29 missense mutations, 10 indels, 14 nonsense mutations, nine 
frameshift mutations, and five splice-site mutations.
Conclusions: Most patients with USH2A-associated nsRP have severe visual impairment 
by age 50. However, those with USH2a have an earlier decline of visual function and 
a higher cumulative risk of visual impairment than those with USH2A-associated nsRP. 
Complete loss of function of the USH2A protein predisposes to USH2a, but remnant 
protein function can lead to RP with or without hearing loss.
Published as: Pierrache, L.H., Hartel, B.P., van Wijk, E., Meester-Smoor, M.A., Cremers, F. P., 
de Baere, E., de Zaeytijd, J., van Schooneveld, M.J., Cremers, C.W., Dagnelie, G., Hoyng, 
C.B., Bergen, A.A., Leroy, B.P., Pennings, R.J., van den Born, L.I., & Klaver, C.C. (2016). Visual 
Prognosis in USH2A-Associated Retinitis Pigmentosa Is Worse for Patients with Usher 
Syndrome Type IIa Than for Those with Nonsyndromic Retinitis Pigmentosa. Ophthal-
mology, 123(5), 1151-1160. doi: 10.1016/j.ophtha.2016.01.021
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introduCtion
Retinitis pigmentosa (RP) is a genetic disorder marked by progressive retinal degen-
eration leading to severe visual impairment. Patients initially experience nightblindness 
and visual ﬁeld (VF) constriction resulting from rod degeneration, followed by dete-
rioration of central vision caused by loss of cone function. Mutations in USH2A form a 
substantial cause of RP and can give rise to two distinct phenotypes: Usher syndrome 
type IIa (USH2a) and nonsyndromic RP (USH2A-associated nsRP). Patients with USH2a 
are characterized by RP and congenital sensorineural hearing impairment, whereas 
patients with USH2A-associated nsRP do not experience extraocular symptoms.
The USH2A gene is located on chromosome 1q41 and codes for the usherin protein, 
which plays an important role in the development of cochlear hair cells and long-term 
maintenance of photoreceptors. There are two isoforms, a short isoform of 170 kDa, 
which is translated from 21 exons,1 and a long isoform of 580 kDa, translated from an 
extra 51 exons.2 Both isoforms are expressed in the photoreceptors and cochlear hair 
cells. Approximately 50% to 75% of Usher syndrome patients and 12% to 25% of nsRP 
patients carry mutations in USH2A, making it one of the most important mutated genes 
in these populations.3 Generally, patients with USH2a can be identiﬁed early because 
of their congenital hearing impairment. At this young age, most photoreceptors are 
still viable and would be amenable targets for gene replacement therapy.4 USH2A is a 
challenge for developers of gene therapy because the size of the gene largely exceeds 
the capacity of adeno-associated virus and lentivirus vectors. Other strategies such as 
antisense oligonucleotide-based therapy 5 and cell replacement therapy with induced 
pluripotent stem cells seem promising.4 As treatment options for USH2A mutations be-
come apparent, it is important to identify individuals who have the greatest chance to 
beneﬁt from these therapies. Therefore, being able to predict the course of the disease 
early in the process is highly desirable.
Thus far, genotype-phenotype correlations have not been very distinct in patients 
with USH2A mutations. Certain mutations in USH2A, such as p.(Glu767Serfs*21), have 
been associated mainly with the syndromic phenotype.6 Others seem to have a pre-
dilection for USH2A-associated nsRP, such as p.(Cys759Phe).7 It remains unknown why 
some mutations in USH2A lead to USH2a and others to USH2A-associated nsRP. A great 
number of mutations are missense mutations and are private, which means that they are 
observed only in one family.6, 8, 9 In addition, most patients are compound heterozygotes 
because they carry different mutations on the maternal and paternal allele. This makes 
it even more difficult to predict the effect of each of these mutations on the phenotype 
and complicates assessing a possible allelic hierarchy.10 Affected siblings are prone to 
having the same phenotype, but differences in severity occur.11 This suggests that each 
phenotype may be caused by a distinct set of genotypes.
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The aim of this study was to investigate the visual prognosis in a large series of patients 
with retinal degenerations resulting from USH2A mutations. We compared the course 
of disease in patients with USH2a with that of patients with USH2A-associated nsRP and 
aimed to investigate whether their genetic constitutions can predict the progression of 
visual function loss.
Patients and MetHods
study population
We ascertained 225 consecutive subjects with RP resulting from mutations in USH2A 
from five ophthalmogenetic clinics in the Netherlands and Belgium. Of these, 152 had a 
diagnosis of congenital hearing impairment based on audiologic test results and were 
identiﬁed as having USH2a (Figure 1). The remaining 73 did not have childhood-onset 
hearing impairment and were classiﬁed as having USH2A-associated nsRP. We included 
siblings and offspring of 22 probands in our cohort. There were 18 USH2a families and 
four families with USH2A-associated nsRP in total; the same phenotype was observed in 
all siblings. The study adhered to the tenets of the Declaration of Helsinki, and all proce-
dures were reviewed by the Medical Ethics Committee of Erasmus Medical Centre and 
225 patients with 
mutations in USH2A
152 Usher syndrome 
type IIa
73 nonsyndromic RP
Solved
110 probands
18 siblings
Unsolved
23 probands
1 sibling
Solved
43 probands
1 sibling
Unsolved
25 probands
4 siblings
figure 1. Flow chart of subjects included in the study.
Patients with biallelic pathogenic mutations were defined as solved, and patients with only 1 known patho-
genic mutation were considered unsolved. RP = retinitis pigmentosa
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the Medical Ethics Committee of the University Hospital of Ghent. Participants provided 
a written informed consent to retrieve data from medical records.
Clinical examination
We strived to establish a database with virtually complete longitudinal data. Participants 
were queried for all ophthalmologists and otolaryngologists they had consulted dur-
ing their lifetimes, and medical records were retrieved. We gathered longitudinal data 
from 171 patients and examined 54 patients cross-sectionally. Eye examinations were 
performed in accordance with good clinical practice at regular intervals by a small 
number of ophthalmologists (n = 6) with expertise in ophthalmogenetics and included 
best-corrected Snellen visual acuity (VA), Goldmann VFs, electroretinography (full-ﬁeld 
electroretinography according to the standards of the International Society for Clinical 
Electrophysiology of Vision; available at www.iscev.org), colour vision testing, slit-lamp 
examination, and ophthalmoscopy. Not all of these examinations had been performed 
at each visit, and not all participants had undergone all examinations. We digitized VF 
retinal area of the V4 target using a method described by Dagnelie.12
genetic analyses
To provide the molecular diagnosis, different molecular testing approaches were used 
over the course of 20 years (1996-2015). In the initial years, participants were analysed 
with polymerase chain reaction ampliﬁcation and subsequent Sanger sequencing. From 
2006 through 2013, participants were analysed with an Usher syndrome APEX (arrayed 
primer extension) genotyping micro-array or an autosomal recessive RP APEX genotyp-
ing microarray. Sanger direct sequencing was performed subsequently to conﬁrm the 
identiﬁed mutation(s). When only 1 heterozygous mutation in USH2A was found, the 
entire USH2A gene was sequenced to screen for a second pathogenic mutation. From 
2014 onward, ophthalmogenetic laboratories used targeted next-generation sequenc-
ing of 160 genes associated with hereditary blindness or whole-exome sequencing to 
identify mutations for RP.13, 14 Pathogenicity of mutations was scored using Combined 
Annotation Dependent Depletion (CADD).15
statistical analyses
Differences in age at onset and age at diagnosis were compared using a Wilcoxon-
Mann-Whitney test. To compare differences in gender ratio, ethnicity, and refractive 
error, we used a chi-square test. Outcome variables were low vision and blindness. These 
functional stages were based on VA and VF and were in accordance with World Health 
Organization standards. Visual impairment was deﬁned as either low vision (0.05 ≤ VA 
< 0.3, 10° ≤ VF < 20° central VF diameter, or both) or blindness (VA < 0.05, central VF 
diameter < 10°, or both). Lifetime cumulative risk of the outcome variables was esti-
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mated using Kaplan-Meier product-limit survival analysis. The log-rank test was used 
to determine the statistical signiﬁcance of risk differences. Analyses were stratiﬁed for 
clinical diagnosis and the number of truncating variants present, because these variants 
are predicted to lead to nonsense-mediated decay, signiﬁcant truncation of the protein, 
or both if translated. Progression of VF loss was evaluated with mixed- model analysis.
results
Clinical Characteristics
The average follow-up time did not differ signiﬁcantly between the groups (Table 1) 
and was 9 years on average with a maximum of 43 years. Participants with USH2a in our 
cohort were younger than participants with USH2A-associated nsRP, but did not differ in 
gender. The vast majority of participants in both groups were of European descent. All 
participants had at least two RP hallmarks on fundus examination, that is, the presence 
of a waxy optic disc, narrow blood vessels, midperipheral and peripheral bone spicules, 
table 1. Distribution of clinical characteristics in patients with USH2A mutations.
Characteristics USH2a 
(n=152)
USH2A-associated 
nsrP (n=73)
P value
Mean age ± SD, yrs 48 (±2.5) 55 (±3.3) <0.001a
Male gender, no. (%) 73 (48) 33 (45) 0.8b
Median follow-up (range) (y) 6.5 (0-43) 3 (0-37) 0.3c
European ethnicity, no. (%) 148 (97) 72 (99) 0.3b
Median refractive error (SE; n=189), D -1.50 (-16 to +5) -0.75 (-14 to +4) 0.2c
High myopia (SE < - 6 D), no. (%) 9 (7) 6 (9) 0.3b
Mild myopia ( -2D > SE >  -  6D) no. (%) 51 (39) 16 (25)
Emmetropia (2 D > SE >  -2 D), no. (%) 66 (50) 38 (60)
Hyperopia (2 D > SE), no. (%) 6 (5) 4 (6)
Cataract extraction
Right Eye, no. 30 21
Median age (range), yrs. (n = 46) 45 (27-64) 56 (31-73) 0.002c
Left eye, no. 32 19
Median age (range), yrs. (n=46) 43 (28-64) 57 (32-78) 0.003c
Electroretinography results (n=142), no.(%) <0.001b
Reduced rods and cones 1 (1) 18 (35)
Rods extinguished, reduced cones 9 (9) 9 (17)
Rods and cones extinguished 86 (90) 26 (48)
a Student t-test, b Chi Square test, c Wilcoxon–Mann–Whitney test, SE = spherical equivalent, USH2a = Usher 
syndrome type IIa, D = Diopter, SD = standard deviation
59
Ch
ap
te
r 2
.2
 V
is
ua
l p
ro
gn
os
is
 in
 p
at
ie
nt
s 
w
ith
 m
ut
at
io
ns
 in
 U
SH
2A
and atrophy of the retinal pigment epithelium. There were no differences in refractive 
error between the patient groups (Table 1). Subcapsular cataract was common (overall 
median age, 48 years), and 46 patients (21%) had undergone cataract extraction. Par-
ticipants with USH2a underwent cataract extraction approximately 10 years earlier than 
participants with USH2A-associated nsRP (Table 1).
Visual function
Subjects with USH2a were younger at age of onset of symptoms, that is, nightblindness 
and VF constriction, and were diagnosed with RP at a younger age (Table 2). The VF 
constriction preceded VA loss in all but 1 patient who had irreversible central visual loss 
resulting from longstanding cystoid macular edema. Participants with USH2a became 
visually impaired approximately 13 years earlier based on VF constriction criteria (VF < 
20°; P<0.001) and 18 years earlier based on VA criteria (VA < 0.3; P<0.001) than subjects 
with USH2A-associated nsRP (Table 2; Figures 2 and 3). At 50 years of age, 83% of par-
ticipants with USH2a had VF constriction versus only 40% of participants with USH2A-
associated nsRP. These numbers were 46% versus 6% for VA. Exclusion of relatives did 
not alter these risk estimates signiﬁcantly (data not shown). To validate our ﬁndings, 
we repeated the analyses and excluded subjects with a single USH2A mutation. This 
exclusion did not alter our estimates (Table 3, available as supplemental table at http://
www.aaojournal.org). Progression of VF loss was evaluated with mixed-model analysis. 
At baseline (intercept), there was no difference between subjects with USH2a and 
USH2A-associated nsRP (P=0.3), but with aging, the difference in progression became 
statistically signiﬁcant (P<0.01; Figure 4).
table 2. Comparison of age difference at onset of disease, at diagnosis, and at onset of low vision and legal 
blindness
Median age time Point (yrs) usH2a 
(n=152)
USH2A-associated nsrP 
(n=73)
P value
Onset of symptoms 15 (0-46) 25 (0-68) <0.001a,c
Diagnosis 26 (8-56) 36.5 (12-74) <0.001a,c
Low vision based on VF (n=176) 41 (15-67) 54 (32-78) <0.001b,c
Low vision based on VA (n=225) 54 (20-74) 72 (15-72) <0.001b,c
Legal blindness based on VF (n=176) 54 (19-58) 80 (34-80) 0.01b,c
Legal blindness based on VA (n=225) 74 (32-74) 77 (49-77) 0.01b,c
a Wilcoxon–Mann–Whitney test, b Log-rank test, c P>0.008, after Bonferroni correction. USH2a = Usher syn-
drome type IIa, nsRP = nonsyndromic retinitis pigmentosa, VA = visual acuity, VF = visual field. Data are 
median (range).
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figure 2. Graphs showing cumulative incidence (%) of low vision based on (A) visual acuity of less than 0.3 
and (B) GVF of less than 20 as a function of age stratified for Usher syndrome type IIa and USH2A-associated 
nonsyndromic retinitis pigmentosa (nsRP). The cumulative incidence of low vision at 0, 20, 40, 60, and 80 
years of age is indicated in the grey box below the graph. Red = Usher syndrome type IIa; Black =USH2A-
associated nsRP
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figure 3. Graphs showing cumulative incidence (%) of legal blindness based on (A) visual acuity of less 
than 0.05 and (B) GVF of less than 10 as a function of age stratified for Usher syndrome type IIa and USH2A-
associated nonsyndromic retinitis pigmentosa (nsRP). The cumulative incidence of legal blindness at 0, 20, 
40, 60, and 80 years of age is indicated in the grey box below the graph. Red = Usher syndrome type IIa; 
Black = USH2A-associated nsRP
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genotype
Pathogenic mutations on both alleles were found in 160 participants (71%), among 
whom 31 (19%) were homozygous and 129 (81%) were compound heterozygous. In 
53 patients (24%), only one pathogenic mutation was detected, and in 12 participants 
(5%), multiple mutations (≥3) in USH2A were found (Figure 1). One hundred twenty-
eight different mutations were recorded, of which 65 were missense mutations, 10 were 
insertions or deletions, 30 were nonsense mutations, 16 were frame-shift mutations, and 
seven were splice-site mutations. Sixty-eight of these variants were newly identiﬁed, 
because they were not present in the Leiden Open Variant Database (accessed July 17, 
2015): 29 missense mutations, 10 insertions or deletions, 14 nonsense mutations, nine 
frame-shift mutations, and five splice-site mutations (Table 4, available as supplemental 
table at http://www.aaojournal.org). The most common mutations in syndromic partici-
pants were p.(Glu767Serfs*21) (65 of 250 observed USH2A variants), p.(Cys419Phe) (29 of 
250 observed USH2A variants), and p.(Cys536Arg) (15 of 250 observed USH2A variants). 
The most frequent mutations in USH2A-associated nsRP participants were p.(Cys759Phe) 
(33 of 130 observed USH2A variants), p.(Glu767Serfs*21) (13 of 130 observed USH2A 
variants), and p.(Arg4115Cys) (8 of 130 observed USH2A variants; Table 4, available as 
supplemental table at http://www.aaojournal.org). Twenty-one of the 225 participants 
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figure 4. Graphs showing the relationship between mean log retinal area and age. Solid line = mixed mod-
el estimation; dashed line = confidence interval. RP = retinitis pigmentosa
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Laminin N-terminal
p.(Arg63*)
p.(Val218Glu)
p.(His308Glnfs*16)
p.(Asp347His)
p.(Asn348del)
p.(Lys402Asn)
c.1328+1G>A
p.(Glu478Asp)
p.(Cys536Arg)
p.(Asp591Gly)
p.(Gly603Glu)
p.(Arg626*)
deletion exon 12-13
p.(Gln672*)
p.(Gln714*)
p.Leu724Valfs*31
p.(Gln748*)
PDZ-binding
Transmembrane
Fibronectin type-III 5-35
Laminin G-like 1-2
Fibronectin type-III 1-4
Laminin EGF-like 1-10
p.(Cys797*)
c.2555-1G>C
p.(Leu908Profs*63)
p.(Cys1195Phe)
p.(Trp1352*)
p.(Ser1381Thr)
p.(Trp1382Gly)
Usher syndrome type IIa USH2A-associated nsRP
p.(Gln1469*)
p.(Arg1549*)
p.(Val1592*)
p.(Asp1604Asn)
p.(His2183Glnfs*48)
c.6658-2A>G
p.(Pro2241Leu)
p.(Arg2323*)
c.7121-8313_11048-962delins12
deletion exon 38-56
p.(Asn2377Ser)
p.(Tyr2378Hisfs*39)
p.(Trp2396*)
c.7301-?_10939+?
p.(Gln2501*)
c.7595-2144A>G
p.(Val2562Ala)
p.(Trp2644*)
p.(Trp2693*)
p.(Trp2876*)
p.(Gly2985Alafs*3)
p.(Glu3088Lys)
c.9372-?_9570+?
p.(Cys3281Phe)
c.10387+2T>C
p.(Trp3521Arg)
p.(Lys3892Asnfs*41)
p.(Tyr3900Asp)
p.(Tyr3940Ser)
p.(Gln3959*)
p.(Trp4243*)
p.(Pro4269His)
p.(Tyr4331Cys)
p.(Leu4406Pro)
p.(Leu4421Pro)
p.(Thr4439Ile)
p.(Val4503Glufs*54)
p.(Gln4711*)
p.(Ile4764Serfs*42)
c.14583-20C>G
p.(Tyr4934*)
c.486-14G>A
p.(Ser307Leufs*17)
p.[=, Tyr318Cysfs*17]
p.(Asn346His)
p.(Trp409*)
p.(Cys419Phe)
p.(Cys759Phe)
p.(Glu767Serfs*21)
p.(Arg1578Cys)
p.(Val1839Glu)
p.(Asn2651Glnfs*10)
p.(Val2908Glyfs*29)
p.(Pro3272Leu)
p.(Lys3509*)
p.(Pro3893Thr)
p.(Trp3955*)
p.(Thr4425Met)
p.(Arg4935*)
p.(Phe4993Profs*7)
c.15053-2A>T
p.(Ser5030*)
p.(Ile485Thr)
p.(Cys655Trp)
p.(Gly660Arg)
p.(Gly764Val)
p.(Cys766Arg)
p.(His1015Gln)
p.(Tyr1123Cys)
p.(Gly1301Val)
p.(Ser1369Leu)
p.(Leu1378Pro)
p.(Ser1455Leufs*21)
p.(Phe1859Cys)
p.(Gln1910*)
p.(Cys2309Phe)
p.(Pro2352Ser)
c.7121-?_11047+?
p.(Gly2752Arg)
p.(Gln3086His)
p.(Thr3115Ile)
p.(Gly3138Asp)
p.(Gly3320Asp)
p.(Cys3358Tyr)
p.(Tyr3563*)
p.(His3634Pro)
p.(Ser3669Arg)
p.(Arg3719His)
p.(Tyr4110Asp)
p.(Arg4115Cys)
p.(Leu4132Trpfs*35)
p.(Arg4192His)
p.(Glu4445Aspfs*32)
p.(Tyr4673His)
p.(Gly4692Arg)
p.(Trp4725*)
p.(Trp4849Arg)
p.(Arg5031Trp)
p.(Pro5107Ser)
p.(Ile5126Thr)
p.(Val5145Ile)
p.(Leu3145Phe)
p.(Trp2618*)
p.(Arg1653*)
figure 5. Schematic representation of the usherin protein and localisation of mutations. Mutations in the 
first column were found only in participants with Usher syndrome type IIa. Mutations in the last column 
were found only in the USH2A-associated nonsyndromic retinitis pigmentosa participants. Mutations in the 
middle column were present in both phenotype groups.
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(9%) resulted from a consanguineous marriage, and in only 10 of them did we ﬁnd a 
homozygous mutation. In the remaining participants carrying homozygous mutations, 
p.(Glu767Serfs*21) was the most frequently observed mutation (n = 12). Figure 5 shows 
the protein structure of usherin and the locations of mutations in the protein per phe-
notype. Strikingly, participants with two mutations in the N-terminal laminin domain 
always had the USH2a phenotype at presentation, independent of the effect on the 
protein (Table 5, available as supplemental table at http://www.aaojournal.org).
We stratiﬁed all variants into two groups: truncating variants (also referred to as 
‘inactivating’ or ‘null variants’) and nontruncating variants. Participants carrying two 
nontruncating variants or one nontruncating and one truncating variant had both phe-
notypes at presentation. All but one participant carrying truncating variants on both 
alleles had USH2a. The number of truncating variants present seems to be associated 
with an earlier decline in visual function (Table 6). As the number of truncating variants 
increases, participants become visually impaired earlier in life. More detailed analysis 
of pathogenicity was performed using CADD scores. Most variants exceeded a CADD 
score of 15, the cut-off score suggested by the authors to identify potentially pathogenic 
variants. No signiﬁcant correlations between the score and age at diagnosis or age at of 
visual impairment were found (data not shown). The CADD score can be used to predict 
whether a variant is deleterious in diagnostics, but we could not use it as a proxy for 
remaining protein function.
disCussion
In this study, we compared the visual course between subjects with USH2a and USH2A-
associated nsRP. We found that USH2a patients demonstrated visual symptoms at an 
earlier age, had an earlier onset of disease, and became visually impaired at a younger 
age than participants with USH2A-associated nsRP. We observed several genotype-
phenotype correlations: the presence of two truncating mutations was restricted to 
table 6. Mutations in Usher syndrome type IIa and USH2A-associated nsRP
nontruncating
nontruncating
nontruncating
truncating
truncating
truncating
P value
USH2a, no. (%) 19 (16) 48 (40) 54 (44) < 0.001a
USH2A-associated nsRP, no. (%) 14 (36) 24 (62) 1 (3)
Median age low vision by VA, yrs (n=160) 59 57 48 0.4b
Median age low vision by GVF, yrs (n=124) 45 48 38 0.06b
a Chi square test, b Log-rank test, USH2a = Usher syndrome type IIa, nsRP = nonsyndromic retinitis pigmen-
tosa, GVF = Goldmann visual field, VA = visual acuity
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the USH2a phenotype, as was the presence of two missense variants in the N-terminal 
laminin of the gene. The presence of at least one truncating mutation was associated 
with an earlier visual decline, regardless of the phenotype.
Our study has beneﬁts and drawbacks. Among the beneﬁts is our establishment of 
the largest cohort of USH2A patients with genetic and longitudinal follow-up data to 
date. The 225 Dutch and Belgian participants had been examined by a small number 
of ophthalmologists and had been followed up for a relatively long period. Finally, our 
analysis focused on the lifetime course of disease and used end points, which are con-
sidered gold standards for functional vision. The drawbacks include the lack of power 
for detailed subgroup analysis and the incomplete genotyping in a proportion of the 
patients. There may have been selection bias because patients with hearing loss are 
more sensitive to visual decline than nsRP patients because they rely more on visual 
cues in daily life. These patients may have been referred for ophthalmologic screening 
at a younger age, and thereby may have received an earlier diagnosis of RP. We do not 
think that the raised alertness explains the difference in visual decline, because this was 
registered by severe outcome measures using standardized criteria. We believe these 
differences to be genuine.
Others studied disease progression of USH2a or USH2A-associated nsRP in smaller 
groups of patients. Fishman et al examined the course of visual function in 58 subjects 
with USH2a by examining change in VF over 3 years.16 They found that the progression 
rate did not depend on initial localisation of the VF defect. Blanco- Kelly et al. compared 
276 subjects with USH2a with 93 subjects with Usher syndrome type I cross-sectionally 
using historical data and found an earlier onset for Usher syndrome type I.17 For subjects 
with USH2a in this study, the age at onset of symptoms (18.1 years versus 15 years) and 
diagnosis (26.8 years versus 26 years) was similar to our ﬁndings. Another large study by 
Sandberg et al. investigated 125 RP patients with mutations in USH2A with and without 
hearing loss and calculated rates of decline in electroretinography results, VA, and VF.18 
Annual decline of cone electroretinography amplitudes was 13.2%, which was a rate 
faster than that of patients with mutations in retinitis pigmentosa GTPase regulator 
(RPGR) or rhodopsin (RHO). The estimated decline of VA and VF in this study occurred 
earlier than in our study. At 65 years of age, 50% were legally blind based on VA or VF in 
the study of Sandberg et al, whereas these proportions were 22% and 49% at 65 years of 
age in our study for both phenotypes combined. Their risk estimates were derived from 
a ﬁtted model based on only a small number of observations in the higher age range, 
whereas our estimates were based on actual data and included a larger number of data 
points. Therefore, we believe our estimates may be more realistic. Note that the rate of 
VF loss, expressed as remaining retinal area capable of detecting the target, follows the 
same time course in both subgroups, with a plateau before onset in the nonsyndromic 
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group and a slowing at older age in the syndromic group. The mixed-model analysis we 
used does not test for the concept of a critical age as postulated by Massof.19 
We studied the distribution of USH2A genotypes and found that less than 19% of mu-
tations were homozygous and that most mutations were private (69%). This indicates 
that the heterogeneity is very large and that de novo mutations may occur frequently. 
We found two pathogenic USH2A mutations in 72%, three mutations in 5%, and only one 
pathogenic mutation in 23% of our study population. The most frequently occurring 
mutation in the USH2a group was p.(Glu767Serfs*21), but this was also the second most 
common variant in the nonsyndromic group. This mutation was found in seven of 16 
homozygous subjects. Carrier frequency of this allele is 0.08% in the general population 
according to the Exome Aggregation Consortium data set (accessed July 17, 2015). This 
mutation was found in control populations of European, African, and Latin descent, but 
seems to be of European ancestral origin.20 In the 25% (n=52) of patients in whom we 
detected only one USH2A mutation using APEX microarray we did not ﬁnd a second 
mutation with Sanger sequencing. This may be the result of deep intronic variants that 
affect splicing, intronic or intergenic variants that affect transcription or deletions, or 
duplications that escaped detection. The disease may also be the result of mutations in 
other genes that mimic this phenotype.
Variants were distributed all over the gene for both phenotypes (Figure 5). We ob-
served only one distinct hotspot; this was located in the N-terminal laminin domain, 
which was associated with the USH2a phenotype. Subjects in our cohort with biallelic 
variants in this domain always had impaired hearing, implying that this protein domain 
is essential for normal cochlear development (Table 5, available as supplemental table 
at http://www.aaojournal.org). Although Baux et al. found a high density of pathogenic 
variants in this domain, they did not report a relationship with function.21 There were 
no other apparent genotype-phenotype relationships; however, all 21 sibling pairs with 
USH2A mutations shared the same phenotype. Most of the unrelated patients with iden-
tical genotypes (13/15) also shared the same phenotype. Therefore, the combination of 
mutations seems to predispose individuals to a certain phenotype.
Approximately half (49.2%) of the mutations were truncating, leading to a shortened 
or absent protein resulting from nonsense-mediated mRNA decay. These were twice 
as frequent in USH2a (60.33% versus 25.00%), and we conﬁrmed that two truncating 
variants always caused congenital hearing loss, but not congenital blindness.3 However, 
we observed that biallelic missense mutations also caused congenital hearing loss in 
19 patients (Table 5, available as supplemental table  at http://www.aaojournal.org; and 
Table 6). Patients with two truncating mutations have an earlier onset of RP and an ear-
lier progression to visual impairment than those with residual protein function (Table 6). 
It seems that at least one functional allele is needed for normal cochlear development, 
but not for retinal development. In the retina, the function of the USH2A protein usherin 
67
Ch
ap
te
r 2
.2
 V
is
ua
l p
ro
gn
os
is
 in
 p
at
ie
nt
s 
w
ith
 m
ut
at
io
ns
 in
 U
SH
2A
is maintenance of photoreceptor cells.22 Zebraﬁsh studies have shown that the long 
isoform of the protein is located at the connecting cilium and photoreceptor synapse 
and that knockdown of the gene caused photoreceptor degeneration.23 In the cochlea, 
both isoforms are present transiently during development, and functional studies in 
mice have shown that knockout of the gene leads to nonprogressive sensory hearing 
loss.22 The protein in the ear seems to function in the ankle link complex that organizes 
stereocilia in a V-shaped pattern in the developmental phase. It does not seem to have a 
role in maintenance of the cochlea. The dissimilar roles of the protein in the eye and the 
ear clarify the difference in age of onset and clinical course. 
Our data do not support the allelic hierarchy theory proposed by Lenassi et al., which 
stratiﬁes disease-causing variants in retinal-disease speciﬁc alleles and USH2a-speciﬁc 
alleles.10 Retinal disease-speciﬁc alleles had to be present in more than one patient 
with USH2A-associated nsRP and did not occur in USH2a. The authors proposed that 
one or more retinal disease-speciﬁc alleles were associated with preserved hearing. 
In our cohort, six patients with USH2a were heterozygous for the c.2276G>T allele, 
which they attributed to the retinal disease-speciﬁc group.21 In the Leiden Open Variant 
Database (accessed July 17, 2015), 31 patients with USH2a also carried the c.2276G>T 
variant.5, 7, 8, 18, 21, 24-31 We suggest that the effect of this variant on usherin is not conﬁned 
to the retina, but also can affect cochlear development. The c.2276G>T variant causes 
a change in amino acid residue from cysteine to phenylalanine. Cysteine is crucial for 
the formation of 1 of the 4 disulphide bonds required for proper protein folding in the 
epidermal growth factor (EGF) domain. Another variant, c.11156G>A, which Lenassi et 
al. proposed to be retina specific, also was present in the Leiden Open Variant Database 
in an USH2a patient.10, 32 Therefore, we do not support this allelic hierarchy theory, but 
suggest that normal cochlear development depends on the presence of at least one 
functional copy of the USH2A protein.
In conclusion, we studied the progression of visual function in a large cohort (n=225) 
of patients with RP resulting from mutations in USH2A. Participants with USH2a had 
a worse visual prognosis than patients with USH2A-associated nsRP. Hence, variants 
causing USH2a seem to have a more deleterious effect on the protein in the retina. Our 
data aid in patient counselling by clinicians and geneticists and can provide valuable 
information for researchers developing therapy for this debilitating disease. 
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Chapter 2.3
Evaluation of hearing in 
patients with USH2A-associated 
nonsyndromic retinitis pigmentosa
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aBstraCt
Objectives: Mutations in USH2A are associated with nonsyndromic retinitis pigmentosa 
(nsRP), which is an inherited progressive retinal degenerative disease. Mutations in this 
gene are also associated with Usher syndrome type IIa (USH2a), which is characterized 
by the combination of retinitis pigmentosa and congenital hearing impairment. The aim 
of this study was to examine hearing in patients with USH2A-associated nsRP, in order to 
draw clear conclusions on their hearing phenotype.
Design: In this cross-sectional study, 21 patients with confirmed USH2A-associated 
nsRP were subjected to audiological tests and a questionnaire to properly examine 
their hearing phenotype. Test results were compared to those previously reported for 
specific groups of normal hearing subjects, patients with USH2a and norms published 
for presbyacusis.
Results: Patients had a mean pure-tone average (0.5 - 4 kHz) of 20.2 dB HL (sd 13.3). A 
significant high number of patients (8/18) showed hearing impairment beyond pres-
byacusis. There was no subjective or statistical congenital hearing impairment. There 
was some progression of hearing impairment at 4 kHz, but this was not significant after 
correcting for presbyacusis and significantly less than observed in patients with USH2a. 
The outcomes on phoneme perception tests in both silence and noise were comparable 
to those of normal hearing subjects, and significantly better than data from patients 
with USH2a. The scores obtained from the questionnaire placed the USH2A-associated 
nsRP patients close to older normal hearing subjects.
Conclusions: The studied patients, clinically and genetically diagnosed with USH2A-
associated nsRP, presented with mild hearing impairment that was not significantly 
progressive, but attained higher levels than could be expected for normal presbyacu-
sis in 8 out of 18 patients. Phoneme and sentence perception were normal. Hearing 
impairment was significantly milder than usual for patients with USH2a. Following the 
clinical criteria, USH2A-associated nsRP represents a different entity compared to USH2a. 
However, in this study, almost half of the USH2A-associated nsRP patients present with 
an adult onset mild hearing impairment.
Submitted as: Hartel, B.P., Pierrache, L.H.M., Huygen, P.L., Homans, N.C., Goedegebure, 
A., van Wijk, E., Snik, A.F., Klaver, C.C., van den Born, L.I., & Pennings,. R.J. Evaluation of 
hearing in patients with USH2A-associated nonsyndromic retinitis pigmentosa
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introduCtion
Nonsyndromic retinitis pigmentosa (nsRP, OMIM 613809) is a progressive inherited 
retinal degenerative disease. It first presents with nightblindness and, as the disease 
progresses, a deterioration in both visual field size and visual acuity as a consequence of 
rod and later cone degeneration.1 NsRP has an overall prevalence of 1:4,000 individuals 
and is inherited in an autosomal dominant, autosomal recessive, or X-linked manner. In 
5-20% of the cases, nsRP inherits autosomal recessively. Mutations in USH2A represent 
the most common cause of autosomal recessive retinitis pigmentosa (RP), accounting 
for 7-23% of cases.2-5
In addition to causing nsRP, mutations in USH2A are also the leading cause of Usher 
syndrome (USH). USH is an autosomal recessively inherited disorder that is characterized 
by congenital sensorineural hearing impairment (HI), progressive RP and occasionally 
vestibular dysfunction. USH is an orphan disease, with a reported prevalence of 4.4 to 
6.2 per 100,000 inhabitants 6-8. The most common genetic type is Usher syndrome type 
IIa (USH2a), accounting for more than half of all USH patients. Patients with USH2a pres-
ent with congenital sensorineural HI, RP diagnosed at a post-pubertal age, and intact 
vestibular function. USH2a is caused by genomic deletions and multiple missense, 
nonsense, frameshift, and splice-modulating mutations in USH2A. This gene encodes a 
transmembrane protein called usherin (OMIM 608400), which has an important role in 
the developing hair bundles, the synapses of hair cells, as well as in the spiral ganglion 
cells in the cochlea.9-13 In the retina, usherin has been localised to the periciliary region 
of photoreceptors.9, 14-16 
The association between USH2A and nsRP was first described by Rivolta et al. in 2000.4 
Patients with nsRP present without extraocular symptoms like hearing loss, hence the 
term nonsyndromic. Audiometric testing is, however, often not performed due to the 
absence of subjective HI. Most studies performed on patients with USH2A-associated 
nsRP focused on the visual phenotype and only marginally described the audiologi-
cal phenotype. However, in their original study Rivolta et al. already suggested that 
USH2A-associated nsRP patients might exhibit adult onset HI, and therefore develop a 
syndromic phenotype at later age.
The aim of this study was to properly examine hearing function in patients with USH2A-
associated nsRP to draw clear conclusions on their hearing status. The results may have 
an impact on disease classification and therefore on patient counselling.
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Patients and MetHods
Patients
All patients, clinically and genetically diagnosed with USH2A-associated nsRP, were ex-
tracted from the databases of three Dutch ophthalmogenetic clinics (Radboud univer-
sity medical centre, Nijmegen, the Netherlands; the Erasmus Medical centre, Rotterdam, 
the Netherlands; the Rotterdam Eye Hospital, the Netherlands). The most important 
criteria in the clinical diagnosis of nsRP was the absence of extraocular symptoms such 
as congenital HI. A total of 28 patients was identified. Five patients refused participation 
and two patients were excluded because of a positive otologic history or ear surgery. 
Finally, 21 patients were included in this study. Some of the presented patients have 
been included in a previous report from one of the participating centres.17 All patients 
agreed to participate in this study by informed consent. This study was approved by the 
local ethics committee (nr. 2015/2030).
audiometric evaluation
Pure tone air and bone conduction thresholds for sound frequencies ranging from 
0.25 to 8 kHz were assessed according to common clinical standards. Bone conduction 
thresholds and tympanometry were evaluated to exclude middle ear problems. Speech 
perception was evaluated using Dutch consonant-vowel-consonant monosyllables 
according to Bosman and Smoorenburg 18 in silence and using standardised Dutch 
sentences according to Plomp et al. in silence and in noise.19 Speech perception of 
monosyllables was measured monaurally and perception of sentences was evaluated 
in sound field. The patients’ demographic, clinical, audiological, and genetic data were 
obtained from databases of participating centres.
questionnaire
The Dutch translation* of the Speech, Spatial and Qualities of Hearing Scale (SSQ) 
questionnaire was used to evaluate subjective hearing complaints over a wide range of 
hearing situations.20 This questionnaire consists of 45 items divided into three subscales. 
Participants responded using a scale from 0 to 10, in which a higher score represents 
better self-reported ability. The results were compared to the outcomes of a young 
normal hearing cohort (n=48, mean age 18.6 years (range 18-22)) and an old normal 
hearing cohort (n=48, mean age 70 years (range 67-80)).21
* The SSQ was translated to Dutch by ExpORL (Department of Neurosciences, Leuven, Belgium) in 
collaboration with VUMC, Amsterdam; AMC, Amsterdam; Erasmus MC, Rotterdam and AZ St.-. Jan, 
Brugge
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data analysis
The audiogram (air conduction threshold) of the best-hearing ear (based on the pure-
tone average for the frequencies 0.5-4 kHz; PTA0,5-4kHz) was used for further analyses. For 
each patient aged below 70 years (n=18), the threshold at a given audio frequency was 
compared to the P95ISO7029 threshold, i.e. the 95th percentile for normal hearing subjects, 
according to the patient’s gender and age.22 HI beyond presbyacusis was accepted if 
the patient’s threshold was higher than the P95ISO7029 threshold at 2 or more frequencies 
(simultaneous significance, see below).
Cross-sectional linear regression analysis was performed for each frequency, sepa-
rately. From these analyses, the onset level of HI (threshold intercept, in dB HL at age 
0 years) and progression of HI, i.e. slope (in dB/year) could be obtained. The residuals 
around the regression line were inspected, and it was tested whether they showed a 
normal distribution around the regression line in first approximation by applying the 
D’Agostino and Spearman (D & S) test. Congenital HI was considered to be significant 
if the 95% confidence interval (95% CI) of the threshold intercept did not include 0 dB 
HL. Progression was considered to be significant, if there was a significant correlation 
and the slope was positive, in which case the 95% CI for slope should not include the 
value of 0 dB/year. If, at any frequency, significant progression was found, it was tested 
whether this represented progression beyond (normal) presbyacusis. This was done by 
subtracting the median (P50ISO7029) threshold for normal presbyacusis according to the 
patient’s gender and age from the raw thresholds of the patients aged below 70 years 
(n=18). The linear regression analysis was then repeated and it was tested whether the 
slope differed significantly from zero. If it did not, it was accepted that the patients had 
progression in line with normal presbyacusis.
The results of the cross-sectional linear regression analysis were used to derive Age 
Related Typical Audiograms (ARTA) as described previously.23 For comparison, similar 
ARTA were constructed for the P50ISO7029 thresholds. 
The 50% speech reception thresholds (SRT) of the participant’s ear that performed best 
on monosyllables and sentences (without noise) were compared to the results of normal 
hearing individuals (n=20, 18). For the perception of sentences in noise, the Speech in 
Noise Ratio (SNR) at 50% speech perception was determined and compared to normal 
hearing individuals (n=20), as well as to previously published results for USH2a patients 
(n=11) by Leijendeckers et al.24
All analyses were performed using Prism 4.02 software (GraphPad, San Diego, CA, 
USA). For the comparison between 2 subgroups (SRT) Student’s t test (unpaired) was 
used, with Welch’s correction if Bartlett’s test had detected unequal variances. For the 
comparison between 3 subgroups (SNR and SSQ) one-way analyses of variance (ANOVA) 
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was used, followed by Tukey’s Multiple Comparison test. A general significance level of 
P=0.05 was applied in all separate tests. Binomial distribution statistics were invoked for 
the simultaneous assessment of significant results in repeated tests, applied on separate 
audio frequencies, or on separate subjects within a subgroup. Simultaneous significance 
was accepted for across-frequencies test if 2 or more frequencies tested significantly (tail 
probability P<0.05 in the binomial distribution with N=6, P=0.05 and q=0.95).
results
Patient characteristics
Twenty-one patients with a mean age of 55 years (range 28-79), clinically and genetically 
diagnosed with USH2A-associated nsRP, were included in this study. Twelve of these pa-
tients reported their hearing to be stable (“unaffected”), six patients reported a “decline” 
of their hearing, and three patients reported their hearing to be “affected”. Three of the 
six patients with hearing that subjectively was getting worse, used bilateral hearing aids. 
None of the other patients used hearing aids. There were no patients with a history of 
noise exposure. The mean age at diagnosis of RP was 39.2 years (sd 13.0). The identified 
pathogenic mutations in USH2A are shown in Table 1.
audiometric evaluation
There were no signs of conductive hearing loss according to the measurements of bone 
conduction thresholds and tympanometry. The first screening of the thresholds indi-
cated the presence of mild HI. The across-subjects PTA0,5-4kHz of air conduction thresholds 
for all patients was 20.2 dB HL (sd 13.3). A significantly high proportion of patients aged 
below 70 years (8 out of 18) had thresholds beyond presbyacusis at 2-6 out of the 6 
frequencies. Six of these 8 patients had worse thresholds mainly at the higher frequen-
cies, i.e. at 2-8 or 1-8 kHz. One patient had such thresholds at 1 and 8 kHz, and another 
at all frequencies (black squares in Figure 1).
Cross-sectional analyses of the threshold data are presented in Figure 1. Each frequen-
cy panel shows the measured thresholds as a function of age. The fitted linear regression 
line and its equation, with 95% CI for slope and intercept, are also presented. The residu-
als around the regression line passed the normality (D & S) test at all frequencies. The 
threshold intercept did not differ significantly from 0 at any frequency; in other words, 
the onset of hearing loss is probably not congenital. The slope was only significantly 
different from 0 dB/year at 4 kHz. To compare this progression to the progression caused 
by presbyacusis, the threshold was corrected for the P50ISO7029 norm value. Linear regres-
sion analysis for (Threshold - P50ISO7029) on age did not disclose any slope that differed 
significantly from zero. The analysis is shown only for 4 kHz in supplemental figure SF.1.
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table 1. Spectrum of USH2A mutations in this study
A. Truncating mutations
nucleotide change Predicted effect no. of alleles loVd exaC (%)
Nonsense mutations
c.1227G>A p.(Trp409*) 1 P
c.4957C>T p.(Arg1653*) 1 P
c.5728C>T p.(Gln1910*) 1 New 0
c.10525A>T p.(Lys3509*) 2 New 0
c.14174G>A p.(Trp4725*) 1 P
Deletions and insertions
c.2299delG p.(Glu767Serfs*21) 4 P
c.7121-?_11047-? del Ex 38-56 1 New
c.8723_8724del p.(Val2908fs) 1 P
B. Intronic mutations
nucleotide change iVs position no. of alleles loVd exaC (%)
c.486-14G>A p.(Met162Ile,Met162_
Cys163insCysPheLeuArg)
2 UV4 0.047
C. Nontruncating mutations
nucleotide change Predicted effect no. of alleles loVd exaC (%) Cadd
c.1256G>T p.(Cys419Phe) 2 P 0.005 34.0
c.1965T>G p.(Cys655Trp) 1 New 0 23.4
c.2276G>T p.(Cys759Phe) 12 P 0.078 33.0
c.2296T>C p.(Cys766Arg) 1 UV3 0.001 25.8
c.3902G>T p.(Gly1301Val) 2 UV2 0.095 32
c.4106C>T p.(Ser1369Leu) 1 New 0.013 7.59
c.4732C>T p.(Arg1578Cys) 1 UV3 0.003 34
c.5516T>A p.(Val1839Glu) 1 New 0 28
c.6926G>T p.(Cys2309Phe) 1 UV3 0.002 33
c.10073G>A p.(Cys3358Tyr) 1 UV3 0.029 28.8
c.12343C>T p.(Arg4115Cys) 4a UV1 0.031 24.2
c.12575G>A p.(Arg4192His) 1 UV2 0.047 24
c.13274C>T p.(Thr4425Met) 3a UV3 0.002 32
total number of alleles 42
Abbreviations: 2T=two truncating mutations, 1T=one truncating mutation and one non-truncating muta-
tion, 2nT=two nontruncating mutations, LOVD=Leiden Open Variant Database, P=pathogenic, UV2=likely 
neutral, UV4=certainly pathogenic, ExAC=Exome Aggregation Consortium, CADD=Combined Annotation 
Dependent Depletion score. a three patients presented with both these mutations on one allele.
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figure 1. Cross-sectional analyses of best-hearing ear air conduction thresholds (dB HL) in 18 patients with 
USH2A-associated nonsyndromic retinitis pigmentosa. 
Each data point represents one patient’s threshold; #2 indicates two patients with the same age and thresh-
old. The regression lines are shown as continuous lines. The grey lines represent the P95ISO7029 thresholds for 
men (continues line) and women (dotted line). At 0.25, 5 and 1 kHz the grey lines are superimposed. The 
black squares represent the patients with thresholds above the P95ISO7029 threshold at 2 or more frequencies 
(simultaneous significance). Panel insets: the linear regression equation Y = slope.X + intercept, with Y for 
threshold (dB HL) and X for age (years), and the 95% CIs for slope and intercept.
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The HI characteristics of the USH2A-associated nsRP patients were compared to P50ISO7029 
and USH2a prediction in ARTA (Figure 2). At each frequency, the vertical equidistant 
differences between adjacent threshold lines reflect the progression per decade. 
The hearing level at 2-8 kHz is generally lower in the P50ISO7029 prediction than in the 
USH2A-associated nsRP patients during the first 5 decades of life. However, the P50ISO7029 
prediction shows more progression in later decades at these frequencies, consequently 
diminishing the difference in hearing levels. Compared to the USH2a ARTA (adapted 
from Figure 3 in Hartel et al. 2016) USH2A-associated nsRP patients have milder HI than 
patients with USH2a, already from early childhood onwards have. In addition, they show 
less progression at the lower frequencies (0.25-1 kHz), however, progression at the 
higher frequencies is almost similar (0.7-0.8 dB/year at 4-8 kHz in patients with USH2a 
versus 0.6-0.8 dB/year in patients with USH2A-associated nsRP).
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figure 2. ARTA of the 21 USH2A-associated nonsyndromic retinitis pigmentosa patients (nsRP). Derived 
from the regression lines shown in Figure 1 (black continuous lines). For comparison ARTA for the P50ISO7029 
presbyacusis are included in for 10-year intervals between 30-70 years (light grey dashed lines), based on 
weighted mean P50 thresholds for 8 men and 10 women. The ARTA for patients with Usher syndrome type 
IIa (USH2a), adapted from Figure 3 in Hartel el al. (2016), are added in dark grey dashed lines. Age (years) 
in italics.
The three panels in Figure 3 represent the phoneme SRT, sentence SRT and sentence 
SNR of all patients. All but two patients attained an unaided maximum phoneme score 
of 100%. One patient attained 98%, and another patient 90%. This last patient was the 
oldest participant aged 79 years and used hearing aids in daily life.
Phoneme SRT values of the USH2A-associated nsRP patients did not differ from the 
normal hearing group (15.4 dB HL versus 15.5 dB HL). Also, the sentence SNR results 
were comparable between the USH2A-associated nsRP and normal hearing group (-4.9 
dB versus -5.5 dB HL, difference of means 0.6 dB HL, Tukey’s test not significant), and 
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figure 3. Three panels representing the Speech Reception Thresholds (SRTs) for phonemes and sentences 
in silence (A and B) and noise (C) for the studied population of USH2A-associated nonsyndromic retinitis 
pigmentosa patients, normal hearing patients and USH2a patients.24
Abbreviations: SRT = Speech Reception Threshold, SNR = Speech in Noise Ratio, NH = Normal Hearing. * 
indicates significant difference.
Age
SS
Q
 T
ot
al
 sc
or
e 
0 10 20 30 40 50 60 70 80
6
8
10
0
*
*
figure 4. Total scores on the Speech, Spatial and Qualities of hearing (SSQ) questionnaire. The total scores 
of the USH2A-associated nonsyndromic retinitis pigmentosa patients (black square) were compared to 
those of the normal hearing young (upside-down black triangles) and old (upright black triangles) groups 
described by Banh et al. in 2012. The mean age and age range (horizontal lines) are shown in the lower part 
of the figure. * indicates significant difference.
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these results were significantly better compared to patients with USH2a (0.9 dB, differ-
ence of means 5.8 dB HL, Tukey’s test significant, P<0.001, 95% CI of difference 4.5 to 
7.1 dB HL). However, sentence SRT values of the USH2A-associated nsRP patients were 
significantly worse compared to the normal hearing group (23.1 dB HL versus 16.4 dB 
HL, difference of means 6.7 dB; Student’s t test with Welch’s correction, P=0.0007, 95% CI 
of difference 3.2 to 10.2 dB HL). 
questionnaire
The total scores for the SSQ, and the Speech, Spatial and Qualities subscale scores for the 
group of USH2A-associated nsRP patients were 7.5 (sd 1.1), 6.8 (sd 1.7), 7.6 (sd 1.3) and 8.1 
(sd 1.0), respectively. The total score, as well as each of the subscale scores appeared to 
be comparable to the corresponding scores for the older normal hearing patient cohort. 
ANOVA followed by Tukey’s test showed that each of these scores was significantly lower 
than the corresponding one for the cohort of younger normal hearing subjects in the 
study of Banh et al. (2012). The mean total scores were 7.5 versus 8.8 (P<0.001, difference 
of means 1.3, 95% CI 0.7 to 1.9). Finally, there was also a similar significant difference 
in score between the reported young and old normal hearing: 8.8 versus 7.7 (P<0.001, 
difference of means 1.1, 95% CI 0.7 to 1.5; Figure 4). 
disCussion
This study shows that a proportion of USH2A-associated nsRP patients presented with 
a level of HI that was higher compared to presbyacusis (8/18 patients). However, the 
overall patient sample did not report or statistically show a congenital onset of HI. 
Neither did the HI show progression beyond presbyacusis. Finally, patients with USH2A-
associated nsRP show normal speech perception in both silence and noise.
From the initial association of nsRP with mutations in USH2A (Rivolta et al., 2000), there 
was uncertainty about its clinical classification. The absence of HI at birth was a clear 
criterion, but Rivolta suggested that “many patients with presumed nonsyndromic RP 
who report mild, subjective hearing impairment actually have Usher syndrome type II”.4 
This instigated us to speculate about the spectrum of clinical presentations associated 
with pathogenic mutations in USH2A. In the present study, congenital HI did not occur 
in medical history, nor could congenital HI be substantiated from the data analyses. 
Following the clinical criteria, USH2A-associated nsRP is considered as a different entity 
from USH2a. However, in this study, almost half of the USH2A-associated nsRP patients 
present with a mild adult onset mild hearing impairment.
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With the improved methods for genetic testing, many large cohorts of RP patients have 
been screened for mutations in USH2A. In most of these studies, no or only subjective 
absence of HI was reported.3, 5, 25-30 In a few studies, the authors mentioned audiograms, 
and some presented audiogram data. Only five studies reported possible adult-onset 
HI 4, 31-34 of which two corrected for presbyacusis.4, 33 They could not confirm any substan-
tial HI in patients with USH2A-associated nsRP.
Most of the mutations found in patients with USH2A-associated nsRP are also identified 
in USH2a patients. There is no clear evidence of specific mutations being solely associ-
ated with either USH2A-associated nsRP or USH2a. However, none of the combinations 
of USH2A mutations identified in the present cohort was found in a previously described 
international cohort of 110 patients with USH2a.35 Possibly, there are unique combina-
tions of mutations that affect hearing more mildly. See Supplemental Table ST.1 for all 
combinations of mutations in the present study.
In two previous studies, differences in auditory and ocular phenotypes between 
USH2A-associated nsRP and USH2a were shown to be associated with different types 
of mutations in USH2A.17, 35 Mutations can be predicted to result in a truncated protein. 
Protein truncating mutations will most often result in nonsense-mediated mRNA de-
cay 36, whereas nontruncating mutations will presumably lead to altered protein folding, 
localisation and function. As Pierrache et al. (2016) described, none of the patients with 
USH2A-associated nsRP presented with two predicted protein truncating mutations. In 
the present study, thirteen patients (62%) carried one allele with a protein truncating 
mutation and one allele with a protein nontruncating mutation. The other 8 patients 
carried two protein nontruncating alleles. No obvious differences between the above-
mentioned subgroups with different types of mutation combinations were observed 
in PTA (0.5 - 4 kHz), SRT, SNR or SSQ outcomes. This suggests that there is no additional 
negative effect on hearing of a protein truncating mutation in USH2A in patients with 
USH2A-associated nsRP. In contrast, Pierrache et al. (2016) demonstrated a positive cor-
relation between the number of truncating mutations in USH2A and an earlier onset of 
RP and more progressive visual deterioration in patients with USH2a. Similarly, it was 
shown that patients with USH2a and two truncating mutations in USH2A presented with 
more severe and progressive HI as compared to patients with one or no truncating mu-
tations.35 Still, not all variations found in HI in patients with USH2a could be explained 
by the presence of absence of truncating mutations. It seems possible that patients with 
USH2A-associated nsRP have mutations, or combinations of mutations with a milder 
effect on the phenotype compared to patients with USH2a. Currently, a large cohort of 
USH2a patients is being analysed in an attempt to correlate the observed variability to 
individual mutations or mutation combinations. This might result in the identification 
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of mutations or combinations of mutations with a milder or more severe effect on the 
phenotype. 
When comparing outcomes of the present study to those of previously reported stud-
ies, there was no age matching between the different data sources. The patients with 
USH2A-associated nsRP in the present study had a mean age of 55 years, range 28-79. 
The normal hearing subjects as studied by Bosman et al. and used for the comparison 
of SRT values had a mean age of 25 years, range 21 - 29.18 The difference in age might 
explain the difference found in sentence SRT. The cohort of patients with USH2a as 
described by Leijendeckers et al., that was used for comparing the SNR, had a mean age 
of 41 years, range 28 - 59.24 Banh et al. presented the SSQ results of two normal hearing 
cohorts, a young cohort with a mean age of 18.6 years, range 18-22 and an old cohort 
with a mean age of 70, range 67-80 (Figure 4).21 The patients with USH2A-associated 
nsRP reported the same scores as the old normal hearing cohort presented by Banh 
et al., but the scores of both groups were lower than those reported for young normal 
hearing subjects. As illustrated in Figure 4, the USH2A-associated nsRP patient group 
had a large overlap with the old normal hearing cohort, possibly explaining the appar-
ent similarity of their scores.
In conclusion, the patients in this study that were clinically and genetically diagnosed 
with USH2A-associated nsRP presented with a level of HI higher than in presbyacusis in 
8/18 patients. There was, however, no reported or statistically extrapolated congenital 
hearing impairment. In addition, there was no progression beyond presbyacusis, and 
the HI appeared to be milder than the HI typical for patients with USH2a. Hence, USH2a 
and USH2A-associated nsRP are considered as different entities. The difference might be 
explained by differences in the effects of specific mutations or mutation combinations, 
or perhaps other factors, such as epigenetics or strong environmental factors, important 
points of interest for future research.
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supplemental figure sf.1. Cross-sectional analysis of ‘threshold - P50ISO7029’ on age. Each data point repre-
sents one patient’s threshold. The regression line is shown as continuous line. Panel inset: the linear regres-
sion equation Y = slope.X + intercept, with Y for threshold (dB HL) and X for age (years). In grey the 95% 
confidence interval values for the slope.
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supplemental table st.1. Spectrum of USH2A mutation combinations in this study.
Abbreviations: see Table 1.
1t
allele 1 allele 2 Patients (%)
c.1227G>A, p.(Trp409*) c.12575G>A, p.(Arg4192His) 1 (4.8)
c.2276G>T, p.(Cys759Phe) c.486-14G>A, p.(Met162Ile,Met162_
Cys163insCysPheLeuArg) 2 (9.5)
c.2276G>T, p.(Cys759Phe) c.8723_8724del, p.(Val2908fs) 1 (4.8)
c.2276G>T, p.(Cys759Phe) c.10525A>T, p.(Lys3509*) 1 (4.8)
c.2276G>T, p.(Cys759Phe) c.14174G>A, p.(Trp4725*) 1 (4.8)
c.2296T>C, p.(Cys766Arg) c.4732C>T, p.(Arg1578Cys) 1 (4.8)
c.2299del, p.(Glu767fs) c.2276G>t, p.(Cys759Phe) 4 (19.0)
c.7121-?_11047+?, del Ex 38-56 c.2276G>T, p.(Cys759Phe) 1 (4.8)
c.12343C>T, p.(Arg4115Cys) c.13274C>T, 
p.(Thr4425Met)
c.5728C>T, p.(Gln1910*)
1 (4.8)
c.12343C>T, p.(Arg4115Cys) c.13274C>T, 
p.(Thr4425Met)
c.10525A>T, p.(Lys3509*)
1 (4.8)
2nt
allele 1 allele 2 Patients (%)
c.1256G>T, p.(Cys419Phe) c.4106C>T, p.(Ser1369Leu) 1 (4.8)
c.1965T>G, p.(Cys655Tr) c.6926G>T, p.(Cys2309Phe) 1 (4.8)
c.2276G>T, p.(Cys759Phe) c.5516T>A, p.(Val1839Glu) 1 (4.8)
c.2276G>T, p.(Cys759Phe) c.12343C>T, p.(Arg4115Cys) 1 (4.8)
c.3902G>T, p.(Gly1301Val) c.3902G>T, p.(Gly1301Val) 1 (4.8)
c.4957C>T, p.(Arg1653X) ; c.7379G>A, 
p.(Arg2460His)
c.10073G>A, p.(Cys3358Tyr) 1 (4.8)
c.12343C>T, p.(Arg4115Cys) ; c.13274C>T, 
p.(Thr4425Met)
c.1256G>T, p.(Cys419Phe) 1 (4.8)
total 21 (100)

Chapter 3
Rehabilitation of patients with 
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Chapter 3.1
Hearing aid fitting for visual and 
hearing impaired patients with 
Usher Syndrome type IIa 
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aBstraCt
Objectives: Usher syndrome is the leading cause of hereditary deafblindness. Most 
patients with Usher syndrome type IIa start using hearing aids from a young age. A seri-
ous complaint refers to interference between sound localisation abilities and adaptive 
sound processing (compression), as present in today’s hearing aids. The aim of this study 
was to investigate the effect of advanced signal processing on binaural hearing, includ-
ing sound localisation.
Methods: In this prospective study, patients were fitted with hearing aids with a nonlinear 
(compression) and linear amplification programs. Data logging was used to objectively 
evaluate the use of either program. Performance was evaluated with a speech-in-noise 
test, a sound localisation test and two questionnaires focusing on self-reported benefit.
Results: Data logging confirmed that the reported use of hearing aids was high. The 
linear program was used significantly more often (average use: 77%) than the nonlinear 
program (average use: 17%). The results for speech intelligibility in noise and sound 
localisation did not show a significant difference between types of amplification. How-
ever, the self-reported outcomes showed higher scores on ‘ease of communication’ and 
overall benefit, and significant lower scores on disability for the new hearing aids when 
compared to their previous hearing aids with compression amplification.
Conclusions: Patients with Usher syndrome type IIa prefer a linear amplification over 
nonlinear amplification when fitted with novel hearing aids. Apart from a significantly 
higher logged use, no difference in speech in noise and sound localisation was observed 
between linear and nonlinear amplification with the currently used tests. Further re-
search is needed to evaluate the reasons behind the preference for the linear settings.
Published as: Hartel, B.P., Agterberg, M.J., Snik, A.F., Kunst, H.P., van Opstal, A.J., Bosman, 
A.J., & Pennings, R.J. (2016). Hearing aid fitting for visual and hearing impaired patients 
with Usher Syndrome type IIa. Clin Otolaryngol. doi: 10.1111/coa.12775
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introduCtion
Usher syndrome (USH) is the leading cause of hereditary deafblindness. This autosomal 
recessively inherited disorder is characterised by sensorineural hearing impairment, 
retinitis pigmentosa (RP) and in part of the cases vestibular dysfunction. USH is clini-
cally and genetically heterogeneous and has a prevalence of 4.4–6.2 per 100.000 in-
habitants.1-3 Usher syndrome type II is one of the three clinical types of USH, and Usher 
syndrome type IIa (OMIM276901) is the most common genetic type, accounting for 
more than half of the USH patients.4-6 Pathogenic mutations of this type are identified 
in the USH2A gene located on chromosome 1q41.7, 8 Patients with Usher syndrome type 
IIa (USH2a) have a congenital moderate to severe high-frequency hearing impairment, 
intact vestibular function and RP, a progressive retinal degenerative disease that usually 
first becomes manifest in the second decade of life and eventually leads to blindness.
Most patients with USH2a use hearing aids from a young age.9 During their lives, 
these patients will therefore face multiple hearing aid fitting procedures. Owing to the 
multiple complex settings and programs of today’s sophisticated hearing aids, fitting 
periods will be prolonged to find the best settings for these double sensory-impaired 
patients as described by patients with this specific syndrome.10 Their report pointed out 
the difficulties experienced during hearing aid fitting and hearing aid use, which is the 
motivation for this study. The additional onset of visual impairment in young adulthood 
is thought to play a major role in the lengthy fitting procedures. The impact of the hear-
ing disability is probably more severe because of the additional effects of RP, like the loss 
of visual feedback.
Nowadays, hearing aids are equipped with advanced algorithms focusing on the larg-
est consumer group: the elderly. Many algorithms have been developed to optimise 
speech intelligibility and to provide comfortable hearing. However, less attention is 
given to the preservation of natural cues used for localisation, such as interaural time dif-
ference (ITD) and interaural level difference (ILD); especially in the horizontal (azimuth) 
plane, the difference in sound arrival at both ears (ITD) for the lower frequencies (<1.5 
kHz) and the difference in sound level between both ears (ILD) for the higher frequen-
cies (>3 kHz) are important for sound localisation.11
The aim of this study was to investigate whether advanced signal processing of sound 
by hearing aids has a positive or negative effect on speech intelligibility in noise (with 
spatially separated speech and noise sources) and on sound localisation. Both tasks 
require binaural hearing abilities. The patients were fitted with novel hearing aids with 
a nonlinear (compressive) and linear amplification program. It was hypothesised that 
the linear program affects sound localisation minimally because the ITD and ILD-cues 
are potentially less perturbed.12 This may lead to better sound localisation performance 
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when compared to the nonlinear program. In contrast, the nonlinear program may pro-
vide better audibility and speech recognition in noisy environments, when compared to 
a linear fitting.13 To test these hypotheses, details of hearing aid use were retrieved from 
data logging and speech reception in noise, and sound localisation was tested in an 
elaborate set-up.14 Furthermore, two questionnaires and a diary were used to evaluate 
the subjective benefit and reported use in daily life of the newly fitted hearing aids.
Patients and MetHods
Patients
The patients with USH2a were extracted from the Nijmegen Usher syndrome database. 
Patients were included if they were clinically diagnosed with Usher syndrome type II, 
had two identified pathogenic mutations in USH2A, had a pure-tone average (0.5–8 kHz) 
better than 80 dB HL and were above 18 years of age. Twenty-four adults were selected 
for participation and contacted. Finally, eighteen of them decided to participate in this 
study. Six patients refused without specified reasons. Some of the patients participated 
in former studies on hearing in USH2a from our centre.15, 16 This study was approved by 
the local ethics committee (nr. 2012/520).
audiometric evaluation and hearing aids
At the first visit, pure-tone air and bone-conduction thresholds were assessed for fre-
quencies ranging from 0.25 to 8 kHz according to the ISO 8253-1 standard.17 All patients 
were bilaterally fitted with Phonak Naida Q SP hearing aids (Phonak AG, Stäfa, Switzer-
land), hereafter referred to as ‘new hearing aids’. The fitting was performed using the 
Target system 3.1. In six patients’, ear-moulds were replaced with the standard occluding 
ear-moulds. These patients could adapt at least 2 weeks with the Phonak hearing aids 
and a nonlinear program to get used to the ear-moulds before the tests started. The vent 
diameter varied according to hearing impairment, but all 18 patients were fitted with 
vents smaller than 2 mm.
Two listening programs were activated, and for 13 patients, a telecoil program was 
added. The first program consisted of a nonlinear fitting on the basis of the NAL-NL2 
rule.18 Minor adjustments in gain were made according to remarks from the patients. 
The nonlinear program used syllabic compression (SC) with an attack time of 10 ms and 
a release time of 80 ms. In this program, microphone directionality was set as a static, 
input independent, beam former (‘Real-Ear sound’; to compensate to some extent for 
pinna function) and the default adaptive features were activated. The linear program 
was adapted to the nonlinear program by setting the same gain for a 65 dB SPL input. A 
compression ratio of one was aimed for as allowed by the patient’s dynamic range, and 
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all adaptive features were deactivated, apart from feedback suppression, which was set 
to medium. Microphone directionality was fixed to omnidirectional.
Figure 1 shows that the CR in the linear program (mean 1.2, standard deviation (SD) 0.2)
was significantly lower at all frequencies compared to the CR in the nonlinear program 
(mean 1.8, SD 0.4) (panel a). The mean CR for the linear program was not 1.0 because 
of the reduced dynamic range in the higher frequencies. This is illustrated in panel b, 
in which a slight increase in CR can be seen in the higher frequencies at input levels 
between 65 and 80 dB SPL.
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figure 1. Compression ratios for the linear and nonlinear program.
(A) The mean compression ratios in the nonlinear program are represented by squares and continuous 
line with the standard deviation on either side of the squares. The mean compression ratios in the linear 
program are represented by the triangles and continuous line with the standard deviation on either side of 
the triangles. (B) Compression ratios for the linear program between 50–65 dB SPL and 65–80 dB SPL. The 
mean compression ratios in the linear program are represented by black triangles and continuous black 
line with the standard deviation on either side of the triangles. The average compression ratios in the linear 
program between 50 and 65 dB SPL are represented by the grey downward triangles and continuous grey 
line. The average compression ratios in the linear program between 65 and 80 dB SPL are represented by 
grey upward triangles and continuous grey line.
When the hearing aids were switched on, half of the patients started with the linear 
program, whereas the other half started with the nonlinear program. Wireless commu-
nication between both hearing aids was activated (Quick-Sync) to enable simultaneous 
change of sound level and program across ears. Volume control was available but at 
follow-up, none of the participants reported to have daily changed the volume. All 
patients were instructed to try both programs in all situations. Between the two test ses-
sions, all patients were contacted and five patients were subsequently referred to their 
own hearing aid dispenser for minor (documented) adjustments of gain, only for the 
nonlinear program. At follow-up, the overall use, individual program use and changes in 
volume were retrieved from the new hearing aids. Moreover, data logging was activated 
to retrieve the number of days, hours and used programs.
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speech intelligibility
Speech intelligibility was measured in silence and in noise with the patient’s own hear-
ing aids before fitting and with their new hearing aids with either program (nonlinear 
and linear) directly after fitting and at follow-up. The speech test used was the Dutch 
matrix test19 in an open-set response format, in which listeners had to repeat the words 
they understood from target sentences spoken by a female. These sentences were al-
ways presented from the front (at 1 m), and noise was either presented from the front or 
randomly from +90 or -90 degrees (at 1 m, S0/Ns90 and S0/Nf90). The stationary noise had 
an average power spectrum equal to that of the sentences. Additionally, a single-talker 
male babble noise was used based on the International Speech Test Signal.20, 21 The level 
of noise was adaptively varied according to the Brand and Kollmeier procedure,22 with a 
minimum step size of ±1 dB. In the measurement of speech intelligibility in silence, the 
same set-up was used without noise and the first word was presented at 65 dB(A). Two 
lists of ten sentences were presented per noise configuration and listening condition 
and the outcomes averaged to limit the intra-individual variation. Two training lists were 
used to familiarise subjects with the task, the first starting with an easy speech level of 
65 dB(A) without noise. The second training list was presented with a 15 dB SNR (target 
speech at 65 dB(A), noise at 50 dB(A)). Noise started 2 s before and ended 2 s after the 
target sentence presentation. The speech level was always held constant at 65 dB(A). 
The 50% speech reception threshold (SRT) was determined over the last 7 reversals.
sound localisation
Apparatus
The patients were seated in a comfortable chair in the centre of a completely dark and 
sound-attenuated room. The ambient background noise level in the room was 30 dB(A). 
Horizontal head movements were recorded using the magnetic search coil induction 
technique. Patients wore a lightweight spectacle frame on which a small coil was 
mounted.14 They were asked to turn their head as quickly and as accurately as possible 
in the perceived stimulus direction. The patient controlled stimulus onset by pressing a 
hand-held button while facing straight ahead.
Stimuli
The stimuli were digitally generated in Matlab (R2012a, The Mathworks, Inc., Natick, 
MA, USA). The sound was presented by a broad-range loudspeaker (MSP-30; Monacor 
International GmbH, Bremen, Germany). Fifty-eight loudspeakers were mounted on 
a vertical hoop at 100 cm of the patient that could turn to every position in azimuth. 
Three different acoustic stimuli were presented; a broadband stimulus (0.5–20 kHz; BB), 
a low-pass filtered noise stimulus (LP; high-frequency cut-off at 1.5kHz) and a high-pass 
filtered noise stimulus (HP; low-frequency cut-off at 3 kHz). For the BB and HP stimuli, 
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sound intensities were roved from 55 to 75 dB(A) in steps of 10 dB. This was carried out 
to prevent the use of perceived loudness as a cue for localisation.23 For a more detailed 
description of set-up and stimuli, see reference14
Experiments
A visual calibration experiment was first run to map the head-position data to known 
spatial locations and to demonstrate that patients had no motoric problems to direct 
their head to the stimulus positions. After this calibration run, 10 practice trials were 
presented to become accustomed to the sounds and the open-loop head-movement 
response procedure.
For the localisation experiment, the patient was asked to orient towards 12 LP 
stimuli and 36 BB and 36 HP stimuli in each condition (own hearing aids, new hearing 
aids nonlinear, new hearing aids linear). The stimuli were presented at randomised loca-
tions between -75 and 75 degrees in azimuth with a minimum of 20 degrees between 
consecutive stimuli and at zero degrees’ elevation. Regular breaks were introduced to 
prevent fatigue and to motivate the patients.
self-reported outcomes
In addition to the objective outcome measures, two questionnaires and a diary were 
used to assess each patient’s reported benefit, satisfaction and use of the new hearing 
aids.
The Abbreviated Profile of Hearing Aid Benefit (APHAB) is a hearing related benefit 
questionnaire.24 It contains 24 items and is a disability-based inventory to document 
the outcome of hearing aid fitting and to evaluate fitting over time. The questionnaire 
yields scores on four subscales: ease of communication, listening under reverberant 
conditions, listening in background noise and aversiveness of sounds. The APHAB was 
used to qualify the disability and the differences in disability between hearing aids. The 
maximum disability was represented by a 100% of the time that certain situation oc-
curred, the patient felt disabled, and the minimum (best score) was 0% (never disabled).
The Glasgow Hearing Aid Difference Profile (GHADP) was designed to evaluate patient 
reported hearing disability, handicap, hearing aid use, benefit, residual disability and 
satisfaction.25 This inventory provided eight possible environments. Four of them were 
predetermined, and four others could be added by the patient. This questionnaire was 
used to address the differences between the patient’s own and new hearing aids.
A nonvalidated diary was provided to the patient for the first week after fitting and the 
last week before the follow-up visit. Questions about the number of changes between 
programs, use of programs and satisfaction on a 1–10 Likert scale were included. Finally, 
patients were also asked to describe situations in which they used a specific program.
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data analysis
Patient characteristics were compared using Student’s t-test or their nonparametric 
counterpart if the data deviated from a normal distribution. All analyses were performed 
using Prism 5.03 software (GraphPad, San Diego, CA, USA). A paired t-test was per-
formed for comparison of compression ratios between programs. Binomial distribution 
statistics were used for simultaneous assessment of the CR over all six audio frequencies. 
Simultaneous significance was accepted if such differences were significant at two of 
more frequencies (P<0.05 tail probability in the binomial distribution with n=6, P=0.05, 
q=0.95). Furthermore, one-way analysis of variance (ANOVA) with post hoc Bonferroni 
correction was used to compare speech intelligibility and self-reported outcomes be-
tween the two fittings and conditions. A general significance level of P=0.05 was applied 
in all separate tests.
Sound localisation
All responses were analysed with Matlab for each patient and condition (R2012a, The 
Mathworks, and Inc.). The best linear fit (least squares criterion) of the stimulus response 
relationship on the azimuth data was determined with the following equation:
αr = b + GαS
in which αr is the response azimuth in degrees, b the response bias in degrees, G the 
response gain (dimensionless) and αS the presented stimulus azimuth in degrees.26 From 
the regression, we calculated the coefficient of determination (r2) of the fit, as well as the 
mean absolute error (MAE; in degrees). A good performer should produce a gain and 
r2 close to 1.0 and a bias and MAE close to 0.0 degrees. Results for each condition were 
averaged across patients, and the gain changes were normalised to enable a direct and 
unbiased comparison between conditions as described by Zwiers et al.27 The normalisa-
tion of the gain change was obtained with the following equation:
GE = |G/GC - 1|
In which G is the measured gain for a particular condition in the patient and GC the gain 
for the control condition in the patient. A value of GE = 0 indicates that the measured 
gain was equal to the control value, that is no change in gain. The absolute value ensures 
that systematic overshoots and undershoots yielded similar measures.
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results
Patients
A total of 18 patients (nine male and nine female) with a mean age of 38.8 years (range 
20–55) were included, and Table 1 shows their general characteristics. Most patients 
reported a childhood onset of hearing impairment and an almost lifetime use of hearing 
aids. All patients but one used their own hearing aids during at least 1 year. The median 
follow-up period was 6.3 weeks (range 5.3– 16.9).
audiometric evaluation
A symmetrical, high-frequency, sensorineural hearing impairment was observed in all 
patients. The mean audiogram, obtained from thresholds of the best hearing ear, is 
shown in Figure 2. The Loudness Discomfort Levels (LDL), relative to the mean thresh-
olds, clearly demonstrates a reduction in dynamic range of hearing, most pronounced 
at the high frequencies. This influences the calculated compression ratios, as shown in 
Figure 1.
table 1. Patient characteristics
Number of patients, n (m/f )  18 (9/9)
Mean age, y (range) 38.8 (20-55)
Median age start hearing impairment, y (range) 0 (0-5)
Median age first hearing aid, y (range) 4 (2-36)
Mean use own hearing aids, y (sd) 3.8 (1.7)
Median follow-up, weeks (range) 6.3 (5.3-16.9)
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figure 2. Average thresholds and Loudness Discomfort Levels of the best ear. 
Average thresholds are represented by black squares and continuous line. Per frequency, the standard de-
viations are represented by thick black lines on either side of the squares. The loudness discomfort levels 
are represented by the grey squares and continuous line. Per frequency, the standard deviations are rep-
resented by thick grey lines on either side of the squares. Abbreviations: LDL, Loudness Discomfort Levels; 
HL, hearing level.
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Hearing aids
All patients used their new hearing aids on a daily basis as shown in Table 2 with a mean 
overall use of 11.6 h/day. All but one patient kept using the new hearing aids after the 
study ended. That one patient preferred his old hearing aids. All patients reported to 
have tried the two programs in different situations. Overall, patients used the linear pro-
gram on average 77% of the time (range 56%–99%), whereas this was only 17% (range 
1%–44%) for the nonlinear program (two-sided; P>0.001; 95% Confidence Interval (CI) 
46.0–75.2). This difference was statistically significant (bold values in Table 2). No differ-
ence was noted between subgroups based on program at starting up.
speech in noise
Table 3a shows no significant differences in mean SRT between the patient’s own and 
new hearing aids with either the linear or nonlinear program. At the second session, a 
decrease in SRT was seen in patients with new hearing aids in both programs compared 
to the first measurement directly after the fitting, but this difference was not significant.
Likewise, no significant differences were found in mean SRT in noise between both 
programs at either visit. However, a significant improvement was seen with the own and 
new hearing aids (in either program) when the noise (stationary or babbled noise) was 
presented at -90 or +90 degrees (Table 3b).
sound localisation
For four patients, we could not obtain localisation performance with their own hearing 
aids: one patient did not use his hearing aids, for one patient the hearing aids failed and 
for two patients the set-up failed. Figure 3 shows two typical results of sound localisa-
tion for broadband stimuli for two of the patients (#6 and #16). Patient #16 localised well 
with his/her own hearing aids, as well as with the two programs for the new hearing 
aids. Note that the bias decreased from -13 deg (with own hearing aids) to nearly 0 deg 
(new hearing aids). Patient #6 localised much better with the new hearing aids for either 
program, when compared to the own hearing aids.
table 2. Data logging from the new hearing aids
Mean data logging, days (sd) 53.7 (18.0)
Mean use new hearing aids/day, hours (sd) 11.6 (4.7)
Mean use linear program,  % (range) 77 (56-99)
Mean use nonlinear program, % (range) 17 (1-44)
Mean use telecoil program, % (range) 6 (0-28)
In bold the values which differed significantly between the linear and nonlinear program.
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table 3. 
(a) Mean SRT values for the own and new hearing aids without noise
own new nonlinear new linear
at fitting follow-up at fitting follow-up
SRT, mean (sd) 39,4 (4,6) 38,9 (4,6) 37,4 (4,7) 42,3 (4,2) 40,6 (4,9)
(b) Mean signal-to-noise ratio values for the own and new hearing aids
own new nonlinear new linear
at fitting follow-up at fitting follow-up
SNR S0/Ns0, mean (sd) -4.1 (1.6) -3.2 (1.5) -4.2 (1.6) -3.8 (1.2) -4.8 (1.8)
SNR S0/Ns90, mean (sd) -7.4 (4.3)* -8.1 (3.3)* -9.9 (3.9)* -7.9 (3.5)* -9.6 (3.7)*
SNR S0/Nf0, mean (sd) n.p. n.p. -6.9 (3.5) n.p. -6.3 (3.6)
SNR S0/Nf90, mean (sd) n.p. n.p. -11.0 (4.6)* n.p. -12.2 (4.4)*
a) Abbreviations: SRT, speech reception threshold. b) The signal-to-noise ratio is the ratio at which the SRT 
is 50%. Abbreviations: SNR, signal-to-noise ratio; S, Signal; Ns, Speech noise; Nf, male babble noise; N0, 0 de-
grees; N90, 90 degrees. *SNR S0/Ns (or f) 90 significantly better compared to SNR S0/Ns (or f) 0.
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figure 3. Sound localisation in azimuth in three conditions for two patients. Graph representing the results 
of two individual patients (#6 and #16) for sound localisation in azimuth (horizontal plane) in three condi-
tions: with their own hearing aids, with the new hearing aids with the nonlinear amplification program and 
with the new hearing aids with the linear amplification program. Each dot represents one of the 36 broad-
band stimuli. The dotted line represents the best linear fit (least squares criterion) of the stimulus–response 
relationship. The parameters of the fit are shown in the panel: g = response gain, b = response bias and r2 = 
coefficient of determination (see ‘Patients and methods’). Abbreviations: deg, degrees.
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Figure 4 shows all the measured values for G, r2, b and MAE for the three conditions with 
broadband sounds. The results for patients #6 and #16 are highlighted. On an individual 
level, the good performers with their own hearing aids seem to perform equally well in 
all three conditions. However, the poor performers with their own hearing aids seem to 
perform better with the new hearing aids, and equally well for both programs.
The normalised gain (GE) was used to compare the average gains between the three 
conditions. Note that GE = 0 when the gains for two conditions are the same (see ‘Pa-
tients and methods’). Figure 5 demonstrates that the overall mean values did not differ 
significantly.
Overall, on all parameters, in all conditions of the sound localisation test, no significant 
differences in sound localisation were found between the own and new hearing aids 
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figure 4. Individual sound localisation parameters. Graphs representing individual gain, bias, coefficient of 
determination and Mean Absolute Error (MAE) values for broadband stimuli in three conditions: with the 
patient’s own (dots) and new hearing aids in nonlinear (squares) and linear (triangles) program. The values 
for patients #6 and #16 are highlighted for they were represented in Figure 3.
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nor between the two programs in the new hearing aids. For the average values of these 
parameters, see Supplemental Table ST.1 (A and B).
questionnaires
Figure 6 shows the results of the AHPAB per subscale compared to the norm percentiles 
obtained in 2010 by Johnson et al.28 for successful hearing aid users. When comparing 
the AHPAB concerning the previous hearing aids and that concerning the new hearing 
aids, on each subscale a decline in disability was seen, which was statistically significant 
on the subscale ease of communication (P=0.018; 95% CI 2.47–22.69). All items in the 
subscale ease of communication concerned situations in quiet, in small groups without 
background noise. Further-more, the overall score on the APHAB improved significantly 
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figure 5. Comparison of normalised average gains. Graph representing the mean gain-error (GE) for the 
differences between the own and new hearing aids in the nonlinear amplification program (nlin), between 
the own and new hearing aids in the linear amplification program (lin) and between the nonlinear ampli-
fication program of the new hearing aids. Per mean GE, the standard deviations are represented by black 
lines on either side of the squares.
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figure 6. Abbreviated Profile of Hearing Aid Benefit (APHAB). Mean scores for the AHPAB subscales for the 
own (black squares _SD) and new (black triangles +SD) hearing aids. For comparison, the norm percentiles 
as defined by Johnson et al. in 2010 for successful hearing aid users were added.28
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(from 46.0, SD 12.4 to 34.8, SD 12.5, P=0.018; 95% CI 2.02–18.46), representing an overall 
benefit of the new hearing aids compared to their own hearing aids. Concerning listen-
ing in background noise or in reverberant places, no significant changes were found.
On the GHADP questionnaire, a high score on device use is reported, with median 
scores above 90% for their own as well as new hearing aids. After using the new hearing 
aids, the mean reported disability, in pre-determined and personal relevant situations, 
showed a significant drop of 16.3% on a baseline of 58.6% (P=0.002).
Finally, using their diary, the patients reported a major decrease in change of programs 
between the first and last week of the study, from 6.6 (SD 4.6) to 2.4 (SD 1.7) changes 
per day (P=0.001). More important, the satisfaction with the linear program, 7.7 (range 
1.0-9.6), was significantly higher than the satisfaction with the nonlinear program, which 
was 5.9 (range 1.1-8.5) (P=0.02).
disCussion
The present study showed that the included patients with USH2a demonstrate a signifi-
cant preference for the linear amplification program with omnidirectional microphone 
over the nonlinear program with pinna imitating directionality, measured objectively 
(mean logged use of 77% versus 17%) as well as subjectively (satisfaction of 7.7 versus 
5.9 out of 10). In addition, the self-reported outcomes showed significantly higher scores 
on ease of communication and overall benefit and lower scores on disability for the new 
hearing aids compared to their own hearing aids. These results are complemented with 
good results for speech intelligibility in noise and sound localisation. The latter tests, 
however, did neither show a difference between hearing aids nor programs. It should 
be noted that the two domains of the APHAB that deal with spatial hearing (hearing in 
noisy places and in reverberant surroundings) did not show a significant improvement, 
which seems to agree with the objective measurements. Therefore, the hypothesis that 
a linear amplification program of hearing aids in patients with USH2a would lead to 
improved sound localisation when compared to a nonlinear amplification setting could 
so far not be confirmed.
On an individual level, differences in localisation were found between the patient’s own 
hearing aids and their new hearing aids at follow-up for BB (Figure 5) and LP sounds. Pa-
tients who performed poorly with their own hearing aids performed better with the new 
hearing aids in either program. Patients who already performed quite well with their 
own hearing aids, performed equally well with the new hearing aids in both programs.
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The good sound localisation performance of the patients with USH2a is not in agree-
ment with their reported subjective difficulties.10 A possible explanation for these dif-
ferences might lie in the validity of the used method. The laboratory set-up and test 
protocol used in this study may not appropriately assess the reported difficulties. Further 
research is needed to evaluate the experienced difficulties by these patients. Possible 
interfering difficulties might be distance estimation, moving sound stimuli, localisation 
of sound stimuli in noise or reverberation.
In 2006, Keidser et al. performed localisation tests on hearing impaired patients with 
different compression techniques and directional microphone settings. They could not 
detect any difference in left–right localisation between a linear program with omnidi-
rectional microphone and a program with syllabic compression and omnidirectional 
microphone. These results corroborate the findings of the present study. However, the 
nonlinear program (with syllabic compression) in our study was complemented by a 
moderate static directional microphone. A possible explanation for the absence of a 
difference may lie in the localisation environment. In our study, no noise was presented 
during the localisation task. A more complex localisation task, with noise, might accen-
tuate any differences in program or microphone setting.
In conclusion, the examined patients with USH2a prefer the linear program over the 
nonlinear program. However, apart from a significantly higher logged use, no difference 
in speech in noise and sound localisation was observed. Further research is needed to 
address the preference of a linear over a nonlinear amplification program and to replicate 
the present results in hearing impaired patients without additional visual impairment.
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suPPleMental Materials
supplemental table st.1. (A) Mean values for Gain, bias, r2 and MAE for BB, LP and HP stimuli for the own 
and new hearing aids in linear program. (B) Mean values for Gain, bias, r2 and MAE for BB, LP and HP stimuli 
for new hearing aids in nonlinear versus linear program at follow up
A
stimulus own hearing aids new hearing aids, linear program
gain Bias r2 Mae gain Bias r2 Mae
Broadband, Mean (sd) 1.1 (0.3) 1.8 (15.3) 0.8 (0.2) 22.2 (9.1) 1.2 (0.2) -1.4 (9.3) 0.9 (0.1) 18.0 (5.3)
Low Pass, Mean (sd) 1.0 (0.3) -1.4 (14.8) 0.8 (0.3) 24.2 (13.1) 1.2 (0.2) -3.3 (10.0) 0.9 (0.1) 19.7 (9.9)
High Pass, Mean (sd) 0.8 (0.2) 2.2 (17.8) 0.7 (0.3) 27.0 (12.1) 1.1 (0.3) -2.0 (9.1) 0.8 (0.1)  21.4 (9.9)
Abbreviations: HA = Hearing Aids, MAE = Mean Absolute Error, r2 = coefficient of determination, sd = Stan-
dard Deviation
B
stimulus new hearing aids, nonlinear program new hearing aids, linear program
gain Bias r2 Mae gain Bias r2 Mae
Broadband, Mean (sd) 1.1 (0.2) -0.7 (8.0) 0.9 (0.1) 19.3 (9.4) 1.2 (0.2) -0.2 (8.5) 0.9 (0.1) 16.9 (8.7)
Low Pass, Mean (sd) 1.1 (0.2) -0.3 (10.1) 0.9 (0.1) 18.5 (10.8) 1.2 (0.2) -2.8 (10.4) 0.9 (0.1) 18.7 (9.6)
High Pass, Mean (sd) 1.0 (0.3) 0.1 (9.0) 0.9 (0.1) 20.2 (10.4) 1.1 (0.3) 0.1 (9.1) 0.8 (0.1) 21.4 (9.8)
Abbreviations: HA = Hearing Aids, MAE = Mean Absolute Error, r2 = coefficient of determination, sd = Stan-
dard Deviation


Chapter 3.2
Cochlear implantation in patients 
with Usher syndrome type IIa 
increases performance and quality 
of life
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aBstraCt
Objectives: Usher syndrome type IIa (USH2a) is characterized by congenital moderate 
to severe hearing impairment and retinitis pigmentosa. Hearing rehabilitation starts in 
early childhood with the application of hearing aids. In a select group of USH2a patients, 
severe progression of hearing impairment leads to insufficient speech intelligibility with 
hearing aids and issues with adequate communication and safety. Cochlear implanta-
tion (CI) is the next step in rehabilitation of these patients. This study evaluates the 
performance and benefit of CI in patients with USH2a.
Methods: Retrospective case-control study to evaluate performance and benefit after CI 
in 16 postlingually deaf adults (8 patients with USH2a and 8 matched controls). Perfor-
mance and benefit were evaluated with a speech intelligibility test and three quality of 
life questionnaires.
Results: Patients with USH2a and a mean age at implantation of 59 years, show good 
performance after cochlear implantation. The phoneme scores improved significantly 
from 41 to 87% in the USH2a patients (P=0.02), and from 30 to 86% in the control group 
(P=0.001). Evaluation of the questionnaires demonstrated a clear benefit from CI. There 
were no differences in performance or benefit between USH2a and control patients 
before and after implantation.
Conclusions: Cochlear implantation in patients with USH2a increases speech intelligibil-
ity and improves quality of life.
Submitted as: Hartel, B.P., van Nierop, J.W., Huinck, W.J., Rotteveel, L.J., Mylanus, E.A., Snik, 
A.F., Kunst, H.P., & Pennings R.J. Cochlear implantation in patients with Usher syndrome 
type IIa increases performance and quality of life
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introduCtion
Usher syndrome is an autosomal recessively inherited disorder that is characterized 
by sensorineural hearing impairment (HI), retinitis pigmentosa (RP) and in some cases 
vestibular dysfunction. Usher syndrome is the leading cause of hereditary deafblindness 
with a prevalence of ~ 1:20,000.1-3 RP is a slowly progressive retinal degenerative disease 
that leads to severe visual impairment over decades.
Usher syndrome type II (OMIM276901) is one of the three clinical types of Usher syn-
drome. Usher syndrome type IIa (USH2a) is the most common genetic type and accounts 
for more than half of all patients with USH.4, 5 It is clinically characterized by congenital 
moderate to severe progressive HI, RP and intact vestibular function. Hearing rehabilita-
tion is usually started with the application of hearing aids in early childhood. Adequate 
long-term hearing rehabilitation is critical as the RP progresses and eventually leads to 
legal blindness based on visual field size at an average age of 54 years.6 Therefore, with 
increasing age, these patients depend more on hearing for communication and safety. 
Previous studies have demonstrated that HI in USH2a is variable.7-10 In the first classifi-
cation of the different types of USH, Usher syndrome type II was characterized by stable 
HI.11, 12 The current concept is, however, that progression of HI is seen in most patients 
with the genetic type USH2a.13 In a select group of patients, severe progression of HI 
leads to insufficient speech intelligibility with hearing aids and issues with adequate 
communication and safety. In these cases, cochlear implantation (CI) is the designated 
choice of rehabilitation. So far, to the best of our knowledge, no results on CI in USH2a 
have been reported in literature.
This study presents the results on performance and an evaluation of quality of life 
after CI in patients with USH2a. The presented results are useful for counselling of USH2a 
patients with progressive sensorineural HI. In addition, the results on performance and 
benefit may serve as baseline data for comparison in future studies on bilateral cochlear 
implantation in these deafblind adults.
Patients and MetHods
Patients and controls
From 292 known Usher syndrome patients in the Nijmegen Usher syndrome database 
(June 2016), 186 (64%) have a clinical diagnosis of Usher syndrome type II. In 113 of 
them (61%), an USH2a diagnosis was confirmed by the identification of two pathogenic 
mutations in USH2A. Eight (7%) of these fully genotyped patients received a cochlear im-
plant and were included in the present study. Three more USH2a patients are booked for 
CI the coming year. All patients agreed to participate in this study by informed consent. 
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Implantation and rehabilitation, performed according to current standard procedures, 
took place at the Radboud university medical centre for seven patients and for one 
patient at the Leiden University Medical Centre.
For comparison, a matched control group was selected from the Nijmegen Cochlear 
Implantation database. This group consisted of eight adults implanted with a multichan-
nel cochlear implant. The matched criteria were in order of importance: audiogram 
before implantation (pure tone average; PTA 0.5-4 kHz and the PTA 0.25-2 kHz), age at 
implantation (the maximal deviation was nine years in one patient), gender and avail-
ability of outcome scores. This study was approved by the local ethics committee (nr. 
2015/1911).
audiometric evaluation
The demographic, clinical, audiologic, and genetic data were retrieved from the Nijme-
gen Usher database and available medical records at the Radboud university medical 
centre (n=15) and Leiden University Medical Centre (n=1). Pre- and postoperative PTA air 
conduction thresholds for sound frequencies ranging from 0.25 to 2 kHz (PTA Low 0.25-
2) and 0.5 to 4 kHz (PTA 0.5-4) were assessed according to the ISO 8253-1.14 Furthermore, 
a Dutch standardised speech perception test was used to obtain phoneme scores: the 
NVA test (an open speech recognition test that consists of monosyllabic wordlists).15 All 
words were presented in free field at 65 dB SPL and the phoneme scores were recorded 
preoperatively and at 12 months postoperatively in the cochlear implant only and best 
aided condition.
quality of life
Three questionnaires were used to evaluate the perceived quality of life after CI. The 
Glasgow Benefit Inventory (GBI) was used to assess the patient’s benefit after CI. This 
questionnaire consists of 18 questions about changes in general, social and physical 
health benefits. Possible scores for each question were based on a five-point Likert scale 
and the numerical data were converted into a GBI score. This is an index score of -100 to 
+100 representing the worst to best outcome.16
The Nijmegen Cochlear Implant Questionnaire (NCIQ) is a hearing impairment/CI 
specific questionnaire. It contains three general domains: physical, psychological and 
social functioning. Each domain is further divided in subdomains, consisting of 10 items. 
The items are formulated as a statement with 5 possible answers. Final scores for the 
subdomains ranged from 0 to 100.17 The GBI and NCIQ questionnaires are obtained from 
all implanted patients in the Radboud university medical centre.
The Usher lifestyle survey is a descriptive questionnaire. In 1980, the Nordic countries 
agreed to a common definition of domains of independence that are adversely affected 
in deafblindness. These domains are access to information, the ability to give and re-
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ceive information (as in communication), and mobility. In the first domain (access to 
information), the recoded answers could be 1 = independently, 2 = with equipment, 3 
= with others, and 4 = not aware. In the communication domain, the recoded answers 
could be 0 = no use to 8 = eight different ways of using modes of communication. At 
last, the last two answers of the communication domain and the two mobility domain 
answers could be 0 = independently and 1 = with others. These results were afterwards 
recoded in percentages of patients needing help from others.18
data analysis
Analyses were performed using Prism 5.03 software (GraphPad, San Diego, CA, USA) and 
IBM SPSS Statistics 22 (IBM Corp. Released 2013. IBM SPSS Statistics for Windows, Version 
22.0. Armonk, NY: IBM Corp). Descriptives were computed for the main characteristics 
(gender, age, age at implantation and follow-up period) of the patients. The results of 
the phoneme scores were compared pre- and postoperatively by the paired nonpara-
metric Wilcoxon matched-pairs signed rank test. For comparison between groups, the 
unpaired Student’s t-test and the nonparametric independent sample Mann-Witney U 
test were used. 
The questionnaire scores were computed following the guidelines. Results were 
tested if they indicated significant benefit with a one sample t-test. Correlation analysis 
was done calculating Spearman’s Rho. A general significance level of P=0.05 was applied 
in all separate tests.
results
Patients and Controls
The USH2a and control patients’ mean characteristics are shown in Table 1. All patients 
were raised with oral communication and were postlingually hearing deprived. All 
but two patients were using bilateral hearing aids preoperatively. One USH2a patient 
(USH-3) had a unilateral active middle ear implant (vibrant soundbridge, Med-El Cor-
poration, Austria) prior to CI in the contralateral ear and one control patient (CON-15) 
used a unilateral hearing aid in the to be implanted ear. Six USH2a patients received 
a multichannel cochlear implant from Cochlear (Cochlear Corporation, Australia) and 
two patients from Advanced Bionics (Advanced Bionics Corporation, USA). All controls 
received a multichannel cochlear implant from Cochlear. All patients had a follow-up of 
at least 12 months. For individual patient characteristics see Table 2.
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audiometric evaluation
The mean preoperative PTA for frequencies ranging from 0.25 to 2 kHz (PTA Low) in 
the best ear was 84 ± 16 dB HL in the USH2a patients. This did not differ from the mean 
pre-implanted PTA Low in the control group (85 ± 15 dB HL). The mean preoperative 
PTA for the frequencies ranging from 0.5 to 4 kHz did not differ between the two groups 
(98 ± 17 dB HL in the USH2a patients versus 101 ± 11 dB HL in the control group). Pre-
implantation, both the USH2a and the control group used hearing aids for a similar 
amount of time (38 years ± 18 versus 32 years ± 20). After implantation, some residual 
hearing in the implanted ear was preserved in four USH2a patients (USH-2, USH-3, USH-
4 and USH-7). In USH-7, residual hearing declined over 12 months after surgery. In the 
remaining four USH2a patients, no residual hearing was seen postoperatively. In the 
control group, some residual hearing was observed in seven patients (CON-1, CON-2, 
CON-3, CON-4, CON-6, CON-7 and CON-8). The individual audiograms of patients and 
controls are shown in Figure 1. The mean postoperative aided hearing threshold in the 
implanted ear was 34 ± 18 dB HL in the USH2a group versus 28 ± 5 dB HL in the control 
group. This difference was not significant. 
Figure 2 shows the best aided phoneme scores one year after implantation at 65 dB SPL 
for both groups. The phoneme score at 12 months of one USH2a patient (USH-5) could 
not be retrieved due to a logistical problem. None of the patients with USH2a, nor the 
controls, underwent bilateral CI due to the fact that in the Netherlands bilateral implan-
tation is (still) not reimbursed for adults. All USH2a patients are using a hearing aid in the 
contralateral ear in the best aided condition after implantation. Two USH2a patients use 
an additional hearing aid in the implanted ear (USH-7 and USH-2) and use it for electro-
acoustic stimulation (EAS). Five controls are using a hearing aid in the contralateral ear 
in the best aided condition, none of them use EAS. In the USH2a patients, phoneme 
scores improved significantly from 41 to 70% in the cochlear implant only condition 
table 1. Distribution of clinical characteristics
usH2a (n=8) Control (n=8)
Gender, n (%) of females 7 (87) 7 (87)
Mean age, y (sd) 64 (10) 64 (9)
Mean HA use pre implantation, y (sd) 38 (18) 32 (20)
Mean age at implantation, y (sd) 59 (8) 60 (9)
PTA Low (0.25 - 2 kHz), dB HL (sd) 84 (16) 85 (15)
PTA (0.5 - 4 kHz), dB HL (sd) 98 (17) 101 (11)
Follow-up period, y (sd) 4 (6) 4 (1)
Abbreviations: USH2a = Usher syndrome type IIa, y = years, sd = standard deviation, HA = hearing aid, PTA 
= pure tone average, kHz = kilohertz, dB HL = decibel hearing level.
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(P=0.02) and from 41 to 87% in the best aided condition (P=0.02). In the control patients, 
phoneme scores improved from 30 to 78% (P=0.008) and from 30 to 86% (P=0.008), 
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figure 1. Pre- and postoperative audiograms of patients with Usher syndrome type IIa and controls. Circles 
represent the right ear and crosses represent the left ear. The grey line represents the threshold in the im-
planted ear post-implantation.
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respectively. No differences were seen between USH2a and control patients before and 
after implantation. Furthermore, no differences were observed between the cochlear 
implant only and best aided condition.
questionnaires
Figure 3 shows the GBI scores for the USH2a patients and the control group. In one 
control patient (CON-13) the scores of the GBI and NCIQ could not be obtained after 
implantation. In both groups, the total GBI score and the general subdomain score 
demonstrated a significant benefit of CI. The mean scores of the total GBI were 41.6 ± 
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figure 2. Individual phoneme scores pre and post implantation in the CI and best aided condition for 
USH2a (open, grey and black circles) and control patients (open, grey and black squares). The mean pho-
neme score is represented by the black line in each condition. Abbreviations: dB SPL = decibel sound pres-
sure level, USH2a = Usher syndrome type IIa, Pre = before cochlear implantation, Post = after cochlear im-
plantation, CI = cochlear implant, best = best aided condition. 
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figure 3. Mean benefit scores measured by the Glasgow Benefit Inventory (GBI) for USH1 patients (light 
grey), USH2a patients (dark grey), USH3 patients (grey) and control patients (white). Error bars represent 
one standard deviation. Abbreviations: GBI = Glasgow benefit inventory USH1 = Usher syndrome type I, 
USH2a = Usher syndrome type IIa, USH3 = Usher syndrome type 3.
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10.1 (P< 0.001; 95% CI 33.2 to 50.1) in the USH2a patients and 61.1 ± 15.0 (P<0.001; 95% 
CI 48.6 to 73.6) in the control group. The mean scores of the general GBI subdomain were 
52.0 ± 15.6 (P>0.001; 95% CI 37.2 to 66.8) in the USH2a patients and 75.2 ± 22.1 (P>0.001; 
95% CI 54.9 to 95.6) in the control group. The differences between both groups were not 
significant. 
Table 3 demonstrates the mean scores of the NCIQ for the USH2a and control groups 
after CI. In five of the six subdomains, the control group scored higher, however, these 
differences were not significant. 
Table 4 represents the results of the Usher Lifestyle survey in the USH2a group. Patients 
with USH2a mostly use additional equipment to wake up. Furthermore, half of the 
patients report to use some form of equipment to hear someone at the front door. Fur-
thermore, to fill out a form, six out of eight USH2a patients report the use of help from 
others. Half of the patients use equipment to receive information on an emergency. 
For communication, half of the patients use the telephone without help and five out 
of eight patients use some form of equipment to help them write or read. To buy food 
or communicate with a doctor, 75% of the USH2a patients report the use of help from 
relatives or friends. Patients also indicate to need help from others to travel to the shop 
or doctor, in 87.5 and 62.5% of the patients, respectively. 
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figure 4. Mean scores measured by the Nijmegen Cochlear Implant Questionnaire (NCIQ) for the patients 
with USH1 (light grey), USH2a (dark grey) and the control patients (white). Error bars represent one stan-
dard deviation. Each pair of bars represents the scores for a subdomain. * = significant difference Abbrevia-
tions: NCIQ= Nijmegen cochlear implant questionnaire, adv = advances, percept = perception, product = 
production, USH1 = Usher syndrome type 1, USH2a = Usher syndrome type IIa
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Correlations
Correlation analyses showed a significant correlation in the USH2a group between the 
phoneme scores at 12 months and total GBI score and two subdomains of the NCIQ. 
When the phoneme scores increase, the total GBI score increases (r=0.77, P=0.048, n=7), 
the NCIQ self-esteem subdomain increases (r=0.85, P=0.024, n=7) and the NCIQ social 
interactions subdomain increases (r=0.84, P=0.024, n=7). 
Furthermore, significant correlations were seen between the phoneme score ben-
efit (‘post-implantation phoneme score’ minus ‘pre-implantation phoneme score’) at 12 
months and subdomains of the NCIQ in the control group. When the phoneme benefit 
increases, the NCIQ speech perception subdomain increases (r=0.92, P=0.006, n=7), the 
NCIQ speech production subdomain increases (r=0.85, P=0.024, n=7) and the NCIQ activi-
ties subdomain increases (r=0.85, P=0.024, n=7).
table 3. Mean Nijmegen Cochlear Implant Questionnaire (NCIQ) scores after cochlear implantation in the 
USH2a and control groups 
usH2a (n=8) Control (n=8)
Mean (%) sd range Mean (%) sd range
Sound perception basic 71.0 10.4 50.0 - 82.0 84.3 10.3 64.0 - 94.0
Sound perception advanced 67.6 15.5 50.0 - 86.7 77.4 13.9 58.0 - 96.0
Speech production 88.0 7.6 78.0 - 100.0 89.9 10.5 72.7 - 100.0
Self-esteem 69.4 15.1 35.6 - 84.0 80.9 8.9 64.0 - 90.0
Activity limitations 67.8 13.3 54.0 - 84.0 86.0 10.1 72.0 - 98.0
Social interactions 67.7 13.3 54.0 - 88.0 82.3 8.7 68.0 - 93.4
Abbreviations: USH2a = Usher syndrome type IIa
table 4. Scores of the USH2a group on the Usher Lifestyle survey
independently equipment others unaware
Access to information Wake up (n) 1 6 1 0
Front door (n) 4 4 0 0
Access form (n) 0 2 6 0
Emergency (n) 3 4 1 0
Communication Telephone use (n) 4 1 3 0
Written communication (n) 2 5 0 1
Buy food (% help from others) 75
Communicate doctor (% help from others) 75
Mobility Visit shop (% help from others) 87.5
Visit doctor (% help from others) 62.5
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disCussion
About 10% of the patients (11/113) with USH2a known in our database have or will 
receive a cochlear implant in the near future. The present study shows that patients 
with USH2a have good performance after CI and that it is beneficial to them. All out-
comes showed similar results when compared to a control group of postlingually deaf 
implanted adults.
Six patients (four with USH2a and two controls) had a pre-implantation phoneme score 
of more than 50% in best-aided conditions and speech presented at 65 dB SPL. Espe-
cially USH-7 (highlighted in Figure 2) showed an exceptionally high pre-implantation 
phoneme score of 74%. Although the hearing phenotype in USH2a patients is variable, 
progression is found in most patients.13 Such was the case in USH-7, who experienced a 
progressive deterioration of hearing and visual function over the previous 10 years. This 
patient obtained good postoperative scores with a phoneme score of 90% and a total 
GBI score of 27.8. The double-sensory progression was fundamental for the decision to 
perform CI and as demonstrated in this study, individuals with exceptional progression 
might benefit from early CI.
In a previous study from our group, HI was evaluated in patients with different types of 
USH2A mutations.13 Patients with two truncating mutations demonstrate a significantly 
more severe and progressive HI compared to patients with two nontruncating (mis-
sense) mutations or one truncating and one nontruncating mutation in USH2A. Of 
the eight USH2a patients included in this study, four patients carried two truncating 
mutations (USH-4, USH-5, USH-6 and USH-8), three patients carried two nontruncating 
mutations (USH-1, USH-2 and USH-7), and one patient carried one truncating and one 
nontruncating mutation (USH-3). This indicates that half of the patients belong to the 
two groups that are considered to have less severe and less progressive HI. A possible 
explanation for this might be that these patients have nontruncating mutations that 
do lead to more progression of HI, they might have genetic modifiers that influence HI 
or may have been exposed to negative environmental factors. Future individual longi-
tudinal analyses could reveal specific nontruncating mutations that are linked to more 
severe and progressive HI. In addition, epidemiological studies might identify other 
negative environmental factors as well.
Previous studies demonstrated that CI in deafblind adults is as successful as in other 
postlingually deaf adults.19-21 Furthermore, CI improves quality of life in adults with 
either Usher syndrome type 1 (USH1) 22, 23 or Usher syndrome type 3 (USH3).21 Unlike 
USH2a, USH1 (OMIM276900) is characterized by congenital, severe to profound HI, 
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pre-pubertal onset of RP, and vestibular areflexia. In 2006, Damen et al. and Pennings 
et al. reported the performance and quality of life in 7 adults with USH1 who received 
a cochlear implant. In Figures 3 and 4, the current results of the USH2a patients were 
compared to those reported for USH1 patients (Damen et al. and Pennings et al.). Figure 
3 shows the GBI scores. In the “general” domain, the USH2a patients (dark grey bar), 
experience significantly more benefit after CI compared to USH1. The “general” benefit 
domain is composed of 12 of the 18 items and represents all items about benefit itself. 
The questions in the other domains “social” and “physical health” benefits inform us 
about the needed help from others and physical problems. Therefore, the mean score 
on the most extensive domain of the GBI is significantly better in the USH2a subgroup 
compared to the USH1 subgroup. The factor influencing this outcome is most prob-
ably the onset of profound deafness. Patients with USH1 are prelingually deaf and the 
patients in Damen’s study were implanted in early adulthood. This difference in onset 
also explains the significant difference in the NCIQ subdomain speech production (USH2a 
patients: 88 ± 7,6 versus USH1 patients 25,4 ±13,6 (P<0,001; 95% CI 34,44 - 90,76) as 
demonstrated in Figure 4. On the other domains of the NCIQ no significant differences 
were found (Figure 4).
Usher syndrome type 3 (USH3, OMIM276903) has a variable onset and degree of HI, RP, 
and vestibular abnormalities.12 In addition, HI in USH3 is progressive, especially in the 
first three decades of life.24, 25 However, this progression is not reported to be signifi-
cantly more compared to USH2a patients.24 In 2012, Pietola et al. studied the results of CI 
in 19 patients with USH3. With a mean age of 41 (sd 17) years, the studied patients were 
implanted at a significantly younger age compared to the USH2a patients in this study. 
(P=0.009). None of the available results for the GBI subdomains differed from the present 
results (Figure 3). The speech recognition scores could unfortunately not be compared 
due to the fact that only word scores and no phoneme scores were published.
Due to the visual decline in RP, especially the peripheral vision, USH2a patients are de-
pendent on auditory input for proper sound localisation. Adequate sound localisation 
is of paramount importance to patients with deafblindness to locate for example cars 
or cyclists, providing a safe situation in traffic. Adults with one cochlear implant are less 
capable of sound localisation compared to adults with bilateral cochlear implants.26 For 
this reason, patients with deafblindness, such as USH2a patients, may especially benefit 
from bilateral CI.
In conclusion, CI in patients with USH2a and severe progression of HI increases speech 
intelligibility and improves quality of life, leading to improved communication.
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Discussion
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The aims of this thesis were to examine patients with pathogenic mutations in USH2A in 
order to elucidate the phenotype, to identify putative genotype-phenotype correlations 
and to evaluate hearing rehabilitation options. In the following discussion, the results of 
this thesis will be discussed according to their position in a care program. Furthermore, 
the effect of the results on this care program, future research fields and the importance 
of patient participation will be discussed. 
genetiC diagnosis
During the first appointment of a hearing impaired patient at an ENT outpatient clinic, 
the physician will differentiate between an acquired cause, such as infection, ototoxic 
drugs or loud sound exposure, or an inherited cause of hearing impairment. Generally, 
once the acquired causes are unlikely or ruled out, genetic testing may be performed 
to identify the potential cause of the phenotype. Recent developments in genome 
diagnostics permit us to detect the genetic defects underlying hereditary disease 
more efficiently and at an earlier age. Where only a few years ago, it was common to 
order sequencing of a single gene, nowadays, this is largely replaced by whole exome 
sequencing (WES). Subsequently, targeted analysis of WES data is performed using 
disease-specific gene panels. In this way, only variants in genes that were previously 
identified to be associated with a certain condition are selected and analysed. In our 
institute, the deafness gene panel currently consists of 141 genes associated with 
syndromic and nonsyndromic forms of hearing impairment.1 Hearing impaired children 
as well as adults are eligible to undergo screening using this diagnostic tool. Since 
implementation of WES for diagnostic purposes significantly increased the percentage 
of genetically solved patients as compared to single gene testing (33.5% versus 16% 
genetically solved patients), we try to reduce single gene testing to a minimum.2
The use of WES as a diagnostic tool presents both new challenges and advantages.3 The 
former order of events in a care program to diagnose patients with Usher syndrome 
has changed. Usher syndrome was previously always clinically diagnosed based on the 
combination of hearing impairment, retinitis pigmentosa and the presence or absence 
of vestibular dysfunction. The order of clinical diagnosis of Usher syndrome > genetic 
diagnosis of Usher syndrome > rehabilitation is labelled as ‘forward genetics’ in litera-
ture.4 However, nowadays the diagnosis Usher syndrome is more often made based on 
the outcome of genetic screening and given way before the first clinical presentation 
of ocular symptoms. The order thus changes to genetic diagnosis of Usher syndrome > 
clinical symptoms of Usher syndrome > rehabilitation, also known as ‘reverse phenotyp-
ing’.5
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A possible disadvantage from this change is that early identified mutations in a hear-
ing impairment-associated gene may not always provide a definite clinical diagnosis. 
This is due to the fact that different phenotypes might result from mutations in one 
single gene. For example, infants with pathogenic mutations in MYO7A (OMIM 276903), 
may develop a syndromic (Usher syndrome type Ib (OMIM 276900) or nonsyndromic 
phenotype (autosomal recessive deafness type 2 (DFNB2, OMIM 600060)).6, 7 This also 
highlights the importance of re-evaluating available WES data as new clinical features 
emerge in a patient over time.
Another disadvantage of a genetics-based diagnosis of Usher syndrome before the 
onset of visual deterioration may be that it will have a considerable psychosocial effect 
on the parents. To our knowledge, no studies have been performed on the parental 
impact of receiving an early genetic diagnosis of a child with Usher syndrome. Oonk et 
al. studied the psychosocial impact of a genetic diagnosis of nonsyndromic hereditary 
hearing impairment in adults (unpublished work).8 They found no differences in psy-
chosocial outcomes between patients receiving a genetic diagnosis for their hearing 
impairment as compared to patients for whom no genetic diagnosis could be obtained 
after testing. However, the impact of a genetic diagnosis of syndromic hearing impair-
ment in patients and parents remains to be studied.
Finally, an early genetic diagnosis of Usher syndrome raises ethical questions. To 
answer these, a care professional has to integrate a new ethical part in the parental 
counselling. This consists of discussing whether the child must be informed before or 
after developing initial visual symptoms.
A genetic diagnosis for Usher syndrome early in life also presents advantages for 
patients, parents and scientists. As a result, patients will receive a treatment already 
at an early stage and will be informed about prognosis. Furthermore, it may lead to 
anticipatory guidance for rehabilitation and the existence of support groups. Parents 
can be informed about the recurrence risks and may become aware of possible Usher 
syndrome-related problems that might arise as a consequence of the defects in hearing, 
balance and vision. Parents of patients with Usher syndrome type I, for example, can 
expect delayed motor milestones of their child as a result of the presented vestibular 
dysfunction. In addition, they may seek support from the patient and parent community 
at an earlier stage. For scientists, a strict follow-up of genetically diagnosed patients with 
specific evaluations is useful to obtain a detailed natural course of the disease, which 
may serve as a basis for further genotype-phenotype studies. Natural history studies in 
patients that are eligible to receive future genetic treatments are of utmost importance 
in order to determine the therapeutic efficacy. 
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To identify all the challenges and advantages of early genetic testing in the current era, 
it is essential to study the effect of an early genetic diagnosis of Usher syndrome on 
patients and parents. The involvement of different care professionals, like an ENT doc-
tor, an audiologist, an ophthalmologist, a clinical geneticist, a psychologist and a social 
worker, may add to the completeness of such a study.
Counselling after a genetiC diagnosis
Counselling is the action of providing information and advice to an individual patient. 
To do so, we not only need the patient’s information, like (medical) background, family 
and social status, symptoms and genetic information, but also knowledge about the 
(course of ) disease. Natural history studies are the preferred choice to examine the 
course of a disease in order to obtain information useful for counselling. These studies 
can be approached in a cross-sectional or longitudinal way. Chapter 2.1 is an example 
of a cross-sectional study and chapter 2.2 of a longitudinal study. Both studies were 
performed on a retrospective basis. Differences in used equipment, experimental setup 
and care professionals that conducted the measurements in both studies may have 
introduced a bias.
In literature, there is extensive knowledge about the type of hearing impairment but 
less about progression of hearing impairment in patients with USH2a. A congenital 
moderate to severe hearing impairment, more pronounced in the higher frequencies 
is generally observed.9-13 The studied populations were, however, small and only in 
part genotyped. In addition, a large variability in hearing impairment was identified. 
In chapter 2.1, we studied severity and progression of hearing impairment in patients 
with USH2a. This study demonstrated that the hearing impairment in these patients is 
progressive. This result has a direct impact on the clinical characterization of USH2a as 
described by Davenport et al. and Smith et al.14, 15 Therefore, we propose a refinement of 
the criteria for clinical characterization of USH2a, including progressive hearing impair-
ment in most patients (Table 1).
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table 1. Proposed refinement of the criteria for clinical characterization of Usher syndrome
Hearing impairmentt Visual impairment Vestibular function
Usher syndrome type I Congenital, severe to 
profound
Diagnosis before puberty, 
progressive
Absent
Usher syndrome type II Congenital, moderate to 
severe 
mildly progressive in 
most patients
Diagnosis around puberty, 
progressive
Intact
Usher syndrome type III Variable onset
progressive
Variable age of diagnosis, 
progressive
Variable
In chapter 2.2, a similar genotype-phenotype correlation was observed in patients with 
USH2A-associated nonsyndromic retinitis pigmentosa (nsRP) and USH2a. In this study, 
the presence of two truncating mutations in USH2A was always associated with hearing 
impairment (thus USH2a), and the number of truncating mutations predicted the sever-
ity of the visual phenotype. The observed association between truncating mutations 
and the course of both the hearing and visual phenotypes has greatly improved our 
knowledge of USH2a and USH2A-associated nsRP. This insight is essential for proper 
counselling of these patients.
Even after taking into account the above described genotype-phenotype correlations, 
the large variability of hearing impairment in USH2a patients remains unexplained. This 
suggests that other genetic and/or environmental factors are important in the develop-
ment of hearing impairment as already suggested by Sadeghi et al. in 2013.16 Possibly, 
individual or combinations of certain mutations may have a more severe effect on the 
phenotypic outcome than others. This theory is supported by the results of chapter 2.3. 
In this study, the hearing phenotype of patients with USH2A-associated nsRP was com-
pared to presbyacusis and hearing impairment in patients with USH2a. The observed 
(combinations of ) USH2A mutations in patients with USH2A-associated nsRP proved to 
be unique as compared to a large sample of 110 patients with USH2a. It was demon-
strated that a proportion of patients (8/18), initially diagnosed with USH2A-associated 
nsRP, developed a mild, adult onset hearing impairment. However, the differences in 
the level of hearing impairment and the age of onset at which the hearing impairment 
manifests clearly differentiates patients with USH2A-associated nsRP from patients with 
USH2a.
Furthermore, mutations in other genes known to be associated with (non)syndromic 
forms of hearing impairment may influence the severity and/or progression of hearing 
impairment in patients with USH2a and USH2A-associated nsRP. To identify these muta-
tions, large cohorts of patients should undergo extensive genetic screening by WES.17 
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This could result in the discovery of mutations or specific Single Nucleotide Polymor-
phisms (SNPs), which might modify the observed phenotype. 
Finally, nongenetic factors may influence the hearing and visual phenotype. These 
might be environmental factors, like loud sound exposure or sunlight exposition, but 
also early rehabilitation, education and support. To identify and study these factors, a 
large database with detailed information of a large USH2a and USH2A-associated nsRP 
cohort could be a useful tool. To be able to aggregate this information, standardized 
evaluation protocols will be necessary on a national and international level.
Further awareness of genetic and environmental factors might improve individual coun-
selling and prognosis. The knowledge of factors influencing hearing impairment, like 
the type of mutation in USH2A, might affect the counselling on hearing rehabilitation 
options in adulthood. The different hearing rehabilitation options will be discussed in 
the next part of the discussion.
Hearing reHaBilitation after tHe diagnosis of usH2a
Chapters 3.1 and 3.2 present the results of the commonly used hearing rehabilitation 
options used in patients with USH2a: hearing aids and cochlear implants. 
Due to the congenital aspect of hearing impairment, most patients use hearing aids 
from young age.18 However, some patients start using hearing aids at later age because 
of the existing variability in hearing impairment. Modern hearing aids are primarily 
developed for sighted individuals with hearing impairment. The possible limitations 
in spatial hearing are considered negligible because these users will have good visual 
abilities to compensate for distorted sound localisation cues presented by the hearing 
aids. Instead, patients with low or no vision, such as patients with USH2a, cannot rely on 
visual cues and, therefore, auditory cues become critical.19 Prolonged hearing aid fitting 
is often necessary to optimize both spatial hearing and communication. In chapter 3.1 
of this thesis, we evaluated the effects of two hearing aid settings on speech perception 
(as an outcome for communication) and sound localisation (as an outcome for spatial 
hearing). The first setting consisted of a linear amplification setting. Hypothetically, this 
setting would preserve auditory cues necessary for sound localisation. The second set-
ting applied a nonlinear amplification. This was thought to offer better performances in 
speech perception. We could, however, not determine any differences in speech percep-
tion and sound localisation between a linear and a nonlinear program. The results, with 
the tests we used, were equally good. Nonetheless, subjectively, patients preferred by 
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far the linear over the nonlinear program. The similar objective outcomes might be due 
to the compression ratios of the two settings. The compression ratio of the nonlinear 
setting was mild. A higher compression ratio might have had a more detrimental effect 
on the auditory cues for sound localisation.20 Other tests to evaluate spatial hearing or to 
compare the effects of different hearing aid settings might include distance perception 
and moving sounds. In addition, more “real world’ stimuli might be used. In other words, 
these suggested tests might be more ecological valid. Ecological validity refers to the 
extent to which results represent the range of experiences in daily life.21 Tests with a high 
ecological validity can be generalised to real-life situations.
The study presented in chapter 3.2 evaluated the performance of and subjective out-
comes after cochlear implantation, a more invasive rehabilitation option, in patients 
with USH2a with profound hearing impairment. In eight USH2a patients using a cochlear 
implant, speech perception and subjective outcomes were compared to matched adults 
with nonsyndromic congenital hearing impairment. Good performances, similar to the 
control group, were observed. In our institute, ten percent of all USH2a patients (all ages 
included) have or are eligible for a cochlear implant in the near future and above the 
age of 50 years, this percentage increases up to 15%. Furthermore, the raised awareness, 
changing implantation criteria and improving implant outcomes may possibly lead to 
a higher prevalence of cochlear implant recipients in patients with USH2a in the future. 
Sound localisation with unilateral cochlear implantation, with or without hearing aid 
in the contralateral ear, is poor. Bilateral cochlear implantation has been proven to be 
of benefit for sound localisation. Concerning speech perception in noise, an absolute 
benefit of bilateral cochlear implantation over a bimodal situation (a cochlear implant in 
one ear and a hearing aid in the contra-lateral ear) is less evident.22, 23 In the Netherlands, 
bilateral cochlear implantation is from 2016 onwards fully reimbursement for deafblind 
adults, including Usher syndrome. To complement chapter 3.2, future research should 
now focus on the additional benefits of a second cochlear implant in deafblind adults 
and the additional value compared to a bimodal situation with regard to speech percep-
tion in noise.
future treatMent oPtions
Besides improvements in diagnostics, counselling and rehabilitation, the most prom-
ising research in the coming decades will focus on the development of therapeutic 
treatments. When we talk about treatment we often think of curing deafness and/or 
blindness. In the case of treatment for USH2a, the current primary goal is to stop the 
progression of visual deterioration. This might be achieved by different forms of therapy. 
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An important concept is genetic therapy. An example of genetic therapy is gene aug-
mentation therapy. This consists of supplying “healthy” copies of the gene (e.g. USH2A) 
to the retina using adeno-associated or lentiviral vectors. However, for USH2a this is very 
difficult due to the size of the coding sequence of USH2A (15.606 base pairs), which 
largely exceeds the capacity of the currently available vehicles for delivery. This prob-
lem of length may be bypassed by the use of minigenes. Minigenes are edited genes 
consisting of only the regions of the gene that encode the most important domains of 
the protein. Consequently, these shortened USH2A minigenes might be packaged into 
the available viral vectors. Another possible approach is the development of a genome-
editing strategy by using CRISPR/Cas9-based RNA-guided DNA endonucleases.24 By 
adopting this approach, specific genomic aberrations could be modified or repaired. 
Finally, another therapeutic option is the use of antisense oligonucleotides (AONs) 
to redirect aberrant splicing caused by (deep-)intronic mutations or to “skip” certain 
protein-encoding regions (exons) that contain deleterious mutations. 25, 26 
A cellular based therapy, such as cell replacement therapy with induced pluripotent 
stem cells also seems promising.27 Stem cell therapy aims to introduce stem cells into 
the target organ (e.g. retina or cochlea) and allow them to differentiate into specific cells. 
These cells may turn into properly functioning photoreceptor cells in the retina or hair 
cells in the cochlea when transplanted.28, 29 
Many mutations in USH2A are private and evenly distributed over the gene. They in-
clude nonsense, frame-shift, splice-modulating (= truncating mutations), and missense 
variants (= nontruncating mutations). It is generally believed that USH2a, due to muta-
tions in this gene, is caused by a loss-of-function mechanism. However, it was recently 
demonstrated that an USH2A missense (nontruncating) mutation could result in the ac-
cumulation of non-functional usherin in the endoplasmatic reticulum of patient-derived 
retinal organoids, leading to cellular stress and consequently apoptosis.27 This observed 
additional pathogenic effect of nontruncating mutations over truncating mutations 
might influence the choice of future therapeutic approaches for different types of muta-
tions. 
For now, therapeutic studies concentrate on the development of treatment options that 
enable to stop the progression of retinal degeneration in Usher syndrome patients in 
the future. An important reason for this is that good hearing rehabilitation options are 
available for hearing impairment, which is not the case for the visual impairment. Natural 
history studies have demonstrated that patients with USH2a are born with apparently 
normal vision and develop the first clinical symptoms shortly after puberty. This leaves 
a time frame for therapeutic intervention before the onset of the first clinical symptoms. 
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Moreover, the concept of delivering genetic material to the retina by injection into the 
subretinal space has been proven adequate.30 In contrast, hearing impairment in USH2a 
has a congenital onset. This is probably caused by a defective cochlear hair bundle de-
velopment as a result of defects in or absence of usherin. In humans, this development 
is completed in utero. Therefore, ideally, treatment should be applied in utero which is, 
both technically and ethically, challenging. Consequently, post-natal treatment options 
should be further explored in the future.31
Patient-PartiCiPatory researCH
To conclude the discussion of this thesis, it is wise to go back to where it all started: 
patient reported problems. The concept of patient involvement in science is spreading 
across the scientific community. Patients have always been involved in research, as ob-
ject of interest or medium on which innovations were tested. Nowadays their engage-
ment may, however, be different. Patients are nowadays encouraged to participate from 
the start of new research projects by formulating research questions and participate by 
attracting and including other patients. In the world of well-known medical journals, 
involvement of patients in journal review boards and strategy planning is a trend and 
is often called “patient partnership”. For example, the British Medical Journal (BMJ) has 
adopted this strategy in 2014 and explains: “it sees partnering with patients, their families, 
carers and support communities, and the public as an ethical imperative, which is essential 
to improving the quality, safety, value and sustainability of health systems” (http://www/
bmj/com/campaign/patiënt-parnership).
The idea of patient involvement in research is part of a bigger philosophy, the concept 
of “patient centered care”. This idea of patient involvement in care and science is highly 
promoted by the Radboudumc. In this institute, “patient centered care” is one of the four 
core values. Our Usher-expert team (part of Hearing and Genes) has adopted this core 
value and promotes patient participation in care, education and research programs. 
Finally, this thesis has adopted and integrated this philosophy by studying research 
questions formulated by patients with USH2a and tried to provide directly applicable 
answers on their care program.32
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suMMary and ConClusions
This thesis is part of an ongoing research project in Nijmegen on Usher syndrome 
started by Cor Cremers in the nineties of the previous century. Unlike previous theses on 
this topic, the patients studied in this thesis were specifically patients with either Usher 
syndrome type IIa (USH2a) or USH2A-associated nonsyndromic retinitis pigmentosa 
(nsRP). 
Chapter 1 is a general introduction. The introduction and following chapters are written 
following the most common steps in the care program of a patient with Usher syndrome. 
For the patient, this often starts shortly after birth with the detection of hearing impair-
ment during the neonatal hearing screening. Afterwards, the patient visits a health care 
professional for a definite clinical and genetic diagnosis. The health care professional 
will try to provide individual information and advice concerning the disease (= counsel-
ling). Finally, together with the patient and parents, optimal hearing rehabilitation will 
be determined. Usher syndrome is a rare disease with a prevalence of about 4.4 - 6.3 per 
100,000 inhabitants. Three clinical types can be distinguished based on the presence, 
severity, progression and age of onset of hearing impairment, retinitis pigmentosa (RP) 
and vestibular dysfunction. To date, mutations in 11 different genes have been identified 
that result in Usher syndrome. USH2a is the most common type of Usher syndrome (> 
50% of all patients), and is caused by mutations in USH2A. Patients with USH2a present 
with congenital hearing impairment, a progressive deterioration of visual function as 
a consequence of retinitis pigmentosa (RP) and intact vestibular function. Mutations 
in USH2A are also associated with nonsyndromic retinitis pigmentosa (nsRP). Little is 
known about the cause of the large clinical variations seen in and between both groups. 
Some patients with USH2a develop severe progressive hearing impairment, whereas 
other patients suffer from a mild and stable hearing impairment. Detailed information 
about the expected course of the disease is, for patients diagnosed with mutations in 
USH2A, essential to his or her future societal perspective. This knowledge also has an 
influence on the determination of the hearing rehabilitation options.
Chapter 2 focuses on the identification of possible genotype-phenotype correlations in 
patients with mutations in USH2A, in order to explain (a part of ) the observed variability 
of the audiological en visual phenotype. In chapter 2.1, hearing impairment of a sample 
of 110 patients with USH2a was studied. Based on this study we can conclude that the 
observed hearing impairment is generally congenital, moderate to severe and progres-
sive. Also, the hearing impairment is more pronounced in the higher frequencies. Fur-
thermore, patients with two protein-truncating mutations showed a more severe and 
progressive hearing impairment as compared to patients with only one or no protein-
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truncating mutation. Our explanation is that, in this case, protein-truncating mutations 
must be regarded as mutations with a severe clinical effect, due to the fact that as a 
result of these mutations, no protein or a non-functional shortened protein is formed. 
The effect of nontruncating mutations on the phenotype is milder as still a protein is 
formed of which, however, the function is significantly reduced. In chapter 2.2, the visual 
phenotype was compared between patients with USH2a and USH2A-associated nsRP. 
This study demonstrated that RP is diagnosed at a younger age in patients with USH2a 
than in patients with USH2A-associated nsRP. In addition, the visual phenotype is more 
progressive in USH2a patients than in USH2A-associated nsRP patients. Consequently, 
patients with USH2a reach the international criteria for blindness at a younger age (aver-
age of 54 years in patients with USH2a versus an average of 80 years in patients with 
USH2A-associated nsRP). The effect of protein-truncating and nontruncating mutations 
on the visual phenotype was also studied. A combination of two truncating mutations 
was found only in patients with USH2a. Furthermore, independent of the audiological 
phenotype, a positive correlation was found between the number of protein-truncating 
mutations (0, 1 or 2), and the severity of the visual phenotype. Chapter 2.3 of this the-
sis studied the hearing in patients with USH2A-associated nsRP. This was necessary to 
determine whether USH2A-associated nsRP could be considered as a different clinical 
entity from USH2a. Previously, the lack of subjective hearing loss was considered to be 
a criterion for nsRP. However, no comprehensive audiological data were available for 
USH2A-associated nsRP patients. After several hearing tests and a questionnaire, it could 
be concluded that 8 of the 18 patients developed a mild, adult-onset hearing impair-
ment. Despite the variability, hearing impairment in patients with USH2a is generally 
present at birth in a moderate to severe form. As the hearing impairment in USH2A-
associated nsRP patients is mild and starts at a later age in only a subset of patients, 
USH2A-associated nsRP can indeed be considered as a separate entity from USH2a.
Chapter 3 of this thesis focuses on the options for auditory rehabilitation in patients 
with USH2a. Fitting hearing aids in these patients is problematic. This was reported 
by two patients with Usher syndrome, Gracia Tham and Ivonne Bressers. In 2012, they 
interviewed both patients with Usher syndrome and healthcare professionals about the 
difficulties in fitting hearing aids. In Chapter 3.1 we studied whether the adaptation 
of hearing aids in patients with USH2a could be improved. In this chapter, the results 
of sound localisation, speech perception in noise and quality of life were compared 
between two hearing aid programs. These programs were developed based on two 
hypotheses:
1. The first, experimental, linear program would interfere as little as possible with the 
incoming sound and should provide better sound localisation.
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2. The second, regular, compression program would be considered more comfortable 
and offer better performance in speech perception in noise.
The results of this study showed that USH2a patients have a clear subjective preference 
for the linear program. However, we found no objective difference between the two 
programs in terms of sound localisation and speech perception. In Chapter 3.2, the 
objective (speech perception) and subjective (questionnaires) results after cochlear im-
plantation in patients with USH2a were examined and compared with a control group. 
Cochlear implantation is an important option for rehabilitation in patients with USH2a 
that present with severe to profound hearing impairment. Approximately 10% of all 
known USH2a patients in our institute received a cochlear implant. Both subjective and 
objective results did not differ from the results in the control group.
In conclusion, the results of this thesis have a direct impact on the different stages of the 
care program for patients with USH2a and USH2A-associated nsRP. Patients, who receive 
this clinical and/or genetic diagnosis, may now be better informed about the prognosis 
of the visual and audiological phenotype and the rehabilitation of hearing impairment. 
This thesis is a new step in the understanding of factors affecting the severity and 
progression of both the audiological and visual symptoms in patients with USH2a and 
USH2A-associated nsRP.
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saMenVatting en ConClusies
Dit proefschrift maakt deel uit van een groter onderzoek naar het Usher syndroom in 
Nijmegen, gestart door Cor Cremers in de jaren negentig van de vorige eeuw. De patiën-
ten die in dit proefschrift bestudeerd zijn, hebben in tegenstelling tot in de voorgaande 
proefschriften over Usher syndroom, enkel Usher syndroom type IIa (USH2a) of niet-
syndromale retinitis pigmentosa (nsRP) veroorzaakt door mutaties in USH2A.
Hoofdstuk 1 bestaat uit een algemene inleiding. Deze inleiding en de overige hoofd-
stukken zijn geschreven aan de hand van de meest voorkomende stappen in het zorg-
programma van een patiënt met USH2a. Voor de patiënt begint dit vaak al kort na de 
geboorte na het vaststellen van gehoorverlies tijdens de neonatale gehoorscreening. 
Vervolgens bezoekt de patiënt een zorgverlener voor een klinische en genetische di-
agnose. Hierna zal de zorgverlener proberen om op individueel niveau een advies te 
geven over de aandoening (counseling). Samen met de patiënt zal vervolgens naar een 
optimale vorm van revalidatie gezocht worden. Het Usher syndroom is een zeldzame 
aandoening met een prevalentie van ongeveer 4,4 - 6,3 per 100.000 inwoners. Drie klini-
sche typen kunnen van elkaar onderscheiden worden op basis van de aanwezigheid, de 
ernst en het moment van optreden van slechthorendheid, retinitis pigmentosa (RP) en 
vestibulaire afwijkingen. Tot op heden zijn mutaties in 11 verschillende genen gevonden 
die allen resulteren in het ontstaan van Usher syndroom. USH2a is de meest voorko-
mende vorm van Usher syndroom (>50% van alle patiënten) en wordt veroorzaakt door 
mutaties in USH2A. Patiënten met USH2a worden slechthorend geboren maar ervaren 
pas de eerste klachten met hun visus rond de puberteit. Daarbij hebben ze een intacte 
vestibulaire functie. Mutaties in USH2A kunnen ook leiden tot niet-syndromale RP (nsRP). 
Er is nog maar weinig bekend over de oorzaak van de grote klinische variabiliteit die 
gezien wordt in en tussen deze beide groepen. Sommige patiënten met USH2a ontwik-
kelen een ernstige progressieve vorm van gehoorverlies, terwijl bij andere patiënten 
een mild, stabiel gehoorverlies wordt geconstateerd. Nauwkeurige informatie over het 
verwachte verloop van het ziektebeeld is, voor een patiënt die gediagnosticeerd is met 
mutaties in USH2A, van essentieel belang voor zijn of haar sociaal-maatschappelijk toe-
komstperspectief. Deze kennis heeft bovendien invloed op het bepalen van de opties 
voor gehoorrevalidatie. 
Hoofdstuk 2 is gericht op de identificatie van mogelijke genotype-fenotype correlaties 
bij patiënten met mutaties in USH2A, met als doel om (een deel van) de waargenomen 
variabiliteit van het audiologische en visuele fenotype te kunnen verklaren. In hoofdstuk 
2.1 is het gehoorverlies onderzocht van 110 patiënten met USH2a. Aan de hand van deze 
studie kan geconcludeerd worden dat het gehoorverlies over het algemeen congenitaal, 
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matig tot ernstig en progressief is. Ook is het gehoorverlies meer uitgesproken in de 
hogere frequenties. Verder lieten patiënten met twee eiwit-truncerende mutaties een 
ernstiger en progressiever gehoorverlies zien in vergelijking met patiënten met maar 
één of geen eiwit-truncerende mutatie. Onze verklaring hiervoor is dat truncerende 
mutaties in dit geval moeten worden beschouwd als mutaties met een ernstig effect 
omdat er ten gevolge van deze mutaties geen of slechts een niet-functioneel, verkort 
eiwit wordt gevormd. Het effect van niet-truncerende mutaties is waarschijnlijk milder 
omdat er nog wel een eiwit gevormd wordt waarvan echter de functie sterk verminderd 
is. In hoofdstuk 2.2 werd het visuele fenotype vergeleken tussen patiënten met USH2a 
en USH2A-geassocieerde nsRP. Hieruit bleek dat RP op jongere leeftijd gediagnosticeerd 
wordt bij patiënten met USH2a dan bij patiënten met USH2A-geassocieerde nsRP. Daar-
naast gaat het zicht sneller achteruit bij USH2a patiënten dan bij USH2A-geassocieerde 
nsRP patiënten. Hierdoor voldeden patiënten met USH2a, in vergelijking met patiënten 
met USH2A-geassocieerde nsRP, op jongere leeftijd aan de internationale criteria voor 
blindheid (gemiddeld 54 jaar in patiënten met USH2a versus gemiddeld 80 jaar in 
patiënten met USH2A-geassocieerde nsRP). Ook werd in dit onderzoek gekeken naar 
de truncerende en niet-truncerende mutaties. Een combinatie van twee truncerende 
mutaties werd alleen gevonden bij patiënten met USH2a. Verder, onafhankelijk van het 
audiologische fenotype, werd er een positieve correlatie gevonden tussen het aantal 
eiwit-truncerende mutaties (0, 1 of 2) en de ernst van het visuele fenotype. Hoofdstuk 
2.3 van dit proefschrift is gewijd aan het bestuderen van het gehoor in patiënten 
met USH2A-geassocieerde nsRP. Dit was nodig om definitief vast te kunnen stellen of 
USH2A-geassocieerde nsRP daadwerkelijk als een andere klinische entiteit dan USH2a 
beschouwd kan worden. Voorheen werd de afwezigheid van subjectief gehoorverlies 
beschouwd als een criterium voor nsRP. Er was echter nog geen uitgebreid audiologisch 
onderzoek verricht naar het gehoor van USH2A-geassocieerde nsRP patiënten. Na di-
verse gehoortesten en aan de hand van een vragenlijst kon geconcludeerd worden dat 
8 van de 18 onderzochte patiënten een mild gehoorverlies ontwikkelen op volwassen 
leeftijd. Ondanks de variabiliteit, is het gehoorverlies bij patiënten met USH2a bijna al-
tijd bij de geboorte aanwezig in een matige tot ernstige vorm. Omdat het gehoorverlies 
bij USH2A-geassocieerde nsRP patiënten mild van aard is, slechts bij een deel van de 
patiënten en daarbij pas op latere leeftijd optreedt, wordt USH2A-geassocieerde nsRP 
daadwerkelijk beschouwd als een andere entiteit dan USH2a.
Hoofdstuk 3 van dit proefschrift richt zich op de opties voor gehoorrevalidatie bij 
patiënten met USH2a. In Hoofdstuk 3.1 is onderzoek verricht ter verbetering van het 
aanpassen van hoortoestellen bij patiënten met USH2a. Het aanpassen van hoortoestel-
len bij deze patiënten is problematisch. Dit werd beschreven door twee patiënten met 
het syndroom van Usher, Gracia Tham en Ivonne Bressers. In 2012 interviewden zij zowel 
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patiënten met Usher syndroom als zorgprofessionals over de moeilijkheden bij het aan-
passen van hoortoestellen. In dit hoofdstuk zijn de uitkomsten van geluidslokalisatie, 
spraakverstaan in ruis en de kwaliteit van leven vergeleken tussen twee hoortoestel-
programma’s. Deze programma’s werden ontwikkeld aan de hand van twee hypotheses:
1. Het eerste, experimentele, lineaire programma zou zo min mogelijk interfereren 
met het inkomende geluid en daardoor een betere geluidlokalisatie opleveren. 
2. Het tweede, reguliere, compressie programma zou als comfortabeler worden be-
schouwd en beter functioneren met betrekking tot spraakverstaan in rumoer. 
De resultaten van ons onderzoek lieten zien dat USH2a patiënten een duidelijke subjec-
tieve voorkeur hebben voor het lineaire programma. Echter vonden we in de verrichte 
testen geen objectief verschil tussen de twee programma’s wat betreft geluidlokalisatie 
en spraakverstaan. In hoofdstuk 3.2 zijn objectieve (spraakverstaan) en subjectieve 
(vragenlijsten) resultaten na cochleaire implantatie bij patiënten met USH2a onderzocht 
en vergeleken met een controlegroep. Cochleaire implantatie is een zeer belangrijke 
optie voor revalidatie bij patiënten met USH2a en ernstig gehoorverlies. Ongeveer 10% 
van alle bij ons bekende USH2a patiënten heeft inmiddels een cochleair implantaat. 
Zowel de subjectieve als objectieve resultaten verschilden niet van de resultaten in de 
controlegroep.
Concluderend hebben de resultaten van dit proefschrift directe gevolgen voor de 
verschillende stadia van het zorgprogramma voor patiënten met USH2a en USH2A-
geassocieerde nsRP. Patiënten die deze klinische en/of genetische diagnose ontvangen, 
kunnen nu beter worden geïnformeerd over de prognose van het audiovisuele fenotype 
en de revalidatie van het gehoorverlies. Dit proefschrift is een nieuwe stap in het onder-
zoek naar factoren die van invloed zijn op de ernst en progressie van zowel de auditieve 
als de visuele symptomen in patiënten met USH2a en USH2A-geassocieerde nsRP.

Chapter 6
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Ch
ap
te
r 6
 D
an
kw
oo
rd
153
De publicatie van dit proefschrift is het resultaat van een gezamenlijke inspanning waar 
niet alleen ik, maar direct of indirect ook vele anderen aan hebben deelgenomen. De 
onderstaande personen hebben me enorm geholpen, aangemoedigd en gesteund.
Prof. dr. ir Snik. Beste Ad, ik kon altijd bij jou terecht voor vragen over de audiologie en 
de audiologische onderzoeken maar ook voor vragen over onderzoek in het algemeen. 
Je nam rustig de tijd voor de uitleg en ik ging vaak met nieuwe inzichten de deur uit. 
Ook lag er altijd wel een ietwat vergeeld manuscript op je bureau dat ik absoluut moest 
lezen. Dit past perfect bij het beeld van een zeer ervaren en bevlogen professor, waar-
aan jij zeker voldoet. Veel dank voor je begeleiding en ik wens je veel succes bij het 
afronden van de laatste promoties.
Dr. Pennings. Beste Ronald, we hebben elkaar veel gesproken en gezien in de afgelopen 
jaren. Hiervoor ben ik je enorm dankbaar. Jouw betrokkenheid en gestructureerde 
manier van werken, met deadlines en wekelijkse afspraken, werkte voor mij zeer moti-
verend. Door het intensieve contact zijn we er ook achter gekomen in welke opzichten 
we verschillen. Ik heb je open houding hierin zeer gewaardeerd en ik denk dat het 
uiteindelijk tot een nog sterkere samenwerking en wederzijds respect heeft geleid. Als 
copromotor hield je bovendien het overzicht over alle onderzoeken en kon je me op zo-
wel audiologisch als genetisch gebied inhoudelijk adviseren. Tot slot heb ik veel geleerd 
van de professionele en geëngageerde manier waarop je samenwerkt met ouders en 
patiënten. Veel dank!
Dr. van Wijk. Beste Erwin, hoe verder ik in de promotie kwam, hoe meer we hebben 
samengewerkt. De genetisch georiënteerde stukken hebben veel meer diepgang gekre-
gen door je toevoegingen en onze inhoudelijke conversaties. Deze gesprekken waren 
een soort privécolleges waarin je met veel enthousiasme zowel de basale genetica als 
de toekomstige therapeutische mogelijkheden uitlegde. Ik heb niet eerder iemand 
ontmoet die met zoveel energie kan vertellen over ingewikkelde basale wetenschap. De 
patiënten waarvoor je een mogelijke therapie aan het ontwikkelen bent, hebben geluk 
met een wetenschapper zoals jij. Erg veel dank voor je bijdrage aan de onderzoeken en 
dit proefschrift.
Dr. Huygen. Beste Patrick, je hebt een erg groot aandeel gehad in dit proefschrift. En 
dat terwijl je eigenlijk al een tijdje niet meer in dienst bent van het Radboudumc. Dit 
vind ik fantastisch en bewonderenswaardig want dat laat zien dat jouw interesse in het 
ontcijferen van het gehoor bij erfelijke slechthorendheid meer is dan alleen werk. Ik 
heb in de afgelopen jaren regelmatig hele pakketten met documenten ontvangen die 
zo groot waren dat ze per e-mail slechts gecomprimeerd verstuurd konden worden. Je 
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Beste leden van de werkgroep Otogenetica, door de maandelijks geplande vergade-
ringen werd mijn otogenetische blikveld opengehouden voor andere oorzaken van 
erfelijke slechthorendheid zodat ik geen kokervisie kreeg op enkel het Usher syndroom. 
Tevens heeft de feedback tijdens een presentatie ervoor gezorgd dat we de verschillen 
in gehoor tussen twee verschillende patiëntengroepen in acht hebben genomen zoals 
beschreven in hoofdstuk 2.1. In het bijzonder dank voor deze bijdrage en commentaar, 
Prof. dr. Hannie Kremer. 
Medewerkers van het Donders instituut. Beste Martijn Agterberg, Beste Prof. dr. John 
van Opstal, veel dank voor jullie uitleg, expertise en begeleiding op het gebied van het 
richtinghoren. De geluidslokalisatietesten, verricht in het lab van de afdeling Biofysica, 
waren een zeer interessante afwisseling. Ik heb veel bewondering voor de onderzoeken 
die jullie uitvoeren bij zowel normaalhorende mensen als bij patiënten.
Beste Loes, veel dank voor de administratieve ondersteuning. Ik kon altijd bij je terecht 
voor uiteenlopende zaken zoals het plannen van afspraken, het opvragen van adreslijs-
ten en voor het bemachtigen van onmogelijk verkrijgbare manuscripten.
De manuscriptcommissie. Hooggeleerde heren en dame, bedankt voor uw tijd ter be-
oordeling van dit manuscript.
Beste staf van de afdeling keel-, neus- en oorheelkunde van het Radboudumc, veel dank 
voor de prettige ambiance op deze afdeling. De goede sfeer heeft me zeer gemotiveerd 
om, naast het promoveren, ook bij alle andere sociale activiteiten aanwezig te zijn. In het 
bijzonder dank aan prof. dr. Marres en dr. van den Hoogen. Het vooruitzicht dat ik na dit 
promotietraject aan de opleiding tot KNO-arts mocht beginnen, was enorm motiverend.
Alle arts-assistenten KNO, dank voor de positieve en goede sfeer in en buiten het zie-
kenhuis. Ik heb enorm veel zin gekregen om jullie collega te worden en kijk uit naar 
alle toekomstige sociale aangelegenheden maar ook naar de aanstaande professionele 
samenwerking. 
Lieve medeonderzoekers, heel veel dank voor alle gezellige koffiepauzes, leuke gesprek-
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van de afdeling. De hechte club op de researchgang heeft ervoor gezorgd dat ik met 
plezier naar het ziekenhuis kwam en vaak met energie weer naar huis ging.
Lieve Mieke, als kamergenoot en mede promovendus Otogenetica heb ik een ontzet-
tend gezellige tijd met je doorgebracht. Bovendien heb je me veel inhoudelijke tips 
en waardevolle adviezen gegeven. Wat me altijd bij zal blijven is jouw tip om dingen 
niet uit te stellen. Of in jouw woorden: “Dit klusje kan ook nú in plaats van morgen, 
overmorgen of pas na de vakantie”. Je bent een harde werker en jouw serieuze aanpak 
en no-nonsense-attitude heeft een positieve invloed op me gehad. Daarnaast ben je 
een lief en leuk mens en waarschijnlijk een topprofessional.
Lieve Luuk, drie jaar geleden zijn we tegelijk begonnen als promovendus op deze 
afdeling. Met heel veel plezier denk ik terug aan het samen reizen in de trein, onze 
gemeenschappelijke toewijding en inzet en de eindeloze gesprekken over onderzoek 
en de verdere indeling van het leven. Zonder enige twijfel is dit proefschrift deels te 
danken aan deze momenten. En nu op naar een nieuw soort professionele relatie, maar 
bovenal vriendschap!
Lieve vrienden, lieve Robin, Sigrid, Nina, en Harmen, veel dank voor alle gezellige mo-
menten in Amsterdam, waar af en toe de wetenschap werd besproken maar veelal ook 
niet.
Lieve familie Hartel en familie de Jong, in de afgelopen jaren ben ik familie meer gaan 
zien als een essentieel onderdeel van een gelukkig leven. De hechte banden, het wonen 
in elkaars nabijheid en de frequente etentjes en kopjes koffie hebben gezorgd voor een 
fijne afwisseling van het onderzoeksleven. Tijd doorbrengen met jullie is echt thuisko-
men. Veel dank daarvoor. 
Lieve Eva, ik zou je bij deze gelegenheid kunnen bedanken voor ontelbaar veel dingen. 
Ik houd het echter bij de twee belangrijkste, dank voor het volle vertrouwen en de 
onvoorwaardelijke steun die ik van je krijg. Dit is liefde zoals ik hem ieder mens zou 
gunnen. Ik geniet van elk moment met je.
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Bas Pieter Hartel werd op 2 juli 1987 geboren te Gouda als 
oudste zoon van een gezin met drie kinderen. Al kort na zijn 
geboorte volgde een aaneenschakeling van verhuizingen 
naar onder andere Engeland, Almere, Delden en uiteindelijk 
eind 1998 naar Argentan, een klein dorp in het Franse Nor-
mandië. In Argentan voltooide hij de middelbare school en 
hij behaalde in 2006 het Franse Baccalauréat Scientifique 
(equivalent van het vwo-diploma in Nederland). Hoewel 
het leven in Frankrijk hem prima beviel, wilde hij toch het 
liefst studeren in Nederland. In datzelfde jaar verhuisde hij 
daarom naar Amsterdam om geneeskunde te studeren aan de Universiteit van Amster-
dam (in het Academisch Medisch Centrum). Hoewel Bas zich als een vis in het water 
voelde in Amsterdam, kreeg hij al gauw de drang om meer van de wereld te zien. In het 
kader van zijn opleiding liep hij daarom onder andere stage in Zwitserland, India en 
Zuid-Afrika. Ook vond hij de tijd om zes maanden met zijn vriendin door Zuidoost-Azië 
te fietsen. Eenmaal terug in Amsterdam begon hij met z’n coschappen en ontdekte hij 
dat het coschap Keel-, Neus- en Oorheelkunde in het Sint Lucas Andreas Ziekenhuis 
er voor hem met kop en schouders bovenuit stak. Het is dan ook geen verrassing dat 
hij, na het behalen van zijn artsenbul in 2014, is gaan solliciteren voor een felbegeerde 
plek als arts-onderzoeker op de afdeling KNO van het Radboudumc te Nijmegen. De 
sollicitatie had een positief vervolg. Vanaf april 2014 is Bas op de bovengenoemde afdel-
ing werkzaam als promovendus en hij zal, na een nieuwe fietsreis (dit keer door Zuid-
Amerika), op 1 augustus 2017 beginnen aan de opleiding tot Keel-, Neus- en Oorarts in 
het Radboudumc. 
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ANOVA   analysis of variance
ARTA   age-related typical audiograms
ATD   annual threshold deterioration
BB   broadband
CADD   combined annotation dependent depletion score
CI   cochlear implantation
CR   compression ratio
DFNB   autosomal recessive inherited sensorineural HI
dB HL   decibel hearing level
ExAC   exome aggregation consortium
GBI   Glasgow benefit inventory
GVF   Goldmann visual field
HA   hearing aid
HI   hearing impairment
HP   high-pass
ILD   interaural level differences
ITD   interaural time differences
kHz   kilo hertz
KS   Kolmogorov-Smirnov
LDL   loudness discomfort levels
LOVD   Leiden open variant database
LP   low-pass
MAE   mean absolute error
n   number
NCIQ   Nijmegen cochlear implant questionnaire
NH   normal hearing
nsRP   nonsyndromic retinitis pigmentosa
nT   nontruncating
OMIM   online mendelian inheritance in man
P   pathogenic
PTA   pure tone average
RP   retinitis pigmentosa
SC   syllabic compression
SD   standard deviation
SNR   signal-to-noise ratio
SPL   sound pressure level
SPSS   statistical package for the social sciences
SRT   speech reception threshold
SSQ   speech, spatial and qualities of hearing scale
164
T   truncating
USH   Usher syndrome
USH2a   Usher syndrome type IIa (genetic type)
USH2A   gene of USH2a
VA   visual acuity
VF   visual field
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Usher syndrome is the most common cause of hereditary deaf-
blindness in man. This condition is characterized by a combina-
tion of hearing impairment, vision loss, and in some cases vestib-
ular dysfunction. Usher syndrome type IIa is the most common 
type of this syndrome explaining up to 50% of all cases. In Oc-
tober 2012, two Usher syndrome patients published a report on 
problematic hearing aid fitting in patients with Usher syndrome, 
based on interviews with care professionals and patients. This 
report, together with ongoing questions about the variability in 
presentation of clinical symptoms in Usher syndrome type IIa 
patients, laid the foundation for this thesis. 
The aims of this thesis were to clinically examine patients with 
mutations in USH2A, the gene causing Usher syndrome type IIa, 
in order to find explanations for the variability in clinical presen-
tation and to evaluate hearing rehabilitation options.
